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ABSTRACT 
 
The vast majority of children undergoing surgical repair of cardiac lesions do 
spectacularly well. However a significant proportion, ~ 25%, struggle to progress in the 
early postoperative period and require additional pharmacological and occasionally 
mechanical circulatory support. All children typically have some degree of postoperative 
myocardial dysfunction, with the severe spectrum termed the low cardiac output state 
(LCOS). LCOS is clinically defined as the requirement for new or escalated inotrope 
therapy, a widened arteriovenous oxygen difference, cardiac arrest or the need for 
reinstitution of mechanical circulatory support. LCOS is largely responsible for the 
morbidity and mortality involved in paediatric cardiac surgery. Despite the predictability 
of LCOS in the initial postoperative hours, the underlying pathophysiology remains 
unclear. The period of decline in cardiac function that typifies LCOS is temporally 
associated with the development of oedema in the tissues of the body, including the heart. 
This relationship between oedema and dysfunction has increasingly become blurred, with 
a tendency to elevate the temporal association to a causal link. We sought to explore the 
causes and contributions to myocardial dysfunction in this setting, including the roles of 
oedema and ischaemia within the heart. In focusing on oedema and ischaemia we also 
examined the effects of these insults on relevant myocardial membrane proteins, 
including those that permit rapid water transport – aquaporins (AQPs), and those 
involved in membrane mechanics – dystrophin, and membrane repair – dysferlin. 
Experimental settings which enabled the in vitro dissection of these insults and proteins 
of interest were combined with a clinically accurate in vivo model.  
 
This thesis describes a series of thematically linked experiments that examined LCOS, 
myocardial oedema and the role of various membrane proteins. We performed isolated 
cardiomyocyte studies, isolated heart studies as well as a clinically relevant large animal 
(lamb) cardiopulmonary bypass (CPB) model. Across these models we also explored the 
role of therapeutically protecting myocardial membranes with Poloxamer 188 (P188) and 
assessed any influence on myocardial function, oedema and membrane proteins.    
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The results from these three models suggest that the clinically accepted dogma of a 
causative link between myocardial oedema and dysfunction overstates the contribution of 
myocardial oedema to LCOS. We found that ischaemia/reperfusion was of primary 
importance in causing myocardial dysfunction. Myocardial oedema without ischaemia 
had a mild and reversible contribution to myocardial dysfunction, but this was minor in 
comparison to the gross dysfunction attributable to ischaemia. Isolated cardiomyocytes, 
with induced oedema, functioned well. Whilst ischaemic cardiomyocytes, with less 
swelling still had severe contractile dysfunction. Isolated hearts, perfused with an oedema 
inducing crystalloid perfusate developed myocardial oedema and had minimal reversible 
systolic and diastolic dysfunction. Isolated hearts which experienced global ischaemia 
had comparable degrees of myocardial oedema, and significantly greater degrees of 
myocardial dysfunction that increased in severity with increasing duration of ischaemia. 
In the lamb CPB model, only those lambs which underwent aortic cross clamping and 
had a period of ischaemia had poor myocardial function. These lambs also had swollen 
hearts, raised myocardial AQP1 mRNA and reduced membrane dysferlin protein 
expression. Membrane dystrophin protein expression was not altered, somewhat 
unexpectedly with CPB with or without ischaemia. Lambs placed on CPB without 
ischaemia had good myocardial function, minimal oedema and unchanged membrane 
protein expression during the survival period. In a blinded lamb CPB trial of P188 there 
were improved haemodynamics and indicies of myocardial function associated with its 
use. This was also associated with preservation of dysferlin expression and reduced 
membrane injury. In parallel isolated heart trials of this therapy, there was a reduction in 
myocardial oedema associated with its use in non-ischaemic experiments. There was also 
a suggestion of improved diastolic function in ischaemic experiments, but no change in 
myocardial water content. 
 
In conclusion, we have highlighted the primacy of ischaemia/reperfusion over oedema in 
contributing to LCOS. We have refuted the accepted dogma that myocardial oedema 
causes significant dysfunction in itself, with important oedema likely to result from 
ischaemia. We have shown that AQP1 may be involved in the pathogenesis of the 
capillary leak syndrome. Finally we have hinted at a role for prophylactic P188 in the 
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setting of LCOS, possibly highlighting the role of membrane repair in recovery after 
surgery. Isolated heart trials of P188 further support a non-rheological mechanism of 
action and also lend support to the causal separation of myocardial oedema and 
dysfunction. The integral membrane protein dysferlin, rather than dystrophin, is relevant 
in the setting of LCOS in the current era. 
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CHAPTER 1: OVERVIEW & LITERATURE REVIEW 
 
1.1 Overview 
 
1.1.1 Background  
 
 One percent of children born each year in Australia have congenital heart disease, 
e.g. a “hole in the heart,” or ventricular septal defect (VSD). A smaller number of 
children develop acquired cardiac disease – such as rheumatic heart disease – which is 
more prevalent amongst Aboriginal children and in children from the neighbouring 
south-western pacific rim. A significant number of these infants and children require 
cardiac surgery to repair or palliate these congenital and acquired cardiac lesions. 
Typically such operations proceed well, the postoperative course is uncomplicated and 
children recover rapidly to lead essentially normal lives. For instance, about 450 children 
per year have cardiac surgery at The Children’s Hospital at Westmead, Sydney, Australia 
and the mortality rate is ~1–2%.  
 
1.1.2 Preoperative period 
 
 The field of paediatric cardiac surgery has developed alongside adult practice as a 
highly specialised and robust field in its own right (Freedom, 2000). Operative repair is 
the culmination of the work of a diverse team of skilled professionals. Initially paediatric 
physicians or cardiologists diagnose the cardiac condition – now often done in utero or 
antenatally to facilitate delivery in a tertiary centre capable of managing an ill neonate. 
Following clinical and echocardiographic (ultrasound) diagnosis and initial stabilisation, 
an operation may or may not be indicated at some stage. Further diagnostic information 
may be required via a cardiac catheter. Cardiac catheter insertion is performed under 
general anaesthetic and provides images that document anatomical blood flows or shunts, 
as well as pressure and biochemical measurements. This information is important in 
complex conditions before surgery to determine the best management. An important 
initial consideration which may arise is whether it is possible to repair the heart in the 
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usual two ventricle fashion, or whether a single ventricle repair will be required, typically 
culminating in a Fontan repair (Fontan and Baudet, 1971). Magnetic resonance imaging 
(MRI) is increasingly being used together with computerised tomography (CT) 
angiography to obtain further information on cardiac anatomical considerations. 
Following the collection and synthesis of diagnostic information it is typical that a period 
of medical therapy is instituted – this may be for weeks, months or years, prior to 
proceeding to an operation. Alternatively it may be necessary to proceed to operative 
repair relatively promptly (2–5 days), based on clinical and echocardiographic findings – 
for instance in the case of transposition of the great arteries (TGA) or in hypoplastic left 
heart syndrome (HLHS).  
 
1.1.3 Operative period 
 
 Following the initial period of diagnosis and stabilisation, the patient may be 
referred for operative repair. Specialist paediatric anaesthetic staff provide a stable 
anaesthetic platform for the surgeon to conduct the operation. This includes sedative, 
analgesic and neuromuscular blocking drugs. Inotropes – medicines which help the heart 
contract and vasodilators – medicines which help the circulation relax and make it easier 
for the heart to pump are utilised. The child is mechanically ventilated via an 
endotracheal tube and also has central venous and arterial lines for monitoring and 
delivery of medications and fluids. Operations are broadly referred to in terms of open or 
closed – the heart is “opened” – e.g. VSD repair. Or the repair is “closed” or extracardiac 
– e.g. Blalock Tausig shunt (BTS) – which involves a modified plastic tube (PFTE) being 
placed between ipsilateral subclavian and branch pulmonary arteries. Open procedures 
invariably require CPB to be instituted to support the body’s circulation whilst the heart 
is opened. This is what is referred to as the “heart lung machine.” It is a circulatory 
support device that is instituted by the surgeon and together with a perfusionist is 
maintained during the operation. It has a number of features that enable safe support of 
the circulation – it temporarily replaces the native circulation taking venous 
deoxygenated blood from the patient, oxygenating it and then returning it at an acceptable 
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flow into the ascending aorta, the large blood vessel which supplies oxygenated blood to 
the body.  
 
1.1.4 Cardiopulmonary bypass 
 
 In essence CPB involves an extracorporeal circuit of ~10mm plastic tubing which 
contains a mix of physiological fluid – crystalloid (saline) together with blood. The 
typical volume of this circuit is 300ml and given that a 3kg neonate has a 240ml blood 
volume, the circuit requires blood in order to partially support the red blood cell 
concentration or haematocrit (Hct) and minimise the degree of haemodilution. The tubing 
is connected to an oxygenator and pump, and both the temperature and chemistry of the 
perfusate are managed by the perfusionist. The tubing connects to the patient via 
cannulae in the right atrium – secured with purse string sutures. Blood enters the heart 
lung machine tubing from the right atrium, and then having passed through the 
oxygenator and pump, returns through a cannula in the proximal ascending aorta. The 
patient is anticoagulated prior to going onto CPB to ensure that blood does not clot within 
the circuit. Thus the circulation is supported and the heart can be repaired. The passage of 
the patient’s blood via this extracorporeal circuit together with all its various pieces can 
create an inflammatory like reaction within the patient – raised temperature, activation of 
white cells and platelet dysfunction (Wan, 1997).  
 
Typically a further important measure is involved – that is stopping or arresting the heart. 
This provides a non beating operative field, an empty heart and facilitates repair integrity. 
To achieve this the heart is arrested in diastole – the relaxed phase of the contraction 
cycle – as opposed to systole – the active contraction phase. A small cannula is placed in 
the aorta – in between the CPB aortic cannula and the aortic valve. The openings to the 
coronary arteries are just above the aortic valve within the aortic root. A clamp is then 
placed across the aorta (aortic cross clamp, AXC) – in between these two cannula. Thus 
the CPB circuit supplies the circulation and the heart is isolated by the clamp. Between 
the AXC and the aortic valve is the small cannula – into which cardioplegia (a mix of 
blood and crystalloid) is administered. Conventional cardioplegia has a high potassium 
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concentration to induce cardiac standstill or arrest. This solution is cooled and delivered 
into the coronary arteries via the aortic root, causing the heart to arrest within seconds. 
The heart is relaxed in diastole and cooled to 25–28oC to further try and preserve it whilst 
it is being operated upon. Cardioplegia is given by repeated small volume infusion every 
20 minutes until the operative repair is complete. During this period the heart is 
essentially having planned and controlled ischaemia – i.e. it is not receiving the nutrients 
required for normal function. The inability to fully protect the heart from this planned 
ischaemic reperfusion injury is a major impediment to improving cardiac surgery 
(Dobson, 2004). At the end of the operation when the heart is restarted – by stopping the 
cardioplegia and rewarming – a reperfusion injury of varying degrees occurs with 
associated myocardial dysfunction. And although dysfunction follows reperfusion – it is 
ischaemia which initiates the processes within the myocardium that lead to the 
development of myocardial dysfunction (Kloner and Jennings, 2001). 
 
Once the heart is rewarmed, restarted and the circulation is stable the CPB circuit can be 
removed from the patient. At this point anticoagulation is reversed, haemostasis achieved 
and if the haemodynamics permit the chest is closed. Occasionally the chest is left open if 
the haemodynamics are borderline or if there is appreciable chest wall oedema present in 
the operating theatre (Odim, 1989; Iyer, 1997; Tabbutt, 1997a). The patient is then taken 
to the paediatric intensive care unit for a period of recovery and restitution.  
 
1.1.5 Deep hypothermic circulatory arrest 
  
 It is worth noting at this point that deep hypothermic circulatory arrest (DHCA) is 
an alternative circulatory support strategy to the combination of CPB and AXC. Aortic 
and right atrial cannulae as described for instituting CPB with AXC are utilised, but after 
establishing a core temperature of less than 20oC the heart is arrested and the circulation 
drained into the oxygenator. Thus the heart is empty and arrested, but the circulation is 
also empty permitting operations on the aortic arch. DHCA in the current era is reserved 
for aortic arch surgery now, rather than other operations as was previously the case. CPB 
has been shown to be superior to DHCA in terms of minimising neurological sequelae 
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and there are no important haemodynamic differences apparent in the postoperative 
period (Newburger, 1993; Bellinger, 1995; Wernovsky, 1995; Bellinger, 2003). Typically 
when DHCA is utilised selective carotid perfusion is employed using the CPB machine 
and appropriate cannulae.  
 
1.1.6 Postoperative period 
 
 The postoperative cardiac surgery patient arrives in the paediatric intensive care 
unit with their heart now repaired, but having also undergone a significant stress. 
Preceding the operation were often other important factors; 1) A period of medical 
therapy – particularly important if there was cardiac failure which can impact growth, 
nutritional reserves and ability to cope postoperatively, 2) previous operations, 3) other 
factors such as related/unrelated syndromes e.g. Trisomy 21 or velocardiofacial syndrome 
(VCFS) which can affect endocrine and or immunological function. On this background 
is the recent operative stress. Important aspects of the operation include the occurrence 
and duration of CPB and aortic cross clamping – this determines the severity of any 
inflammatory and ischaemia/reperfusion insult respectively. Other contributions to the 
postoperative setting are myocardial surgical trauma and haemodilution as part of CPB. 
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1.2  Myocardial dysfunction 
 
1.2.1 Reduced cardiac performance 
 
 The vast majority of patients do well following surgery. However all have a 
reduction or decline in cardiac performance to some degree – this is a period of recovery 
from the operative repair. A period of reduced myocardial performance is typified by 
reduced stroke volume (volume of blood ejected from the heart with each contraction), 
increased heart rate and lower perfusion pressure (blood pressure). A temporary and mild 
reduction in urine output can occur and the peripheries can be cool suggesting reduced 
perfusion and increased peripheral vasoconstriction (increased systemic vascular 
resistance – or afterload). 
 
About 25% of patients have a more severe decline in myocardial performance loosely 
defined and termed the low cardiac output state (LCOS). Classically there is a 25% 
decline in cardiac output and a rise in systemic vascular resistance also of around 25% 
(Parr, 1975; Burrows, 1988; Wernovsky, 1995). These patients require careful attention 
and management necessitating optimisation of inotropic and vasodilator therapy and 
occasionally reinstitution of mechanical support (extracorporeal membrane oxygenation, 
ECMO or ventricular assist device, VAD) in order to maintain the circulation until the 
heart can recover (Wessel, 2001). LCOS is broadly defined clinically, based on the 
following signs and symptoms; tachycardia, oliguria, poor perfusion, or cardiac arrest 
with or without a widened arterial-venous oxygen saturation difference or metabolic 
acidosis. In addition the institution of ECMO or VAD, an increase in inotropes relative to 
baseline (≥100%) or the administration of a new inotrope  completes the defining criteria 
for the LCOS (Hoffman, 2003). Onset of LCOS usually occurs 6–12hrs postoperatively 
and it causes the majority of morbidity and mortality in the current era. Although the 
impact of LCOS is lessened by early supportive measures, such as milrinone (Primacor, 
Sanofi-Aventis, Macquarie Park, NSW, Australia) – an inotrope which is used in the 
early recovery period, the precise aetiology of LCOS remains unclear (Hoffman, 2003).  
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1.2.2 Myocardial stunning 
 
 The temporary diminishment in cardiac performance is largely predictable after 
cardiac surgery. The specific decline in cardiac output should be referred to as 
myocardial stunning and is largely responsible for the myocardial component of LCOS. 
Other features of LCOS are essentially reactionary – i.e. the increase in systemic vascular 
resistance is likely a response to reduced perfusion pressure (Wernovsky, 1995; Hoffman, 
2003; Stocker, 2007). The term myocardial stunning, has been used to describe a period 
of myocardial hypocontractility despite normal coronary perfusion (Braunwald and 
Kloner, 1982). It is well described in adults (Breisblatt, 1990; Royster, 1993), but poorly 
in paediatrics (Booker, 1998). The resulting hypoperfusion of important organs including 
kidney and brain accounts for the majority of morbidity in current adult and paediatric 
cardiac surgical practice (Parr, 1975; Wernovsky, 1995; O'Connor, 1998). Stunning is 
considered to be mainly the result of ischaemia reperfusion (I/R) injury – the duration and 
severity of ischaemia determining the degree of stunning which then becomes apparent 
following reperfusion. Stunning also involves a degree of myocardial oedema (swelling 
of the tissues due to water) within the heart (Bolli and Marban, 1999). Induction of 
apoptotic pathways has also been suggested as a mechanism of cell loss contributing to 
myocardial dysfunction in the paediatric setting (Caldarone, 2004). The key mediators of 
injury are currently felt to be oxygen derived free radicals and calcium overload resulting 
in injury to myocellular components of the contractile apparatus (Bolli and Marban, 
1999). Myocardial stunning is associated with cell swelling, altered mitochondrial 
morphology and function (Bolli and Marban, 1999; Akao, 2003). Haemodilution, which 
results mainly from the use of CPB has also been temporarily associated with myocardial 
dysfunction following CPB and its minimisation has been associated with improved 
outcomes (Jonas, 2003).  
 
1.2.3 Association of dysfunction with oedema  
 
 LCOS occurs during the early postoperative period and is temporally associated 
with increased total body water and generalised tissue oedema (Wernovsky, 1995; 
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Hamada, 2004). The increase in total body water and tissue oedema is coincident with the 
predictable decline in cardiac output, leading many to speculate that oedema and 
myocardial dysfunction are causally related (Maehara, 1991; Wernovsky, 1995; Hamada, 
2004). This increase in tissue oedema is often termed “capillary leak syndrome”. This 
syndrome is well described following cardiac surgery, particularly in neonates and infants 
undergoing corrective surgery for congenital heart disease. It has been described as an 
‘endotheliopathy’ and attributed to an increase in vessel permeability, induced by a 
systemic inflammatory process initiated by exposure of blood to foreign surfaces of the 
CPB circuit (Edmunds, 1998). In adults, capillary leak accounts for a 2–5% gain in 
extracellular fluid volume peaking at four hours post CPB (Hamada, 2004), again 
corresponding to the peak of myocardial dysfunction (Mangano, 1985; Breisblatt, 1990). 
The occasional practice of delayed sternal (chest) closure in the setting of paediatric 
cardiac surgery is a result of concerns relating to a swollen (oedematous) myocardium 
exacerbating early postoperative dysfunction through relative “tamponade’ within the 
closed chest (Odim, 1989; Tabbutt, 1997a). 
 
The temporal association of LCOS related dysfunction and increased total body and 
myocardial water has led to an accepted clinical dogma that LCOS and the oedema that 
occurs in the myocardium and throughout the body are causally linked. Recent examples 
of this include the following;  
 “Capillary leak and oedema associated with cardiopulmonary bypass continue 
 into the postoperative period and can compromise myocardial function in infants 
 and children” (Tabbutt, 1997a) 
 “It is well understood that the capillary leak syndrome developing in the early 
 postoperative course will aggravate myocardial oedema and myocardial 
 dysfunction.” (Kostelka, 2005) 
 “Our study (on aprotinin) has important implications in the development of 
 molecular strategies to prevent tissue oedema and myocardial dysfunction, 
 particularly in the setting of cardiac surgery.” (Khan, 2005) 
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Contrary to these views however, in a large neonatal trial of DHCA versus CPB it was 
shown that despite differences in postoperative water balance there were no differences in 
haemodynamic function; 
 “Despite the increased total body oedema (associated with CPB), there was no 
 significant effect on postoperative haemodynamics, laboratory studies, duration 
 of mechanical  ventilation, length of stay in the ICU or hospital.” (Wernovsky, 
1995) 
 
We sought to unravel this linking of dysfunction and water accumulation, therefore we 
reviewed water transport in the heart and how this may vary in pathological 
circumstances. Concurrently we explored the proteins within the myocardial membranes 
and the potential role of transcellular water movement mediated by aquaporins (AQPs). 
Subsequently we explored AQP related proteins, dystrophin and dysferlin, which 
additionally have important functions related to their membrane location and have not 
been explored in this setting. Existing anti–inflammatory therapies, such as 
corticosteroids and aprotinin that seek to target the CPB related systemic inflammatory 
response syndrome (SIRS) do not prevent the extravasation of water (Seghaye, 2003; 
Farstad, 2004; Tassani, 2007), leading us to investigate other possible avenues for 
intervention, such as the role of myocardial water channels or AQPs (Farstad, 2004; 
Castle, 2005). 
 10
1.3 Aquaporins 
 
1.3.1 Background 
 
 The body consists of approximately 70% water, and AQPs in part serve as the 
“plumbing for cells”. They are responsible for the secretion and absorption of cerebral 
spinal fluid, tears, saliva and the impressive concentrating ability of the kidneys (Agre, 
2004). AQPs are a family of proteins that form channels across cell membranes 
permitting high capacity rapid movement of water along osmotic gradients. There are 13 
AQPs found in mammals (AQP0 – 12), most of which permit transcellular passage of 
water while some also allow passage of glycerol (AQP3, 7, 9 and 10). In some 
circumstances, heavy metal salts, chloride, CO2 and ammonia may also be transported by 
AQPs. Most AQPs display organ and cell specific expression which sometimes differs 
between species. Highly specific regional expression of different AQPs combine to 
coordinate water movement in a number of organs. For instance AQP1 expression in the 
proximal tubule of the kidney facilitates the initial extraction of water to concentrate 
urine. This process is an example of near-isosmolar water movement driven by active 
solute transport. Later, in the principal cells of the collecting duct AQP2 is sequestered 
within vesicles which, in response to vasopressin receptor activation, insert into the apical 
membrane to facilitate water reabsorption into the tubular cell. Expression of AQP3 and 
AQP4 in the basolateral membrane then allows water to move into the hypertonic 
interstitium of the renal medulla and finally to return to the circulation. AQPs are 
specific, but passive transporters, they provide a water specific pore across the cell 
membrane. Water can diffuse across the cell membrane (lipid bi-layer) without accessing 
an AQP, but transit is less rapid.  
 
1.3.2 Aquaporin function 
 
 Much of our understanding of AQP function comes from analysis of pathological 
situations. Within the brain, AQP4 is integral to the blood brain barrier and is primarily 
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responsible for permitting the development of cerebral oedema following cytotoxic 
(cellular oedema) injury (Manley, 2000). Thus, AQP4 knockout mice demonstrate 
significant survival benefits compared to wild type mice following stroke and traumatic 
brain injury, two different models of cytotoxic oedema (Manley, 2000; Agre, 2004; 
Manley, 2004). Conversely, AQP4 knockout mice suffer a worse outcome in models of 
vasogenic (or interstitial) oedema as this water channel facilitates removal of water from 
the brain (Papadopoulos, 2004). AQP4 is anchored to the blood vessel-encapsulating 
astrocytic foot processes through a protein complex involving syntrophin and dystrophin. 
In skeletal muscle where the role of AQP4 is less well defined it is similarly associated 
with the dystrophin protein complex. In the skeletal muscle disease Duchenne muscular 
dystrophy (DMD), AQP4 protein is reduced in association with absent dystrophin 
protein, although this does not appear to primarily contribute to the muscle weakness 
(Verkman, 2000). 
 
1.3.3 Aquaporin structure 
 
 Information on mammalian AQP structure is mainly based on analysis of AQP1. 
Monomers consist of six transmembrane helices which form “hourglass” pores. Protein 
monomers combine within the cell membrane to form a tetrameric complex, although 
each monomer is independently functional. Due to the design of the channel, requiring 
reorientation of water molecules during transit, the pore is highly specific to water and 
excludes H+ passage (King, 2004). Gating of mammalian water channels does not appear 
to be a consistent feature in studies thus far, however pH and phosphorylation have 
influenced permeability in some experimental settings e.g. pulmonary AQP3 
permeability was reduced by low pH (Zelenina, 2003) and Xenopus oocytes containing 
AQP4 had reduced permeability when phosphorylated (Han, 1998). However overall 
AQP function is largely subject to transcriptional, rather than short term regulation by pH 
or other influences (Verkman, 2005). 
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1.3.4 Aquaporin 1 
 
 AQP1 is the ubiquitous water channel found in endothelial cell membranes of 
vascular tissues throughout the body. It is also found in the plasma membranes of the red 
blood cell, kidney, lung, brain and eye (King, 2004). It was the first AQP discovered after 
being demonstrated in erythrocytes and shown to permit rapid water permeability in 
response to an osmotic gradient (Preston and Agre, 1991; Preston, 1992), although others 
have contended that it was found earlier (Benga, 2003).  
 
The study of AQP1 null individuals, arising as a result of a mutation in the AQP1 gene 
leading to little or no AQP1 expression has provided an insight into the function of AQP1 
in humans. In these subjects, the permeability of pulmonary endothelium was studied by 
computerised tomography following a three litre intravenous volume load. Pulmonary 
venules of AQP1 null humans were engorged, compared to control subjects that showed 
imminent interstitial pulmonary oedema in the form of peribronchiolar oedema, the 
thickness of the airway walls increasing by 40–50% in control subjects (King, 2002). It is 
likely that this was due to a decrease in pulmonary vascular permeability. The study of 
AQP1 knockout mice, under different conditions, has not revealed defects in alveolar or 
pleural reabsorption, with no impairment in lung fluid or gas transport physiology (Song, 
2000; Verkman, 2002a). Interestingly, the analysis of the role of AQPs within the heart 
has been limited in comparison to studies of other tissues and organs.  
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1.4 Myocardial water handling 
 
1.4.1 Background 
 
 There are essentially three compartments within the heart – intravascular, 
interstitial and myocellular, (Figure 1.1). Typically the heart has a neutral fluid balance, 
with accumulation of excess interstitial fluid in the heart prevented by anatomical and 
physiological factors. As blood traverses the myocardial capillary bed, it may return to 
the circulation via either the coronary sinus or the thebesian veins, emptying into the right 
atrium. As the majority of fluid flux occurs in the post capillary venules, easy passage or 
‘run off’ is important. This flux in response to osmotic and oncotic gradients occurs 
regardless of rate of flow (Kellen and Bassingthwaighte, 2003b). Fluid that accumulates 
in the interstitium is handled by myocardial lymphatics which return water to the 
circulation via the thoracic duct.  
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1.4.2 Endothelium 
 
 When describing myocardial water permeability, most authors are actually 
describing the net effect of water movement between the vascular compartment and the 
interstitium. This is partly determined by exposure of the interstitium to blood vessels, 
essentially capillary density or surface area available for water flux, which is very high in 
the heart compared to other organs (Wearn, 1928).  
 
Kellen and Bassingthwaighte using a crystalloid perfused isolated rabbit heart model, 
have described the routes of water movement across capillaries within the heart (Kellen 
and Bassingthwaighte, 2003a, b). There are two important routes that water moves 
through, in response to osmotic and oncotic gradients. The majority of water (67%) 
passes through small pores (~7nmØ) which are formed by tight junctions within the 
interendothelial clefts – these are referred to as endothelial cell gap junctions in Figure 
1.1. Most of the remainder of water (28%) passes through the endothelial cell directly. 
Water transits across an endothelial cell by i) diffusion through the lipid bi-layers, ii) 
coupled to ion–channels or substrate transporters, such as glucose, Na+, K+ or Ca2+ and 
iii) via AQPs (Wright and Rees, 1998). AQPs are considered to be the most important of 
these transendothelial cell routes. AQPs span both the luminal and abluminal lipid bi-
layers as well as the sarcolemma of the cardiomyocytes. It is calculated that in vivo with 
blood perfusing the capillaries, rather than crystalloid perfusate (used for experimental 
modelling), that the contribution of AQPs in the transendothelial route would increase 
from 28% to 40-50% (Kellen and Bassingthwaighte, 2003b). Lastly there is a third and 
minor route by which water can leave the intravascular compartment and that is via 
infrequent large pores (24nmØ) in the endothelium that mainly exist to permit large 
proteins to egress into the lymphatic circulation (Kellen and Bassingthwaighte, 2003b).  
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1.4.3 Microvascular fluid balance 
 
 The balance of microvascular fluid filtration is modelled by the Starling forces, 
reviewed in detail by Mehlhorn et al (Mehlhorn, 2001). Many of the factors driving water 
movement are affected during cardiac surgery, including the plasma colloid osmotic 
pressure, which is reduced by haemodilution, and the compressive force of regular 
myocardial contractions, which cease when the heart is arrested in diastole (impairing 
myocardial lymphatic drainage) for the duration of the operation. These factors combine 
to produce altered water handling and a shift in the balance towards accumulation of 
water in the interstitium. On the other hand myocellular accumulation of lactate in the 
setting of I/R is likely to lead to intracellular accumulation of fluid, with the myocellular 
compartment experiencing a hypo-osmotic stress with ischaemia (Wright and Rees, 
1998). 
 
1.4.4 Water handling in pathological circumstances 
 
 Water movement between the interstitial and intracellular space has been 
relatively ignored compared to factors regulating microvascular permeability which are 
pertinent to vascular – interstitial flows. This may be because in normal circumstances, 
cardiomyocytes are not subject to variations in the extracellular osmotic environment. 
Intracellular water represents approximately 77% of total tissue water (Polimeni and Al-
Sadir, 1975) and maintenance of interstitial and cardiomyocyte volumes are inextricably 
linked through osmotically obliged water movement. Water movement between the 
interstitial and intracellular compartments may become important in circumstances where 
i) interstitial fluid volumes are increased because of pathologically increased 
microvascular permeability, such as CPB (Hoffmann and Dunham, 1995), or reduced 
colloid osmotic pressure (Kellen and Bassingthwaighte, 2003b) – leading to an expanded 
interstitial space and so called interstitial or vasogenic oedema, and ii) when there is an 
inwardly directed osmotic gradient as a result of cellular events such as ischaemia, where 
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accumulation of lactate osmotically draws water into the cell during reperfusion, leading 
to cytotoxic or myocellular oedema (Garcia-Dorado and Oliveras, 1993; Wright and 
Rees, 1998).  
 
1.4.5 Role of aquaporins 
 
 The contribution that AQPs make to myocardial water handling has been explored 
in a number of species with differing conclusions. The techniques used included isolated 
cardiomyocytes with video-microscopic observation of osmotically induced changes in 
cell volume and assessment of sarcolemmal water permeability by measuring the rate of 
swelling or shrinkage. Together with an assessment of the Arrhenius activation energy 
(Ea), which is a measure of the energy barrier to water flux (normally high because 
diffusion of water is limited by the lipid bi-layer), the contribution of AQPs to net 
sarcolemmal water permeability can be estimated. On the basis of these measurements, 
Ogura et al. showed that AQPs represent a major route of water transport in guinea pig 
and rat heart cells (Ogura, 2002a; Ogura, 2002b). The inhibitory effect of adding mercury 
(a non-specific AQP inhibitor) on interstitial fluid volumes supported these findings. 
Similar techniques were used by Suleymanian and Baumgarten (Suleymanian and 
Baumgarten, 1996) in rabbit ventricular cardiomyocytes. They demonstrated similar 
sarcolemmal permeability, but a higher Ea, and concluded that diffusion, not water 
channels, were the predominant path of water movement in the rabbit. Species 
differences in AQP expression may explain this discrepancy and the contribution of 
AQPs to human cardiomyocyte water movement is at present unknown. Although these 
isolated cardiomyocyte models suggest a role for AQPs of varying degrees in the heart, 
they have only modelled the movement of water into the cardiomyocyte and have 
disregarded the important vascular and interstitial components. 
 
The vascular and interstitial compartments, both of which are lined by endothelial cells 
with AQPs, are key to water movements within the heart. Hence it is considered in more 
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developed recent work that the contribution of transcapillary water passage via the 
transendothelial AQPs is of the order of 40-50% in vivo (Kellen and Bassingthwaighte, 
2003b). Furthermore as already alluded to, in several non-cardiac tissues, such as brain 
(Manley, 2000; Manley, 2004; Papadopoulos and Verkman, 2005) and lung (King, 2002) 
the involvement of AQPs in the development and resolution of tissue oedema has been 
demonstrated. This further supports a rational basis for postulating a role of AQPs in 
myocardial water handling and the development and resolution of myocardial oedema. 
 19
1.5 Myocardial oedema 
 
1.5.1 Background 
 
 Accumulation of body water occurs in the context of cardiac surgery and whilst in 
adults this is 2–5% (Hamada, 2004), it appears greater in paediatrics, ranging from 11% 
(Maehara, 1991) to ~20–30% (Wernovsky, 1995). Human myocardial water gains in this 
setting have not been established, but comparable large animal studies have found gains 
in the order of 1 – 3% (Foglia, 1978; Mehlhorn, 1995a). 
 
Myocardial oedema may develop through a combination of vasogenic and 
cytotoxic/myocellular pathways. Typically interstitial or vasogenic oedema is described 
(Mehlhorn, 1995b; Tassani, 2007), associated with increased capillary leak. In addition, 
the heart suffers the metabolic effects of ischaemia and reperfusion. This leads to the 
generation of intracellular lactate and creates a strong inwardly directed osmotic gradient 
that causes cardiomyocytes to swell and leads to myocellular or cytotoxic oedema 
(Wright and Rees, 1998; Kloner and Jennings, 2001). Myocardial oedema should thus be 
considered a secondary phenomenon and a downstream effect of the primary pathological 
processes involved in cardiac surgery requiring CPB. 
 
1.5.2 Functional consequences of myocardial oedema 
 
 Relatively small increases in myocardial fluid content have been associated with 
significant systolic ventricular dysfunction (Cross, 1961; Utley, 1974; Foglia, 1978; 
Goto, 1991; Carlson, 1992; Weng, 1992; Spotnitz, 1995; Allen, 1997; Geissler and Allen, 
1998; Albers, 2001; Jia, 2002). In one analysis, a 2.6% gain in myocardial water 
produced by hypo-osmotic priming solutions for CPB was associated with a 43% decline 
in left ventricular performance and a similar order of reduction in compliance (Foglia, 
1978). A second study demonstrated similar increases in myocardial water (↑3%) content 
impacting significantly on myocardial function (↓30%) (Laine and Allen, 1991).  
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Diastolic function has also been shown to be compromised in association with 
myocardial oedema (Pogatsa, 1976; Mavroudis and Ebert, 1978; Garcia-Dorado and 
Oliveras, 1993; Spotnitz and Hsu, 1994; Geissler and Allen, 1998; Jia, 2002). This could 
be particularly relevant in the paediatric setting following cardiac surgery, as many 
infants already have impaired diastolic function as a result of hypertrophy related to pre-
existing structural lesions.  
 
However the associations between oedema and dysfunction have been temporal only, 
with varied models, confounding variables – particularly ischaemia, and no established 
mechanistic links.  
 
1.5.3 Pathogenesis of myocardial oedema 
 
 Recently in an animal model of regional ischaemia it was postulated that oedema 
led to impaired myosin–actin interaction and resulted in stunning (Bragadeesh, 2008). 
This was an interesting finding and although it makes intuitive sense, it is still uncertain 
whether the oedema itself was responsible or merely a bystander event or process. 
Regional myocardial ischaemia was induced in pigs in short repeated bursts, with a 
duration totalling 50 minutes. Also associated with this was a decline in myocardial 
function measured by 2D echocardiography. Associated with this ischaemic insult was an 
increase in myocardial water of 10% and an increased distance between adjacent myosin 
contractile filaments on electron microscopy. After five days of observation there was no 
substantial improvement in myocardial function, but the extra myocardial water had 
declined to 5%. This divergence in the degree of dysfunction and degree of oedema 
suggests that other factors – namely the ischaemia, resulted in the contractile dysfunction 
and the oedema is merely a bystander phenomenon. Alternatively this 5% gain in 
myocardial water content (MWC) exceeded a threshold necessary for normal myocardial 
function. Ischaemia/reperfusion is a recognised cause of contractile injury leading to 
dysfunction through calcium excess and oxygen derived free radicals (Bolli and Marban, 
1999). The study by Bragadeesh et al did demonstrate a temporal relationship between 
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the onset of oedema and dysfunction in the heart, but the induced ischaemia confounded 
any plausible causative link between oedema and dysfunction(Bragadeesh, 2008). 
 
A recent study from a group who have done extensive work in the field appears to have 
been more helpful in elucidating the contribution of oedema to dysfunction. In an animal 
model of CPB with cardioplegia, it was found that oedema without injury to the 
myocardium – e.g. via I/R, did not result in dysfunction (Fischer, 2006). Myocardial 
oedema of the order of 2% was not associated with dysfunction when produced by either 
brief CPB ~ 12 minutes with cardioplegia or coronary sinus hypertension – a non-
ischaemic insult. So myocardial oedema occurring on CPB – with only brief ischaemia, 
was not associated with detectable myocardial dysfunction. Hence it follows that oedema 
of this degree did not have important functional implications. Suggesting that other 
factors – such as those implicated in causing stunning, are responsible for dysfunction 
and that oedema is a secondary phenomenon (Bolli and Marban, 1999). The two main 
purported causes of myocardial oedema are discussed below. 
 
1.5.3.1 Haemodilution 
 
 Haemodilution occurs in the context of CPB and cardiac surgery and has been 
shown to negatively impact on outcome (DeFoe, 2001; Jonas, 2003). Given the lowering 
of colloid osmotic pressure with CPB it is postulated that water transits into the 
interstitium of the tissues of the body and that interstitial oedema results (Rosenkranz, 
1980; Mehlhorn, 2001). Furthermore the occurrence of the so called capillary leak 
syndrome is considered to result in increased interstitial volumes and interstitial or 
vasogenic oedema (Farstad, 2004). This has been attributed to loss of albumin via the 
endothelium (Seghaye, 1996) and perhaps mediated by complement activation (Zhang, 
2005). Although there is a drop in colloid osmotic pressure (COP), this does not appear to 
be due to albumin loss and may reflect water movement instead (Tassani, 2001; Tassani, 
2002b; Farstad, 2004; Tassani, 2007). It has also been previously shown that interstitial 
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pressure increases following CPB – consistent with increased interstitial fluid volumes 
(Menninger, 1980). Supporting the movement of water as being intrinsic to interstitial or 
vasogenic oedema is the utility of modified ultrafiltration (MUF) in rapidly reducing 
myocardial wall thickness and haemodilution in clinical studies (Davies, 1998; 
Chaturvedi, 1999). MUF in the setting of cardiac surgery is carried out at the completion 
of the operation just prior to removal of the CPB circuit from the patient. Essentially the 
patients blood is passed through an artificial kidney (a series of microscopic membranes 
within a hollow tube) and water is removed down a osmotic gradient. This has the effect 
of reversing to some extent the haemodilution which occurs during CPB. 
 
1.5.3.2 Ischaemia and reperfusion 
 
 As in the recent work by Bragadeesh et al, myocardial oedema has been attributed 
to ischaemia and reperfusion injury (Garcia-Dorado and Oliveras, 1993; Spotnitz and 
Hsu, 1994; Palmer, 2004). In several species and models, myocellular oedema is evident 
if the ischaemic injury exceeds 15 – 20 minutes (Garcia-Dorado and Oliveras, 1993; 
Spotnitz and Hsu, 1994; Kloner and Jennings, 2001; Palmer, 2004). Swelling of 
organelles and in particular mitochondria is an early event, with mitochondria potentially 
having a role in myocardial stunning. Mitochondria are involved in preconditioning, 
liberation of reactive oxygen species and controlled cell death (apoptosis). The initial 
movement of water into mitochondria is thought to be part of the early protective 
response to ischaemia, countering the effect of mitochondrial matrix shrinkage that 
increases the inter-membrane space and is deleterious to respiration (Dos Santos, 2002). 
In this context, water is thought to move in response to an influx of K+ ions, as a result of 
mitoKATP channel opening. Chemical openers of this channel, such as diazoxide, have a 
cardioprotective effect, however the pore-forming proteins underlying this protective 
effect have yet to be identified (O'Rourke, 2004). 
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1.5.4 Myocardial oedema and mitochondria 
 
 After reperfusion, swelling of cardiac mitochondria occurs due to increased 
permeability of the inner mitochondrial membrane and is probably driven by the osmotic 
effect of accumulation of anionic proteins, monovalent cations, intermediates of the 
Krebs cycle and other small organic molecules (Beavis, 1985). This occurs even with the 
major ion channels closed, and is reversible with long periods of reperfusion (Bosetti, 
2004). Again, the route by which water travels in this setting is unknown. Excessive 
swelling may occur with opening of the mitochondrial permeability transition pore 
(mPTP) which allows non-selective movement of small molecules. This leads to 
irreversible loss of the mitochondrial membrane potential, uncoupling of the respiratory 
chain and release of cytochrome C, initiating apoptotic or necrotic cell death (Akao, 
2003). 
 
1.5.4.1 Mitochondria and aquaporins 
 
 In the kidney the inner mitochondrial membrane was found to contain AQPs, 
possibly AQP8, that allowed excessive swelling without mPTP opening (Lee, 2005). 
Chemical inhibitors of AQPs prevented mitochondrial swelling, organelle disruption and 
cell death. Thus it was considered that inwardly directed water movement into 
mitochondria may be beneficial early, then deleterious in subsequent stages of the 
mitochondrial response to ischaemia and reperfusion. Expression of mitochondrial AQPs 
has been reported in hepatic (Ferri, 2003; Calamita, 2005) and renal tissue (Lee, 2005). 
However more recently Yang et al suggested that AQPs in mitochondria have no 
functional relevance. Water permeability was similar in mitochondrial preparations from 
wild type and AQP knockout mice by stopped-flow light scattering. Furthermore the 
addition of mercury altered permeability similarly across groups and AQP8 was not 
expressed in hepatic mitochondrial preparations utilising wild-type/AQP8 null mice as 
positive/negative controls (Yang, 2006). 
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1.6 Myocardial aquaporins 
 
1.6.1 Background 
 
 The myocardial expression of AQPs is poorly characterised. Soon after the initial 
description of AQP1, it was noted that the cardiac microvasculature and the endocardium 
expressed this protein (Bondy, 1993). The abundance of AQP1 protein in cardiac tissue 
was thought to reflect the dense vascular supply of this organ, however early reports 
suggested that water channels did not play a major role in microvascular filtration in the 
heart (Suleymanian and Baumgarten, 1996). In normal circumstances, cardiomyocytes do 
not experience osmotic imbalance and to date, cardiac AQPs have not been investigated 
to the same extent as renal, pulmonary and brain AQPs. 
 
1.6.2 Myocardial aquaporins and the three compartment model 
 
 A contemporary view of myocardial AQP expression would include cells on both 
sides of the interstitial space, namely the endothelial barrier, as well as the sarcolemma of 
the cardiomyocyte. Evidence of a functional role for AQP1 expression in endothelial 
cells has been outlined earlier (Ogura, 2002b; Kellen and Bassingthwaighte, 2003a, b). 
Myocellular expression has been noted in rat cardiomyocytes, (Page, 1998), with 
functional interactions demonstrated with caveolae in response to changes in the osmotic 
environment. Our group has demonstrated AQP1 expression within t-tubules (Au, 2004), 
themselves invaginations of the sarcolemma extending into the myocardium within the Z 
line structures, (Figure 1.1). Ionic fluxes, particularly relevant to Ca2+ homeostasis are 
fundamental to electromechanical coupling and K+ flux is involved in attenuating the 
cardiac action potential. These ionic fluxes may require accompanying rapid osmotic 
equilibration, although the potential role of AQPs in this context has not been established. 
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1.6.3 Myocardial aquaporins and potassium 
 
 Links between potassium and water transport are evident in the glial cells of the 
brain, with the possibility that such interactions may also be relevant in the heart. AQP4 
has been shown to co-localise with the Kir4.1, potassium channel in astrocyte end feet 
(Nagelhus, 2004) and this interaction involves the dystrophin-associated proteins (DAP) 
(Guadagno and Moukhles, 2004). Loss of DAP integrity reduces AQP4 expression and 
the clearance of extracellular potassium leading to seizures (Amiry-Moghaddam and 
Ottersen, 2003; Dudek and Rogawski, 2005). In the eye, co-localisation of Kir4.1, AQP4 
and DAP has also been demonstrated (Connors and Kofuji, 2006) and reduced expression 
of AQP4 and Kir4.1 channels may contribute to proliferative retinopathy following 
disruption to the retinal blood supply, occurring with retinal detachment (Tenckhoff, 
2005). Thus a link may exist between rapid potassium transport and water permeability at 
the sarcolemma, which impacts upon ionic balance and tolerance of ischaemia. AQP4, 
Kir4.1 potassium channels and the DAP complex are all present in the mouse heart 
although the role of cardiac AQPs in these processes has yet to be established.  
 
1.6.4 Aquaporin 1 and cardiac disease models 
 
 Two reports describe myocardial AQP1 expression in cardiac disease models. 
Jonker et al. demonstrated up-regulation of myocardial AQP1 mRNA and protein 
expression in a model of chronic foetal haemodilution (Jonker, 2003). 
Immunohistochemistry showed AQP1 mostly within the vasculature and comparatively 
little within cardiomyocytes. It is not known whether the observed increase in AQP1 
expression acts to increase interstitial oedema or facilitates clearance through movement 
of water back through endothelial cells into the vascular compartment.  
 
 
 26
The second study of AQP1 in a model of clinical practice focused on the effect of CPB in 
the lamb (Tabbutt, 1997b). In this study lambs underwent CPB and DHCA with six hours 
of reperfusion, following which AQP1 mRNA levels were unchanged. Of note in this 
study was the utilisation of an operative technique now not commonly employed 
(DHCA) and which is also associated with less tissue oedema (Wernovsky, 1995). AQP1 
mRNA abundance was also not correlated with protein expression, myocardial oedema or 
myocardial function. It remains unclear what effect current CPB techniques might have 
on expression of AQP1 and how this may affect myocardial oedema and function. We 
viewed these two studies as preliminary in terms of investigating the mechanisms 
involved in this setting. 
 
1.6.5 Other myocardial aquaporins  
 
 A number of AQPs in addition to AQP1 have been identified in myocardial tissue. 
Most reports have focused on the identification of relevant mRNA by PCR without 
correlation with protein expression or site of expression. While many AQP mRNAs are 
present in the heart, protein is detectable for only a few of them and AQP1 expression is 
the most prominent in immunohistochemical studies (Au, 2004). The expression of AQPs 
within the heart is summarised below, (Table 1.1). 
 
There are limited published data on human myocardial AQP expression, other than 
AQP1. AQP3 transcript was identified by microarray, but without the positive staining by 
immunohistochemistry as shown for other tissues in the study (Mobasheri, 2005). In an 
earlier report AQP3 was not found in myocardium using Northern analysis (Ishibashi, 
1995). AQP4 mRNA has also been identified by Northern analysis (Yang, 1995). AQP4 
is of particular interest due to the noted loss of AQP4 expression in muscular dystrophies 
associated with the loss of dystrophin (Frigeri, 2004) and the cardiomyopathy occurring 
with such diseases (Muntoni, 2003). Human cardiac AQP7 mRNA expression has been 
identified (Kuriyama, 1997; Ishibashi, 1998b) and may be derived from cardiac 
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associated adipose tissue where AQP7 is well described. Screens of human myocardial 
tissue by PCR using degenerate primers based on the Asparagine-Proline-Alanine (NPA) 
motif common to many AQPs failed to demonstrate any novel AQPs in the heart (Au, 
2004) although low levels of expression may limit the usefulness of this strategy.  
 
In the hearts of other species, numerous AQPs have been found. AQP7 has been found 
within the capillaries of adipose tissue associated with cardiac tissue. AQP7 which also 
permits glycerol transport, has been shown to be important in avoiding obesity in mice, 
but its role in adipose tissue remains to be determined (Hibuse, 2005; Skowronski, 2007). 
AQP8 is reported within the mitochondrial fraction of rat heart by Western blot 
(Calamita, 2005), but is reportedly absent in this species by Northern analysis (Ishibashi, 
1997b; Koyama, 1997). AQP8 would be interesting, if it indeed was myocardial and 
mitochondrial in location, but in functional and expression analysis using knockout tissue 
there is no apparent expression or function of any AQPs in mitochondria (Yang, 2006). 
 28
Table 1.1: Myocardial aquaporin expression 
  
Human 
 
Sheep 
 
Rat 
 
Mouse 
AQP0     
AQP1 PRESENT 
i)RT-PCR, IHC, Western – 
endothelial & myocellular 
distribution (Au, 2004) 
 
ii)Northern (Hasegawa, 
1994) 
 
PRESENT 
i)RNAse protection assay 
(Tabbutt, 1997b) 
 
 
 
ii)Northern, Western, IHC – 
endothelial and minimal 
myocellular distribution (Jonker, 
2003)  
 
 
 
PRESENT 
i) IHC – endothelial and 
myocellular distribution 
(Page, 1998) 
 
 
ii)RT-PCR, IHC, Western – 
endothelial and myocellular 
distribution (Au, 2004) 
 
iii)Western, Northern and 
autoradiography – 
endothelial (Bondy, 1993) 
 
iv)Northern (Hasegawa, 
1994) 
 
v)RNAse Protection Assay 
(Umenishi, 1996) 
vi)IHC – endothelial 
(Nielsen, 1993) 
 
PRESENT 
i) Western (Nejsum, 2000) 
AQP2 ABSENT 
i)Microarray and IHC 
(Mobasheri, 2005) 
 ABSENT 
i) RNAse protection assay 
(Umenishi, 1996) 
 
ABSENT 
i)Northern (Yang, 1999) 
 
AQP3 CONFLICTING 
REPORTS 
i)Microarray and IHC – 
present (Mobasheri, 2005) 
ii)Northern – absent 
(Ishibashi, 1995) 
 
 
 
ABSENT 
i & ii)Northern (Echevarria, 
1994; Ishibashi, 1994) 
 
iii) RNAse protection assay 
(Umenishi, 1996) 
 
AQP4 PRESENT 
i)Northern (Yang, 1995) 
 
 ABSENT 
i) RNAse Protection Assay 
(Umenishi, 1996) 
 
PRESENT 
i)Northern (Ma, 1996b) 
AQP5   ABSENT 
i & ii)RNAse protection 
assay (Umenishi, 1996; 
Funaki, 1998) 
ABSENT 
i)Northern (Krane, 1999) 
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Table 1.1: Myocardial aquaporin expression continued 
 
 
 
 
 
  
Human 
 
Sheep 
 
Rat 
 
Mouse 
AQP6 ABSENT 
i)Northern (Ma, 1996a) 
 
   
AQP7 PRESENT 
i & ii)Northern (Kuriyama, 1997; 
Ishibashi, 1998b) 
 PRESENT 
i & ii)Northern (Ishibashi, 1997a; 
Ishibashi, 1998b) 
PRESENT 
i)RT-PCR, western, 
IHC(Nejsum, 2000; 
Skowronski, 2007) 
 
AQP8 ABSENT 
i)Northern (Koyama, 1998) 
 
 CONFLICTING REPORTS 
i & ii)Northern – absent (Ishibashi, 
1997b; Koyama, 1997) 
 
iii)Western – present (Calamita, 
2005) 
 
PRESENT 
i)Northern (Ma, 1997b) 
 
AQP9 ABSENT 
i)Northern (Ishibashi, 1998a) 
 
   
AQP10 ABSENT 
i) RNAse Protection assay 
(Hatakeyama, 2001) 
 
ii)Northern (Ishibashi, 2002) 
 
  ABSENT 
i)Northern (Morinaga, 
2002) 
AQP11    PRESENT 
i)Northern (Morishita, 
2005) 
 
AQP12    ABSENT 
i) RNA dot blot  (Itoh, 
2005) 
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1.6.6 Other aquaporin roles  
 
 AQP1 may transport CO2 as well as water and this could benefit the heart during 
metabolic stress (Nakhoul, 1998; Cooper, 2002; Miller, 2004). AQP1 expression in 
Xenopus oocytes increased CO2 permeability by 40% over controls and this increase was 
inhibited by blocking AQP1 function with mercury (Nakhoul, 1998). However 
physiologically relevant CO2  transport via AQPs could not be demonstrated during both 
normal and stressed states in erythrocytes, lung and kidney cells utilising relevant 
knockout mouse materials, despite water permeability being altered by more than 100 
fold (Yang, 2000; Fang, 2002; Verkman, 2002a, b; Miller, 2004). Thus physiologically 
important CO2 transport by AQPs within the heart seems unlikely, but has not been 
directly studied.  
 
Somewhat similarly, AQP1 is purported to transport nitric oxide (NO–). In isolated cell 
constructs, NO– transit was found to be increased in the presence of AQP1 and reduced in 
the presence of mercurials or with RNA interference. However, true controls in the form 
of knockout tissue were not available and the results remain intriguing at this stage, 
(Herrera, 2006). 
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1.7 Other myocardial membrane proteins 
 
1.7.1 Dystrophin 
 
 Given the membrane location of AQPs we sought to determine the contribution to 
LCOS of other myocardial membrane relevant proteins. Specifically we focused on 
dystrophin. Dystrophin was isolated in both skeletal and cardiac muscle in 1987 by Eric 
Hoffman and colleagues. It is absent in sufferers of Duchenne muscular dystrophy and 
was named after its isolation from the genetic locus of that inherited disease (Hoffman, 
1987). It is a large (427kDa) membrane imbedded protein which is important in 
mechanotransduction (force transfer) in muscle, linking the intracellular contractile 
apparatus with the extracellular attachments (McNally and MacLeod, 2005). The absence 
or loss of function of dystrophin is felt principally to affect muscle through loss of 
membrane integrity (Glover and Brown, 2007). Dystrophin has been shown to be 
abnormal (termed dystrophinopathy) in various more severe settings, i.e. 1) ischaemic 
cardiomyopathy, 2) Coxsackie B viral myocarditis and 3) Duchenne muscular dystrophy 
(Vatta, 2002; McNally and MacLeod, 2005; Lee, 2006).  
 
The role of dystrophin following CPB and in the setting of LCOS is unknown. 
Dystrophin has been shown in some animal models to be upregulated as a result of 
ischaemic preconditioning (Kido, 2004) and therefore may have a role in ameliorating 
LCOS.  
 
1.7.1.1 Dystrophin in ischaemic preconditioning 
 
 Ischaemic preconditioning (IPC) is the practice of training cardiac muscle to cope 
with ischaemia. Essentially I/R injury is lessened following a series of brief sequential 
ischaemic insults ~ four periods of 5 minutes, prior to a more sustained planned 
ischaemic event (Murry, 1986). This has been verified in a number of models over the 
last 20 years, although the exact mechanism remains to be determined and it has not 
become part of conventional practice (Peart and Headrick, 2008). Nevertheless, in two 
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small animal models IPC has been shown to be associated with both improved function 
and restoration of membrane dystrophin (Kido, 2004; Kyoi, 2006). 
 
1.7.1.2 Dystrophin in ischaemic and dilated cardiomyopathy 
 
 Investigators have found that dystrophin was important in the contractile 
dysfunction of end stage ischaemic and dilated cardiomyopathy (Vatta, 2002). In 18 of 20 
patients with severe cardiomyopathy, the amino terminus of dystrophin was affected. 
Interestingly this change was reversed in a smaller group of patients who had ventricular 
assist devices inserted (Vatta, 2004). The other two commonly tested domains of 
dystrophin – rod and carboxy-terminal, were not affected in this study. However in other 
comparable models, others have found the amino terminus and rod domains were both 
affected (Toyo-Oka, 2004). Hence it was concluded that impaired dystrophin was a 
common cytoskeletal mechanism for the resulting myocardial dysfunction seen in end 
stage cardiomyopathy. Such cardiomyopathies represent severe pathology and the degree 
to which abnormalities of dystrophin contribute to contractile dysfunction in the setting 
of post CPB cannot be inferred. 
 
1.7.2 Dysferlin 
 
 Whilst dystrophin is important to maintaining membrane integrity in response to 
injury, dysferlin has been shown to be a key protein in the restoration or repair of injured 
membranes in skeletal and cardiac muscle (Han, 2007; Han and Campbell, 2007). Thus 
dysferlin absence also leads to a dystrophy because of a diminished capacity for rapid 
muscle membrane repair after injury and or normal muscle use (Glover and Brown, 
2007). Dysferlin protein (230kDa) was discovered by Jing Liu and colleagues during 
their investigations using skeletal muscle and DNA from patients suffering from Miyoshi 
myopathy and limb girdle muscular dystrophy (LGMD). It was named because of its 
dystrophy association and similarities to a previously found protein called fer–1. Fer–1 is 
a similarly large protein which is involved in membrane fusion and mobility in 
spermatozoa of C. elegans (Liu, 1998). A partial or complete absence of dysferlin in 
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humans is responsible for Miyoshi myopathy and LGMD2B. Both diseases present with 
weakness and atrophy of proximal skeletal muscles, elevated creatinine kinase (CK) and 
have slowly progressive courses (Glover and Brown, 2007). Both conditions have 
generally been accepted as not having a cardiac phenotype – until recently. A case report 
of cardiomyopathy in a patient with LGMD2B (Kuru, 2004) was followed by a case 
series in which two of seven patients had congestive cardiac failure (Wenzel, 2007). 
Wenzel et al have also shown in a mouse model that dysferlin deficient mice have a poor 
response to an inotrope induced stress, exhibit deficiencies in cardiomyocyte membrane 
integrity and develop a cardiomyopathy – in agreement with the work by Han et al (Han, 
2007).  
 
Dysferlin has been demonstrated to mediate the sealing of breaches in muscle cell 
membranes. Dysferlin facilitates the docking and fusion of a membrane patch into a 
membrane defect and has been found to have important protein interrelationships with 
Caveolin-3, Calpain 3 and Affixin (Glover and Brown, 2007). In dystrophin deficient 
mice, skeletal muscle membrane injury occurred when they were exercised, and dysferlin 
laden vesicles were shown to be vital in repairing these membrane defects. It was 
demonstrated that dysferlin was integral to membrane repair mechanisms in skeletal 
muscle (Bansal, 2003). A similar response to myocardial membrane injury was seen – 
with dysferlin having a role in repairing defects in cardiac cell membranes. It was 
remarked that dysferlin mediated membrane repair was indispensable for maintaining the 
sarcolemma integrity of cardiomyocytes (Han, 2007). Dysferlin has been shown to be 
expressed in endothelial cells within the brain and associated with increased permeability 
in inflamed areas of the brain in multiple sclerosis (Hochmeister, 2006). Interestingly this 
endothelial expression could be induced by tumour necrosis factor, which incidentally is 
known to be increased in the setting of CPB and I/R (Wan, 1997; Hochmeister, 2006). 
Although dysferlin has not been described in muscle endothelium, the response of 
dysferlin to the potentially membrane injuring effects of CPB and I/R has not been 
determined.  
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Given that dysferlin is considered an important membrane reparative protein and whilst 
studying the impact of CPB and I/R on membrane integrity, we also tested the role of a 
pharmacological membrane protecting agent – Poloxamer 188, in this setting.  
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1.8 Poloxamer 188 
 
 Poloxamer 188 (P188), with a MW of 8400 is a non–ionic copolymer surfactant. 
It has hydrophilic and hydrophobic moieties which insulate hydrophobic substances such 
as fibrin, reducing aggregation, blood viscosity and improving blood flow (Hunter, 1990; 
Fatkin, 1997). This insulating attribute also appears to confer membrane sealing or 
protecting properties (Maskarinec, 2002). It has been used in a number of human clinical 
settings on the basis of its effects. The main proposed effects of P188 can be categorised 
into 2 groups. Firstly, haemorheological effects have seen it used to improve viscosity 
and improve small vessel blood flow in the setting of myocardial ischaemia, 
thromboembolic disease and sickle cell anaemia (Schaer, 1994; Adams-Graves, 1997; 
Fatkin, 1997). Secondly, membrane protection or repair effects have seen it used in 
models of electrocution, cerebral ischaemia, myocardial membrane fragility and muscular 
dystrophy (Colbassani, 1989; Lee, 1999; Yasuda, 2005; Ng, 2008). The impressively 
short timeframe over which myocardial function improved in vivo in dystrophin deficient 
mice in the study by Yasuda et al prompted us to explore it in LCOS. We further 
considered it was a reasonable therapy to trial given its myriad of potential beneficial 
effects in the setting of CPB and its safety profile in human studies (Adams-Graves, 
1997; Yusuf, 1997). 
 
1.8.1 Haemorheological studies 
 
 P188 has been demonstrated in vitro to improve blood viscosity following 
coronary artery bypass surgery using CPB. Uniquely it appears able to reduce viscosity, 
without causing haemodilution. This has been attributed to its lubrication of endothelial 
cells and its ability to reduce adhesiveness of fibrin, platelets and other cellular elements 
without causing haemodilution (Hunter, 1990; Fatkin, 1997). Early experimental use was 
in the setting of frost bite where sludging and rouleaux formation is problematic and 
tissue viability is reduced (Knize, 1969). Fatkin et al in an in vitro study of blood 
echogenicity demonstrated reduced red blood cell rouleaux formation with P188, 
confirming this proposed mechanism of action (Fatkin, 1997). Because of these attributes 
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P188 has progressed to phase three human trials in the setting of sickle cell disease. It 
appears particularly beneficial in reducing the duration and pain of sickle crises in 
younger patients (Gibbs and Hagemann, 2004). In an initial trial of 50 patients it was 
found to be well tolerated. It significantly reduced the duration and pain of a sickle crises 
as well as reduced the total analgesic use and duration of hospitalisation. It was 
considered to potentially offer benefit in this difficult setting (Adams-Graves, 1997). 
 
Because P188 may reduce red blood cell aggregation, it is considered to have some 
benefits in reducing thromboembolic phenomena (Fatkin, 1997). It has been trialled as an 
adjunctive agent in an animal model of myocardial infarction (Schaer, 1994). P188 was 
administered during a focal myocardial ischaemic insult – prior to reperfusion in a series 
of dogs. P188 administration was associated with a significant reduction (42%) in infarct 
size. There was also an associated improvement in renal function as well as 
improvements in global (ejection fraction was 10% better) and regional ventricular 
function compared with controls. The authors also confirmed in vitro work that found 
neutrophil adherence was inhibited by P188 and this was considered an important 
element of the mechanism of P188 in this setting (Lane and Lamkin, 1984). Somewhat 
concerningly, the associated effect of P188 on reducing neutrophil activity was supported 
by later work, where it was found to increase sepsis in mice receiving Fluosol – an 
artificial blood substitute of which P188 is a component (Lane and Lamkin, 1986). 
Nevertheless Schaer et al proceeded with a clinical trial based on their large animal study 
and randomised 114 patients with acute myocardial infarction to P188 or placebo in 
addition to conventional thrombolytic therapy (Schaer, 1996). The results of this study 
demonstrated a significant associated benefit with P188 in terms of reduced infarct size 
(38%) based on nuclear medicine studies and improved function (ejection fraction 8% 
better). It was speculated that haemorheological mechanisms were the most likely 
explanation for its benefit. Subsequently an expanded large placebo controlled trial of 
P188 was undertaken (Yusuf, 1997). In this multicentre trial involving almost 3000 
patients, no benefits associated with P188 were found, when administered after the 
ischaemic event. There was no difference in infarct size or myocardial function. There 
was also some concern with regard to renal toxicity with measures of renal function being 
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worse in a subset of older patients with pre-existing renal impairment. It was concluded 
that P188 did not have any demonstrable benefits in this setting and that there were risks 
associated with its administration. We note however the heterogeneity of subjects and 
that treatment was post I/R injury.  
 
Whilst P188 continues to be explored in the clinical setting of sickle cell disease (Gibbs 
and Hagemann, 2004) its haemorheological effects have not been studied in the cardiac 
setting since it was found not to have benefit following acute myocardial infarction. 
However in parallel, work has been occurring on the membrane protecting attributes of 
P188 in various cardiac settings. Interestingly in one of the earliest myocardial infarction 
animal models Justicz et al administered P188 and Mannitol following regional infarction 
and demonstrated ~50% reduction in infarct size and improved function. The attributed 
mechanism was haemorheological, but because there were no differences in the blood 
flow between treatment groups, this was questioned. The authors speculated that because 
the Evans blue staining of the infarcted and adjacent regions was significantly reduced in 
the P188 treated animals, that P188 may have been associated with improving the 
integrity of the damaged myocardial membranes (Justicz, 1991). 
 
1.8.2 Membrane protection and repair studies 
 
 P188 has been shown in vitro to squeeze into defects in lipid monolayers and then 
to be extruded by the repaired membrane (Maskarinec, 2002). It has been used in 
experimental studies of electrical injury where electroporation of cell membranes occurs 
and it appears to improve membrane integrity in this setting (Lee, 1992). In animal 
skeletal muscle that was electropermeabilised there was improved functional and 
histological findings associated with P188 administration. In the P188 treated muscles 
there was also less oedema. The muscle cells performed particularly well if they were 
pretreated with P188 prior to electropermeabilisation.  
 
P188 was administered to dogs prior to 2½ hours of DHCA with brief CPB (Mezrow, 
1992). Because of the neurological concerns related to DHCA this was the focus of the 
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outcome measures, and those animals that received P188 prior to DHCA had an 
improved neurological outcome. It is unclear if there were any haemodynamic 
differences in the study. The authors speculated that mechanisms involving the protection 
of membranes may have resulted in these improvements(Mezrow, 1992). 
 
In an isolated heart model of sepsis induced dysfunction, membrane injury was 
associated with systolic and diastolic dysfunction. P188 was found to prevent the 
membrane induced injury as well as the associated contractile dysfunction. Importantly 
P188 was administered prior to the injury. It was considered that P188 had a role in 
sepsis induced cardiac injury, but to our knowledge it has not been trialled in humans in 
this context (Watanabe and Okada, 2003).  
 
Yasuda et al published the use of P188 in a dystrophin deficient mouse model and found 
in vivo and in vitro that it inferred a number of benefits. In isolated cardiomyocytes there 
was improved cell compliance and less stretch induced membrane damage and cell loss. 
Whilst in vivo there was rapidly improved diastolic function in the setting of inotrope 
induced myocardial stress, measured with pressure–volume loops. It was concluded that 
P188 may have a role as a chemical sealant in the setting of cardiac failure related to 
dystrophinopathy (Yasuda, 2005). Subsequently there have been two conflicting reports 
using P188 in the setting of skeletal muscle injury in dystrophin deficient mice. Soon 
after Yasuda et al, there was a report of exercise induced skeletal muscle injury in 
dystrophic mice being pretreated with P188 (Quinlan, 2006). There was no associated 
benefit in function or membrane leakiness with P188. This lack of effect was considered 
to possibly be due to excessive exercise, insufficient P188 availability/dose or perhaps 
differences between cardiac and skeletal muscle. Recently isolated skeletal muscles from 
dystrophin deficient mice were found in vitro to have restored force transfer and function 
with P188 therapy (Ng, 2008). The rapidity of effect and improved functional result was 
similar to that observed in the isolated cardiomyocytes by Yasuda et al and it also 
suggested benefit in skeletal muscle.    
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1.9 Summary 
 
 The occurrence and importance of the LCOS in the postoperative setting, together 
with the perceived causal association with total body and myocardial water accumulation 
warrants further investigation. The pathogenesis of myocardial oedema and its 
relationship to the premier perioperative insults of CPB and I/R also deserves study. 
Myocardial membrane proteins may have a role in this setting, in particular a group of 
water specific proteins – AQPs – have not been explored adequately. In other comparable 
settings membrane proteins – such as dystrophin and dysferlin – have roles and so merit 
investigation. Poloxamer 188 has been shown in an animal model of dystrophinopathy to 
rapidly improve myocardial function and its utility in the setting of CPB and I/R is not 
known. 
 
1.10 Specific aims of the thesis 
 
 1. To evaluate the relative importance of myocardial oedema and ischaemia in 
causing myocardial dysfunction. 
 2. To define the role of myocardial AQPs in the setting of myocardial oedema and 
dysfunction. 
 3. Determine the role of dystrophin and dysferlin in the setting of myocardial 
dysfunction. 
 4. Assess the effect of a membrane sealant (P188) in clinically relevant settings of 
myocardial dysfunction.  
 
The aim – to determine the relationship between function and oedema, was examined in 
three models – isolated cardiomyocytes (single isolated heart cells), isolated hearts (ex 
vivo rodent hearts with retrograde aortic perfusion) and a clinically relevant lamb CPB 
model. Incorporated into this was a study of the proteins of interest – AQPs, dystrophin 
and dysferlin. Finally, in vivo trials of a potential therapy – P188, were conducted, in 
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which we studied the functional responses to P188, as well as the effects of P188 upon 
oedema, ischaemia and the proteins of interest. 
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CHAPTER 2: METHODS  
 
Summary 
 
 Three related models were used to study dysfunction, ischaemia, oedema and 
membrane proteins in the myocardium. These were isolated cardiomyocytes, isolated 
hearts and a large animal CPB model. Preceding these models was a period of 
confirmation and characterisation of myocardial AQP expression. These methods are 
outlined in detail in this chapter, together with details of the techniques used in assessing 
myocardial water content (MWC) and the molecular biology techniques used. 
 
All projects were conceived as part of meetings involving the Kids Heart Research group. 
Experiments and figures were performed and prepared by myself unless noted in the 
figure legend as otherwise. The initial characterisation of myocardial aquaporins was 
greatly enhanced by collaboration with Professor Alan Verkman and the knockout mouse 
experiments conducted in his laboratory at the University of California, San Francisco by 
Dr Tanya Butler. Dr Tanya Butler took over the isolated cell work once it was established 
locally at the Children’s Hospital at Westmead. Dr Tanya Butler also performed the last 
two series of isolated heart experiments, following a period of observation and training. 
Having assisted in the development and establishment of these techniques locally, my 
main focus became conducting and analysing the two series of sheep experiments. 
 
2.1 Ethical approval 
 
2.1.1 Human muscle specimens 
 
 The Human Ethics Committee at The Children’s Hospital at Westmead approved 
the use of tissue for these studies. Human ventricular myocardium was obtained fresh 
from the operating theatre. Tissue normally discarded as part of corrective surgery for 
children with structural heart disease was used. Ventricular myocardium was most 
commonly obtained from the right ventricular outflow tract in children undergoing repair 
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for Tetralogy of Fallot. Samples from left ventricular outflow tract and inter-ventricular 
septum were also available. The tissue was obtained while the patient was on CPB after 
cardioplegic arrest of the heart. Specimens were immediately frozen in liquid nitrogen 
after resection, with a warm ischaemia time of around 30 seconds. Additional cardiac 
tissue was obtained from donor hearts that were not used for transplantation. Human 
skeletal muscle was obtained from a bank of tissue that included muscle with normal 
histology derived from children undergoing amputation for osteosarcoma. 
 
2.1.2 Animal experiments 
 
 The Animal Ethics Committees of The Children’s Hospital at Westmead and 
Western Sydney Area Health Service approved these studies and all animals received 
humane care in compliance with National Health and Medical Research Council animal 
care guidelines (NHMRC, 2004). The initial pilot isolated cardiomyocyte experiments 
performed at Victor Chang Cardiac Research Institute (VCCRI) with Dr Aisling 
McMahon were done under the auspices of the St Vincent’s Hospital and Garvan 
Institute of Medical Research Ethics Committee, and were in compliance with National 
Health and Medical Research Council animal care guidelines (NHMRC, 2004).  
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2.2 Molecular techniques 
 
2.2.1 Neonatal cardiac myocyte preparations 
 
 Primary cultures of cardiac myocytes were prepared from the hearts of neonatal 
Wistar rats using the Worthington Cardiomyocyte Isolation System (Worthington 
Biochemical Corp’, NJ, USA). Cells were prepared from two day old rats following the 
manufacturer’s instructions. The cells were plated onto plastic culture dishes coated with 
Type IV Collagen (Sigma-Aldrich, St Louis, MO, USA) at 7.5µg/ml and harvested at 
various times between zero and four days of culture. Spontaneous beating of the cells was 
observed from day one of culture. Isolation and culture of cardiac myocytes using this 
method produces cultures that are more than 90% pure with the major cellular 
contaminant being fibroblasts (Wagner, 1998).  
 
2.2.2 Subcellular fractionation for mitochondrial preparations 
 
 Mitochondrial and sarcolemmal membrane fractions were prepared from wild-
type mouse skeletal muscle and heart using OptiPrep gradients (Axis-Shield, Oslo, 
Norway) following the manufacturer’s methods. Fresh tissue was finely minced and then 
dispersed in ice-cold buffer [250 mM sucrose, 10 mM HEPES pH7.4, 1 mM EDTA, 
protease inhibitor cocktail] with a dounce homogeniser. Nuclei and whole cells were 
removed by centrifugation at 700g for 10 minutes (x2). The supernatant was then 
centrifuged for 10 minutes at 16,000g to produce a mitochondrial pellet. The supernatant 
of this spin was retained as the cytoplasmic/membrane fraction. The mitochondrial pellet 
was washed twice with homogenisation buffer. Each fraction was separately added to 
20% iodixanol in homogenizing buffer and centrifuged at 300,000g for two hours at 15°C 
to produce a continuous gradient. Fractions were retained and the membranes 
concentrated with further centrifugation at 100,000g for 30 minutes. Proteins were 
solubilised in equal concentration of 5x SDS sample buffer [240 mM Tris-HCl (pH6.8), 6 
mM EDTA, 6% SDS, 0.01% bromophenol blue, 3% β-mercaptoethanol] prior to Western 
analysis. 
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2.2.3 Water permeability measurements 
 
 Hearts from three mice were pooled, homogenised and membrane fractions 
purified by centrifugation through a discontinuous sucrose gradient as described 
previously (Yang, 1996). Membrane fractions were pelleted, resuspended at 
approximately 1 mg protein/ml in PBS and passed ten times through a 27-gauge needle. 
Stopped-flow measurements of vesicle osmotic water permeability were carried out on a 
Hi-Tech Sf-51 (Hi-Tech Co, Salisbury, UK) instrument with measurements repeated five 
to 10 times per group and repeated in two independent experiments. Membrane vesicles 
were subjected to a 140 mosM osmotic gradient by mixing with an equal volume of 280 
mM mannitol in PBS. The kinetics of decreasing vesicle volume was measured from the 
time course of 90 degree scattered light intensity at 530nm. The data were fitted to a 
single exponential function. The osmotic water permeability coefficient (Pf) was 
calculated as described previously by Verkman et al (Verkman, 1989). 
 
2.2.4 Western blot 
 
 For Western analysis of whole cell lysates, frozen tissue was homogenised in ice-
cold lysis buffer [50 mM Tris (pH8.0), 150 mM NaCl, 0.1% sodium n-dodecyl sulfate 
(SDS), 1% NP-40, 1 mM phenylmethyl sulfonyl fluoride (PMSF)] containing protease 
inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA) using a dounce homogeniser on 
ice. The homogenate was briefly spun at 1,000g to pellet cell debris. Protein 
concentrations were determined with Bio-Rad protein assay dye reagent concentrate 
(Hercules, CA, USA). The homogenates were mixed with an equal volume of 5x SDS 
sample buffer before loading onto 12% SDS-PAGE gels. 
 
Electrophoresis was followed by transfer to PVDF Immobilon-P membranes (Millipore 
Australia, Sydney, NSW, Australia). Membranes were blocked then incubated with 
AQP1 (AQP11-A, 1:1000 dilution, Alpha Diagnostics, San Antonio, TX, USA), AQP3 
(sc-9885, 1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), AQP4 (sc-
9888, 1:1000 dilution, Santa Cruz Biotechnology), AQP5 (1:500 dilution, MERCK, 
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Boronia, VIC, Australia), AQP7 (sc-28625, 1:500 dilution, Santa Cruz Biotechnology), 
mitochondrial porin (1:3000 dilution, Molecular Probes, Invitrogen, Carlasbad, CA, 
USA), β-dystroglycan (1:250 dilution, Novocastra Laboratories, Newcastle upon Tyne, 
UK), cardiac/skeletal actin (5c5, 1:3000 dilution, Sigma-Aldrich) or VE-cadherin (sc-
6458, 1:1000 dilution, Santa Cruz Biotechnology) antibodies. Secondary antibodies were 
horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology), 
donkey anti-rabbit IgG (Amersham Biosciences, Rydalmere, NSW, Australia) or sheep 
anti-mouse IgG (Amersham Biosciences) and the signal was visualised using ECL 
(Amersham Biosciences). 
 
2.2.5 Membrane separation technique for dystrophin, dysferlin and caspase 3  
 
 Membrane preparations were prepared according to the published method of Kido 
et al (Kido, 2004) following ultracentrifugation and then run as previously described for 
Western blots. Membranes were probed with the following primary antibodies for 
dystrophin: MANDRA-1 (1:250); (Sigma-Aldrich) for the C terminus, Dys1 (1:200); 
(Novocastra) for the rod domain and Dys3 (1:20); (Novocastra) for the N-terminus, with 
appropriate positive and negative controls (Vatta, 2002; Kido, 2004; Rodriguez, 2005). 
Dysferlin was detected with the antibody Hamlet1(1:200); (Novocastra). Loading was 
controlled with an antibody to α-actinin-2 (4B3; affinity-purified rabbit; 1:200,000; 
kindly provided by Alan Beggs, Boston, MA, USA).  
 
2.2.6 Immunohistochemistry 
 
 Cryosections 8μm thick were fixed with 3% formaldehyde in PBS, washed and 
incubated in blocking buffer (PBS containing 2% serum). AQP4 (sc-20812; 1:50 dilution, 
Santa Cruz Biotechnology), AQP1 (AQP11-A, 1:1000 dilution, Alpha Diagnostics) or α-
sarcomeric actinin (EA53, 1:400 dilution, Sigma-Aldrich) antibodies were applied for 
one hour. Samples were washed then incubated with Cy3-conjugated donkey anti-goat or 
donkey anti-rabbit IgG (1:250 dilution, Jackson ImmunoResearch Laboratories, West 
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Grove, PA, USA). Samples were washed and mounted onto glass slides using Immu-
Mount (Shandon, Pittsburgh, PA, USA). 
 
2.2.7 Quantitative RT-PCR 
 
 Quantitative RT-PCR (qRT-PCR) was performed with LUX primers (Invitrogen, 
Carlsbad, CA, USA) for rat AQP1 (5’-CAACGTGTGTGGGAGCCATCG[JOE]TG-3’; 
5’-CCAGGTCATTTCGGCCAAG-3’), for sheep AQP1 (5’-CGA GAT CGC CAC TGT 
CAT CCT CT[FAM]G-3’; 5’-CAT TGA GGC CAA GCG AGT TG-3’). For rat AQP4 
(5’-CAC TTA GAG GCG GTG GGG TAA G[JOE]G-3’; 5’-TTG AGT CCA GAC GCC 
TTT GA-3’), for sheep AQP4 (5’-GAC AGA AGA AAA GCC ATT ACC TGT[FAM]G-
3’; 5’-GAT GCT GAG TCC AAA GCA GAG G-3’) and r18S (5’-GAC CTG CCG AGA 
TTG AGC AAT AAC AGG[FAM]C-3’; 5’-GTA GGG TAG GCA CAC GCT GAG-3’) 
using the Platinum PCR SuperMix-UDG kit. All samples were run in duplicate. AQP 
levels were quantified during 45 cycles using a Corbett Research Rotor-Gene RG 3000A 
(Mortlake, NSW, Australia) and analysis was performed using Rotor-Gene Real Time 
Analysis Version 6.0 (Corbett Research, 2004). mRNA levels were quantified using r18S 
RNA to normalise the raw AQP signals, this is the preferred house keeping gene in the 
setting of ischaemia (Jenner, 2004). Quantification of transcript was achieved through use 
of appropriate standard curves for mRNA of r18S and gene of interest. The Delta delta 
method of quantification was then utilised – essentially this calculates a fold change in 
gene of interest after first measuring the change in gene of interest transcript from 
baseline tissue (e.g. control) less the change in r18S RNA in these 2 tissue samples 
(Jenner, 2004). 
 
2.2.8 Apoptosis 
 
 Assessment of apoptotic cell death was performed with a TUNEL assay (TdT-
mediated dUTP Nick-End Labelling) using the In Situ Cell Death Detection Kit (Roche, 
Basal, Switzerland). Positively labelled cells vs. total cells were counted to quantify cell 
death. The entire slide was scanned at high power magnification by an observer blinded 
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to animal allocation. Haematoxylin and eosin (H+E) stained slides were also reviewed in 
a blinded fashion to review tissue integrity and exclude necrosis. Western blots for active 
caspase 3 were prepared using cytoplasmic fractions obtained as part of the separation 
technique (Kido, 2004). These were then probed using the caspase 3 antibody (active 
rabbit anti-caspase 3, 1:2000, BD Pharmingen, BD Biosciences, North Ryde, NSW, 
Australia). 
 
2.2.9 Myocardial membrane integrity 
 
2.2.9.1 Evans blue analysis 
 
 Paraformaldehyde immersed sections were cut and mounted on slides by Aysen 
Yuksel of histopathology at the Millennium institute, (Westmead, NSW, Australia). 
Evans Blue staining of the myocardium was assessed as an estimation of extracellular 
water accumulation and membrane integrity (blinded to allocation) by reviewing 5 –
100X fields and staining rated as abundant – (2), present – (1) or absent – (0). 
 
2.2.9.2 Creatinine kinase 
  
 Blood was drawn from lambs having CPB post anaesthetic induction and then 6hr 
post CPB for total CK. This was transported at 4ºC to the Biochemistry department at the 
Children’s Hospital at Westmead and CK measured by the production of ATP in a 
coupled enzyme reaction using the Vitros CK Slide method on a Vitros Fusion 5.1 
(Ortho-Clinical Diagnostics, Beerse, Belgium).  
 
2.2.9.3 Troponin 
 
 Plasma troponin T was measured in lambs having CPB post anaesthetic induction 
and then 6 hr post CPB. Collected blood was immediately spun for 15 minutes at 5000g 
and stored briefly at 4ºC, prior to being frozen at 80ºC prior to measurement. 
Measurement was performed at the Institute of Clinical Pathology & Medical Research, 
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Westmead Hospital, (Westmead, NSW, Australia). Measurement of troponin T was by an 
electrochemiluminescence immunoassay conducted on the Roche E170 machine, (Roche, 
Mannhein, Germany). 
 
2.2.10 Myocardial water content – desiccation 
 
 Samples of intraventricular septum, left and right free walls were weighed after 
blotting. They were then dried at ~80ºC for 48 hours in an oven (Hybaid limited, 
Hampshire, UK) or until their weight was static. Myocardial water content was then 
calculated by [weight(wet)–weight(dry)]/weight(wet) and expressed as a proportion (Jia, 
2002). 
 
2.2.11 Colloid osmotic pressure 
 
 Colloid osmotic pressure (COP) was measured using plasma from lambs having 
CPB. About 3ml of blood was placed in a glass heparinised test tube and spun at room 
temperature for 10 minutes at 5000g. Plasma (150-200μl) was pipetted into a plastic test 
tube and COP measured in mmHg, using the OSMOMAT 050 (Gonotec, Berline, 
Germany). 
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2.3 Isolated cardiomyocytes  
 
2.3.1 Introduction 
 
 Isolated cardiomyocytes – obtained by digestion of the extracellular myocardial 
mass – allowed the manipulation and study of the unfettered contractile apparatus. This 
model enabled us to study the contractile response of the cell to oedema and ischaemia 
inducing insults. In conjunction we were also able to determine any change in cell size in 
response to these stresses. Thus we gained an insight into the effects of these insults on 
the contractile machinery of the heart. The limitations of this model relate to its 
remoteness from the in vivo state and that it also requires a substantial amount of capital 
investment to establish. Consequently our initial pilot experiments were undertaken at the 
VCCRI to establish proof of principle, prior to establishing the model at The Children’s 
Hospital at Westmead. 
 
2.3.2 Mouse cells at Victor Chang Cardiac Research Institute  
 
 Mice were wild type C57B16 x 129/Sv and housed at the Garvan Institute of 
Medical Research in Sydney, Australia. Animals were caged with up to four other mice. 
They were fed standard feed (irradiated mouse pellets, Gordon’s Specialty Stock feed, 
Yanderra, NSW, Australia) and acidified water. Facility temperature was maintained at 
19-20ºC, humidity was 50% and there was a split 12hr light day cycle. 
 
2.3.2.1 Anaesthesia and perfusion 
 
 The mice received intraperitoneal heparin 5U/g (1000U/ml, AstraZeneca, North 
Ryde, NSW, Australia). Anaesthesia was then given 20 minutes later by intraperitoneal 
injection (0.0025ml/g) of a xylazine (20mg/ml) and ketamine (100mg/ml) mix. This mix 
consisted of 1mg of xylazine (Ilium Xlazil-20, Troy Lab. P/L, Smithfield, NSW, 
Australia), 4.35g of ketamine (Ilium Ketamil, Troy Lab. P/L, Smithfield, Australia) and 
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was reconstituted to 0.5ml with heparinised saline (Heparin Sodium, 50U/5ml, 
AstraZeneca, North Ryde, NSW, Australia).     
 
2.3.2.2 Digestion and preparation 
 
 The heart was removed via sternotomy from the anaesthetised mouse. The heart 
was placed in semi-frozen Krebs buffer in a plastic dish. The aorta was identified under a 
dissecting microscope and cannulated – with the tip of the cannula secured by 3.0 silk 
suture, just distal to the aortic valve, (Figure 2.5B). 
 
The cannulated heart was attached to the Langendorff apparatus and the heart perfused at 
70mmHg with Krebs buffer containing 2mM[Ca2+] at 37ºC. Steady flow of ~3ml/min was 
maintained for five minutes. The perfusion was then switched for five minutes to the low 
calcium buffer inducing arrest. The protease medium (Protease type XXIV(P-8038, 8.8 
U/mg) was perfused for one minute – initiating tissue breakdown. The final collagenase/ 
hyaluronidase (Collagenase type II(CLS-2, 34.2U/mg)(Worthington Biochemical Corp., 
NJ, USA) and (Hyaluronidase Type I-S(H-3506,999U/mg) solution was then run for 10 
minutes, (Figure 2.2). The ventricles were removed, finely cut up and placed in a small 
flask containing 5ml fresh collagenase/ hyaluronidase. This was shaken for five minutes 
at 37ºC. The medium was strained via a 200μm gauze into a tube. This supernatant was 
then centrifuged at 15g for one minute. A loose cell pellet was collected and resuspended 
in Krebs buffer with increasing concentrations of calcium, from 200μM[Ca2+], 
500μM[Ca2+] and finally 1mM[Ca2+]. This solution was then placed in the microscope 
stage dish of the IonOptix setup (IonOptix, Milton, MA, USA), (Figure 2.2). 
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2.3.2.3 Microscope and image capture  
 
 The cells were placed in a shallow cell chamber (University NSW) on an inverted 
microscope (Eclipse TE200, Nikon, Japan) and after five minutes were viewed at 40X. 
Cells were perfused with gassed Krebs solution, pH 7.4, 1.25mM Ca2+ , 32ºC and 
perfusate inflow/outflow were controlled by 505DU (Watson Marlow, UK) and Minipuls 
3 (Gilson, France) pumps respectively. Perfusing solutions were kept at 32ºC in a water 
bath (Type 05, R.A.P, Montgomery, UK). Solutions used were a baseline isotonic Krebs 
buffer (sodium chloride 119mM, potassium chloride 4.7mM, magnesium sulphate 
0.94mM, potassium phosphate 1.2mM, sodium bicarbonate 25mM, glucose 11.5mM and 
calcium chloride 1mM) and then a hypotonic Tyrodes (sodium chloride 70mM, 
potassium chloride 5.4mM, magnesium chloride 1mM, Hepes 5mM, glucose 10mM, 
sucrose 70mM and calcium chloride 1.8mM (Ogura, 2002b)– they were substituted 10 
minutes each as the inflow perfusate. 
 
  
 
Figure 2.2: The VCCRI IonOptix isolated cardiomyocyte set up. 
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Cell images illuminated by the microscope red light (>620λ) were transmitted to the 
charge-coupled device (CCD)-camera, Myocam (IonOptix, Milton, MA, USA), sampling 
at 240Hz. Digital images of 20 cells per heart were captured at 60Hz and stored using an 
image capture program (Rapview, InoOptix, Milton, MA, USA). Cell length and width 
were measured using Image tool software (UTHSCSA, USA). 
 
Information pertaining to the methodology of studies performed at VCCRI was 
confirmed by reference to the PhD thesis of Ju Chiat Tan – who also assisted in these 
pilot experiments. His thesis is accessible at http://www.library.unsw.edu.au/~thesis/adt-
NUN/uploads/approved/adt-NUN20071010.103345/public/02whole.pdf 
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2.3.3 Rat cardiomyocytes at Children’s Hospital at Westmead 
 
 Adult male Wistar rats (200–400g) were housed, maximum four per cage in the 
Westmead Hospital Dept of Animal Care, Research Holding. They were fed a 
commercial balanced diet from Glenn Forest Specialty Feeds (Perth, WA, Australia). 
They had 12hr light/dark cycles, experienced ambient humidity and room temperature 
was maintained at 22 – 24ºC. 
 
2.3.3.1 Anaesthesia and perfusion 
 
 Wistar rats (200–350g) were anaesthetised with inhaled isoflurane (Aerrane, 
Baxter, Old Toongabbie, NSW, Australia). Sternotomy was performed, the heart excised 
and immediately placed in ice-cold Krebs buffer (Sigma-Aldrich, St Louis, MO, USA). 
All solutions were made with deionised and filtered (0.04μm) water (Merck, Kilsyth, 
VIC, Australia). Hearts were then cannulated on a modified Langendorff setup, (Figure 
2.3). In essence this consisted of custom made glassware (University of Queensland 
glassblowing services, Brisbane, QLD, Australia), tubing (Tygon Lab tubing, Cole-
Parmer Instrument Co, Ill, USA), tubing pump (Masterflex combo drive and easy load 
head, Cole-Parmer instrument, Barnant Co, Burlington, Ill, USA) and a water bath heater 
(Ratek thermoregulator, Ratek instruments, Boronia, VIC, Australia). Hearts were 
perfused at 6-8ml/min with oxygenated solutions warmed to 37ºC. Perfusion for five 
minutes with Krebs buffer was followed by five minutes perfusion with nominally 
calcium-free Tyrode’s buffer containing (in mmol/L) 140 NaCl, 5.4 KCl, 1MgCl2, 5 
HEPES, 20 taurine, 10 glucose. Digestion was then achieved by perfusion for 20 minutes 
with Tyrode’s buffer containing 1mg/ml collagenase type II (Worthington Biomedical, 
Lakewood, NJ, USA), 1mg/ml hyaluronidase type I (Sigma-Aldrich, St Louis, MO, 
USA) and 175μM CaCl2. 
 
Hearts were then removed from the apparatus, coarsely minced and subject to three times 
five minute rounds of digestion at 37ºC with gentle mechanical agitation. Cells were 
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filtered through a 180μm filter, pelleted by gravity and washed in Tyrode’s buffer 
containing increasing amounts of calcium to a final concentration of 1mM. 
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2.3.3.2 Digestion and preparation 
 
 Cardiomyocytes were placed in a custom chamber (IonOptix, Milton, MA, USA) 
on an inverted Nikon Eclipse TE2000U microscope (Coherent Scientific, Hilton, SA, 
Australia) and perfused at 1-2mL/min with buffers warmed in-line (Cell MicroControls, 
Norfolk, VA, USA) to 25ºC. Buffers for swelling studies were taken from the work of 
Ogura (Ogura, 2002b) with some modification. The primary buffer was Tyrode’s buffer 
containing (in mmol/L) 140 NaCl, 5.4 KCl, 1MgCl2, 5 HEPES, 10 glucose, 1 CaCl2, 
referred to as Isotonic (=1T). Tyrode’s buffer in which 35mM NaCl was replaced with 
70mM sucrose was referred to as LowNa Isotonic and Tyrode’s buffer with 35mM NaCl 
removed to make the solution hypotonic was referred to as 0.75T. This degree of 
hypotonicity was chosen as an estimate of the hypo-osmotic stress associated with 
ischaemia and modified from the extremes used by others (Suleymanian and Baumgarten, 
1996; Ogura, 2002b) to more closely reflect the subtle changes occurring during surgery 
and recovery in infants. Buffers for ischaemia experiments were taken from Lu et al (Lu, 
2005) and contained (in mmol/L) 140 NaCl, 5.4 KCl, 1MgCl2, 5 HEPES, 1 CaCl2, 2.5 
Na-lactate. Isotonic, LowNa Isotonic and 0.75T buffers were adjusted to pH 7.4 and 
oxygenated while the ischaemic buffer was adjusted to pH 6.8 and bubbled with 100% 
N2. 
 
2.3.3.3 Isolated cardiomyocyte functional analysis 
 
 Cardiomyocytes were loaded with Fura-2-AM (Invitrogen, Carlsbad, CA, USA) 
by incubation in a 5μM solution at room temperature for 10 minutes, followed by 
washing. Intracellular calcium was measured by exciting cardiomyocytes alternately at 
340 and 380nm and reading emission at 505nm. Function was measured using video-
based detection and calculation of sarcomere length (IonOptix, Milton, MA, USA), 
(Figure 2.4). Unloaded cells were paced (MyoPacer, IonOptix, Milton, MA, USA) to 
contract at a frequency of 1Hz while sarcomere length and Fura-2 transients were 
recorded. A minimum of 10 transients were averaged from each cell and treatment. 
Measures of sarcomere length and intracellular calcium analysed included resting 
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(diastolic) and peak (systolic) values, maximum departure and return velocities, the time 
of transient onset, peak time, and the constant tau describing calcium removal. Cells were 
excluded from analysis if they displayed membrane blebs, resting sarcomere lengths of 
less than 1.6μm, frequent spontaneous contractions without stimulation or less than 5% 
shortening. 
 
 
 
Figure 2.4: The Children’s Hospital at Westmead, IonOptix set up for cardiomyocyte 
imaging. 
 
2.3.3.4 Isolated cardiomyocyte experimental protocol 
 
 Cells were separated into three treatment groups. The numbers of cardiomyocytes 
per group ranged from 9-21 and were derived from four to six individual rats. Each 
treatment group consisted of a baseline, test, and recovery phase with functional 
parameters measured at the end of each phase.  
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For swelling studies, cells were first perfused with LowNa Isotonic buffer, followed by 
eight minutes in 0.75T buffer and recovery in LowNa Isotonic buffer for eight minutes. 
Control cells were perfused continuously with LowNa Isotonic buffer and recordings 
made at equivalent times with the test group.  
 
In ischaemic experiments, cells were perfused with Isotonic buffer followed by 10 
minutes in ischaemic buffer. Recovery was measured at three and 10 minutes of 
reperfusion in either LowNa isotonic buffer or 0.75T buffer.  
 
Cell area was calculated for all cells during diastole, using images captured at the end of 
each treatment time (baseline, test and recovery). Cell borders were manually traced and 
area in μm2 calculated using Image J (NIH, Bethesda, MD, USA). 
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2.4 Isolated heart (Langendorff) experiments  
 
2.4.1 Introduction 
 
 The Langendorff technique is an ingenious method of studying myocardial 
function, see Skrzypiec-Spring et al (Skrzypiec-Spring, 2007) for a recent review. A 
series of figures purpose drawn under our guidance by Animated Biomedical Productions 
(Westmead, NSW, Australia) below further outlines the technique, (Figure 2.5). 
 
2.4.2 Isolated heart perfusion and ischaemia 
 
 Rats were anaesthetised with inhaled isoflurane (Aerrane, Baxter, Old 
Toongabbie, NSW, Australia) and oxygen mixture and injected with 0.5ml heparin 
(Heparin sodium 5000U/5ml, Pharmacia, Bentley, WA, Australia) into the left renal vein. 
Thoracotomy was performed and the hearts rapidly excised and plunged into ice-cold 
Krebs-Helseleit perfusate solution [118 mM NaCl, 25 mM NaHCOB3 B, 4.8 mM KCl, 1.2 
mM KHB2 BPOB4 B, 1.2 mM MgSOB4 B, 11 mM glucose, 1.2 mM CaCl B2B]. Baseline control hearts 
(no perfusion) were processed immediately after removal from the animal. For perfused 
hearts, the aorta was cannulated and the hearts perfused via the ascending aorta using a 
Langendorff apparatus (Radnoti Glass Technology Inc., Monrovia, CA, USA) at a 
constant pressure of 80mmHg, (Figure 2.6). The perfusate was gassed with 95% OB2 B/5% 
COB2 B and maintained at 37ºC, (Figure 2.7). Thebesian vein drainage was vented with a 
polyethylene (PE) tubing, 0.90 x 0.50mm (Microtube extrusions, North Rocks, NSW, 
Australia) placed through the left ventricular apex. The left atrial appendage was 
removed and a latex balloon was placed in the left ventricle via the atrium. The balloon 
was connected to a pressure transducer (Capto, Skoppum, Norway) and filled with saline 
to produce an end-diastolic pressure of 5mmHg. The system was calibrated using a 
tracheal tube cuff pressure manometer (Mallinckrodt Medical, Athlone, Ireland). 
Measurements of left ventricular developed pressure (systolic and diastolic), contractility 
– change in pressure over change in time, minimum – (dP/dtBmin B) and heart rate were 
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collected online in real time PowerLab 8/30 (ADInstruments, Sydney, Australia), (Figure 
2.5 and 2.6). 
 
Individual hearts were only accepted if the intrinsic heart rate was above 200 beats/min 
and achieved a developed pressure > 100mmHg systolic pressure within twenty minutes 
of perfusion. 
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Figure 2.6: Rat Langendorff set up.  
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Figure 2.7: Crystalloid perfusate being gassed. 
 
2.4.3 Balloon design 
 
 Design was as per Dr Tamsin Jenner of Griffith University, (Gold Coast, 
Queensland, Australia). 
 
Latex from the thin end of a condom – with the lubricant rinsed off in soap and water was 
used. Silk suture – 3.0 (Sofsilk, Syneture, Norwalk, CT, USA), 21-guage x 1¼ needle 
(Terumo, Tokyo, Japan), 3ml syringe (Terumo, Elkton, MD, USA), and polyethylene 
(PE) tubing, 1.45 x 0.75mm (Microtube extrusions, North Rocks, NSW, Australia) were 
used in construction. A small 1-2mm wide flange was formed at one end of a 10cm 
length of PE tubing, the other end was carefully threaded over the 21-guage needle tip 
(this was carefully blunted prior by snipping off and filing the sharpest and most distal 
needlepoint). The tubing was placed flange first into the distal 3cm of the condom 
(excess latex having been discarded). A 15cm length of suture was tied around the 
condom/tubing about 8mm from the end of the condom – this was the approximate final 
length of the balloon and was suitable for a 200-400g rat. A half knot was tied on the 
front and a full knot secured on the back. The tubing was pulled back until the flange 
abutted the suture. The balloon was filled with saline via the needle/syringe, and bubbles  
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removed. Excess suture and latex were removed. The balloon was stored in water, in the 
dark and was used for ~ 1 month, (Figure 2.8 and 2.9).  
 
 
 
Figure 2.8: A distended latex balloon. 
 
 
 
Figure 2.9: Rat heart, with cannula and LV balloon in situ. Note heart is sitting above 
organ bath for the image. 
 
 
 66
2.4.4 Langendorff protocols 
 
2.4.4.1 Twenty minute ischaemia experiments 
 
 Hearts were removed from the anaesthetised animal, plunged into 4ºC buffer and 
then processed without being perfused to form the non perfused control group. The next 
group of animal hearts were first stabilised on the Langendorff set up for 20 minutes and 
processed immediately after this time to produce the 20 minute control group. An 
additional control group was produced by maintaining perfusion for an additional 100 
minutes.  
 
Hearts in the ischaemic treatment group received 20 minutes of perfusion followed by 20 
minutes of zero-flow ischaemia and 70 minutes of reperfusion.    
  
2.4.4.2 Poloxamer 188 – low dose study 
 
 The dose of P188 used was calculated to minimise free Poloxamer 188 (P188) 
and was based on work which suggested a lower dose ~50μM reduced free micelle 
formation (Maskarinec, 2002). Maskarinec et al found that P188 only inserted into 
damaged membranes at or below this concentration and that higher concentrations 
impeded this effect. They also found that non-specific sealing did not occur – only 
sealing of defects at relatively low doses. We chose this concentration of 50μM or 
0.42mg/ml – which was significantly less (~350 times) than that used clinically – 
150mg/ml (Adams-Graves, 1997). The P188 (3.36g) was mixed with the Krebs-Henseleit 
perfusate (8L) and delivered at constant pressure into the heart. Gassing of the perfusate 
in the presence of P188 led to bubble formation – this led to a gradual loss of perfusate – 
necessitating additional aliquots being made. It also meant that we were not blinded to 
the solution being delivered. Ischaemic duration for these hearts was 30 minutes. 
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2.4.4.3 Poloxamer 188 – high dose study 
 
 The dose used here was based on the conventional weight based human doses 
used in the various sickle cell (Adams-Graves, 1997) and myocardial infarction studies of 
300mg/kg using a concentration of P188 of 150mg/ml. The weight of the rat was used to 
calculate the dose/rate at 300mg/kg pre ischaemia. P188 was reconstituted in phosphate 
buffered saline (PBS) which was given without P188 for the placebo/ control arm. It was 
delivered as a constant infusion from an infusion pump into the perfusate line via a T 
piece connector. Infusion syringes were made independently, wrapped in foil and then the 
experiments were performed blinded to allocation. The allocation code was broken once 
analysis was complete. Ischaemic time for these hearts was 30 minutes. 
 
2.4.4.4 Thirty minute ischaemia and hypotonic experiments 
 
 Control non-perfused hearts were removed from the animals as for cannulated 
hearts but immediately processed without perfusion. For all other treatment groups, 
hearts were first stabilised for 20 minutes.  
 
Two main experimental designs were used to investigate the effect of i) osmotic or 
oncotic pressure changes, and ii) ischaemia.  
 
Mild osmotic and oncotic changes were produced following the methodology of Kellen 
and Bassingthwaighte (Kellen and Bassingthwaighte, 2003b). Hearts were perfused with 
Krebs buffer plus an additional infusion of 15mM NaCl + 30mM sucrose or 0.5% 
dextran. Hypotonicity was achieved by removing 35mM NaCl from the Krebs buffer. 
This produced a 0.75T hypotonic equivalent to that used in the cardiomyocyte 
experiments. Infusion of 70mM sucrose to the 0.75T Krebs produced isosmotic Krebs.  
 
For ischaemia experiments, hearts were perfused with Krebs buffer and baseline function 
was measured for 20 minutes followed by 30 minutes of zero-flow ischaemia and 50 
minutes of reperfusion. These were matched by a perfusion control group, produced by 
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maintaining perfusion for 100 minutes. At the end of perfusion, all hearts had MWC 
determined by desiccation. 
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2.5 Lamb cardiopulmonary bypass model 
 
2.5.1 Introduction 
 
 Time-mated Poll Dorset cross ewes from the University of NSW farms, (Hay, 
Riverina, NSW, Australia) were transported by road whilst 80-90 days gestation to 
holding pastures at Little Bay, Sydney, NSW. Shortly after they were transported by road 
to The Westmead Hospital Department of Animal Care, Vivarium. Ewes grazed on a 
large predominantly kikuyu pasture with shelter available and a fresh water river 
frontage. Water was supplied ad libitum and Lucerne hay was provided twice daily. 
Natural delivery of lambs occurred around term (~147days). Lambs were aged between 
three to 10 days of age for the first series of experiments and were 14–36 days of age for 
the subsequent P188 series. Animal weight was measured preoperatively and groups 
arranged to maintain statistically similar weight ranges. 
 
2.5.2 Obtaining blood for the cardiopulmonary bypass circuit 
 
 The maternal ewe was anaesthetised with isoflurane (Aerrane, Baxter, Old 
Toongabbie, NSW, Australia) and a 20-guage cannula (Terumo, Tokyo, Japan) inserted 
into a shaved forelimb vein. Ketamine 100mg, midazolam 1mg, 5000U heparin (Heparin 
sodium 5000U/5ml, Pharmacia, Bentley, WA, Australia) was given. Isoflurane was 
maintained and ketamine and midazolam given as required to maintain anaesthesia. The 
ewe was nursed in the lateral decubitus position, slightly head up on a mobile lift trolley. 
The trolley was raised to one metre from the ground. The neck was shaved and a 12-
guage cannula (Terumo, Tokyo, Japan) was secured in an internal jugular vein. The 
cannula was connected to a 450ml blood collection bag (Baxter, Old Toongabbie, NSW, 
Australia). Venous blood drained via the cannula serially into three blood collection bags. 
A terminal dose, 150mg/kg of pentobarbitone (Lethobarb, 325mg/ml, Virbac Animal 
Health, Peakhurst, NSW, Australia) was then given into the jugular vein. The three units 
of blood was utilised to create the blood cardioplegia (one unit) and to prime the CPB 
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circuit (two units), (Figure 2.10). Any remaining blood was used for colloid replacement 
post CPB for chest drain losses mainly. 
 
 
Figure 2.10: Sheep blood cardioplegia being cooled to 4°C. 
 
2.5.3 Experimental preparation 
 
 Neonatal lambs were anaesthetised by spontaneously breathing isoflurane 
(Aerrane, Baxter, Old Toongabbie, NSW, Australia) and given IVI ketamine (1mg/kg), 
(Ketalar, Pfizer, West Ryde, NSW, Australia) and midazolam (100mcg/kg), (Hypnovel, 
Roche, Dee Why, NSW, Australia). The lamb was intubated with a 5.5mm cuffed 
endotracheal tube (Mallinckrodt Medical, Athlone, Ireland). Ventilation was maintained 
with a Campbell ventilator (ULCO, Marrickville, NSW, Australia) aiming for 
physiologically normal oxygen saturations (100%) and paCO2 (40–45mmHg) – typical 
ventilation parameters were 20–25/5cmH2O in 100% oxygen, (Figure 2.11). General 
anaesthesia was maintained with inhaled isoflurane (0.1–1%) continuously via the circuit, 
intermittent ketamine, midazolam and pancuronium (Faulding Pharmaceuticals, 
Melbourne, VIC, Australia), were also administered as required. Intravenous 
flucloxacillin (25mg/kg), (Faulding Pharmaceuticals, Melbourne, VIC, Australia), was 
given sixth hourly.  
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A three lumen 5.5Fr 13cm central line (Arrow, Reading, PA, USA) was placed 
percutaneously into the right internal jugular vein. A single lumen 20cm 3Fr catheter 
(Cook, Bloomington, IN, USA) was inserted percutaneously into the right femoral artery, 
(Figure 2.12). Cutaneous three lead electrocardiograph (ECG), rectal temperature probe, 
central venous pressure and intra–arterial pressure were monitored continuously. Venous 
and arterial blood gases were taken regularly. 
 
   
 
Figure 2.11: Lamb anaesthesia. Left, is a lamb being breathed down with a mask and 
circuit. On the right is an intubated lamb, with monitoring in situ. 
 
   
 
Figure 2.12: Invasive lines in the sheep. Left is a 3Fr femoral (right) arterial line. On the 
right is the jugular (right) triple lumen central venous line.  
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2.5.4 Cardiopulmonary bypass technique 
 
2.5.4.1 Initial series 
 
 Midline sternotomy was performed and the pericardium opened. CPB was 
established after heparin (Heparin sodium 5000U/5ml, Pharmacia, Bentley, WA, 
Australia) administration (400U/kg) with right atrial and ascending aorta cannulation. 
The activated clotting time (ACT) was checked 20-30 minutely and maintained over 400 
seconds with bolus doses of heparin. ACT was checked on a Hemochron Jr. Signature 
(ITC, Edison, NJ, USA), using Hemochron ACT+ cuvettes (ITC, Edison, NJ, USA). The 
extracorporeal circuit was established using a heart lung machine (Cobe, Arvada, CO, 
USA). A standard ¼-¼ or ¼-⅜ inch bypass circuit was used connected to a Terumo RX5 
or SX10 oxygenator with an open venous reservoir and Terumo Capiox AF02 arterial 
filter (Terumo, Tokyo, Japan). About 90% of the bypass circuit prime volume comprised 
of maternal sheep blood and about 10% of Baxter Plasma Lyte-148-Replacement fluid 
(Baxter, Old Toongabbie, NSW, Australia) buffered with sodium bicarbonate and about 
three units of heparin per ml of prime fluid. Nonpulsatile flow rates were adjusted to 
maintain a flow rate of about 150ml/kg/min and the mean systemic pressures between 
30–40mmHg. If necessary the isoflurane dose was also varied to maintain the desired 
blood pressure range. The lambs body core temperature was slowly lowered to 28–30°C, 
via a heater cooler unit (Conair-Churchill, Pittsburgh, PA, USA), (Figures 2.13, 2.14 and 
2.15).  
 
In the CPB+AXC group, following establishment of CPB, the aorta was cross clamped 
and blood cardioplegia at 4°C was administered 20ml/kg into the proximal ascending 
aorta. The cardioplegia comprised of a 4:1 blood to crystalloid mix. The average 
composition was pH 7.4, pCO2 30mmHg, pO2 70mmHg, K 19mmol/L, Ca 0.8mmol/L, 
bicarbonate 17mmol/L and haematocrit 12%. This was delivered 20 minutely into the 
aortic root for 90 minutes at which point bypass was weaned and the native circulation 
re–established. The average composition of the initial CPB machine prime, which did not 
 73
significantly differ between treatment groups was pH 7.6, pCO2 24mmHg, pO2 
202mmHg, haematocrit 21%, K 4.4mmol/L, Ca 0.4mmol/L and bicarbonate 21mmol/L. 
 
 
 
Figure 2.13: Lamb experiment utilising CPB. 
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Figure 2.14: Open lamb chest with venous and arterial cannula in situ. 
 
Figure 2.15: The operating theatre set up at the Vivarium. Anticlockwise from left are 
two pefusionists, surgical fellow, surgeon and two anaesthetic/ ICU staff. 
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Modified ultrafiltration (MUF) was performed on all lambs having CPB. Internal 
defibrillation (0.5–1.0J/kg) and or lignocaine (1mg/kg), (Xylocaine, AstraZeneca, North 
Ryde, NSW, Australia) were administered as required. Routine surgical techniques in 
maintenance and weaning from CPB were used, including venting of the left atrial 
appendage in all cases. 
 
2.5.4.2 Lamb Poloxamer 188 trial 
 
 The protocol was the same apart from the following three differences: 
 
Lambs received a blinded solution (2ml/kg) as a bolus load over one hour, immediately 
prior to CPB and then an infusion (0.2ml/kg/hr) of the same solution for the remainder of 
the experiment (11hrs). Administration was through the central line via an opaque 
extension (Codan, Santa Ana, CA) and a dedicated syringe driver (Graseby 3200, 
Graseby Medical, Watford, UK). The solution was prepared immediately prior to the 
experiment. It was filtered via a 0.22µm filter unit (Millipore, Co. Cork, Ireland) and 
wrapped in foil. Phosphate buffered saline (PBS) was the carrier solution administered 
without P188 to placebo animals. In treatment animals P188 also called Pluronic F-68 
(Sigma-Aldrich, St Louis, MO, USA), was added to give a concentration of 150mg/ml in 
PBS and thus a one hour loading dose of 300mg/kg and then a maintenance infusion of 
30mg/kg/hr – as per previous reports (Adams-Graves, 1997). Staff involved in animal 
experiments were unaware of the animal allocation until all data had been analysed.  
 
Cardioplegia was repeated 20 minutely for 120 minutes. 
 
Baseline full blood count, coagulation, liver function, urea, creatinine, creatinine kinase 
(CK) were measured prior to CPB. These were repeated six hours after CPB.  
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2.5.5 Postoperative management 
 
2.5.5.1 Initial series 
 
 Following the reestablishment of the native circulation protamine (1–3mg/kg) was 
given and haemostasis achieved. The sternotomy was closed over two 28Fr intrathoracic 
drains which were placed on low pressure wall suction. Dopamine (~5mcg/kg/min), 
(CSL, Parkville, VIC, Australia) and sodium nitroprusside (~1mcg/kg/min), (Faulding 
Pharmaceuticals, Melbourne, VIC, Australia), were commenced after CPB and kept at 
these rates. Crystalloid (0.9% saline, Baxter, Old Toongabbie, NSW, Australia), or 
maternal blood was given to maintain an adequate preload – (central venous pressure, 
CVP, CVP>4mmHg) and (haemoglobin, Hb, Hb>8g/dL) and isoflurane was continued 
together with intermittent intravenous agents(ketamine and midazolam) and 
pancuronium. Ventilation was maintained and adjusted according to blood gas 
parameters. All animals were managed by a paediatric intensive care consultant (JRE) 
using conventional techniques relevant to the care of human infants. 
 
2.5.5.2 Lamb Poloxamer 188 trial 
 
 The protocol was the same apart from the following differences: 
 
The period of post CPB support was nine hours. 
 
Seven hours after completion of CPB 0.2mg/kg of 0.1% Evans blue was given 
intravenously (Zhang, 2005). 
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2.5.6 Tissue collection 
 
2.5.6.1 Initial series 
 
 After a period of reperfusion following bypass (range 3–6hrs), the sternotomy was 
re–opened and the aorta cross clamped and a further dose of ~4°C cardioplegia was 
delivered. Following electrical and cardiac standstill ~ 60 seconds, the heart was removed 
and placed on an ice cooled board whilst being dissected for further analysis. The heart 
was transversely sectioned into atria, great vessels and ventricles. The ventricles were 
sectioned for MWC and together with other organ tissues were either frozen at –80°C or 
placed in 4% paraformaldehyde for sectioning. 
 
2.5.6.2 Lamb Poloxamer 188 trial 
 
 Nine hours following bypass the sternotomy was re–opened and an intravenous 
dose of pentobarbitone was delivered. 
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2.6 Statistical analysis 
 
 Data were expressed as means±SEM unless otherwise stated. Statistical 
significance was determined by the Mann-Whitney U test (MWU). Repeated measures 
ANOVA and linear mixed models using covariance type AR–1 when appropriate – 
typically for longitudinal continuous haemodynamic data – e.g. in the Langendorf 
experiments or in the sheep experiments. A p value of less than or equal to 0.05 was 
considered statistically significant (Kusuoka and Hoffman, 2002). Microsoft Excel 
(Microsoft Corp, Seattle, WA, USA) was used for the collection of raw data, it was also 
used to produce graphs and tables. The statistical package SPSSv15.0 for Windows, 
(SPSS, Chicago, Ill, USA) was used for analysis. Power calculations were performed for 
the two series of sheep experiments in view of their small sample sizes. This was done 
using Sample Power 2.0, (SPSS, Chicago, Ill, USA).  
 
Statistical issues relevant to the particular models used were included in the methods 
sections of the following chapters. 
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CHAPTER 3: MYOCARDIAL EXPRESSION OF AQUAPORINS 
 
Abstract 
 
 In studying AQPs in the setting of LCOS, we sought to refine the characterisation 
of AQP expression in the hearts of mammals.  
 
We focused on the species relevant to the planned initial animal models – rats and sheep, 
with reference to mice and keeping in mind the basic relevance of human expression. We 
focused on the AQPs that had been previously described in the myocardium – AQP1 and 
AQP4. Immunohistochemistry, Western blot, semi-quantitative and quantitative RT-PCR 
were conducted on whole cell preparations and subcellular fractions to define more 
precisely the expression and localisation of AQPs in the myocardium. Additionally a trial 
of in vitro ischaemia was undertaken to determine if there was a change in AQP 
expression with ischaemia in rat myocardium. Ambiguities in expression were resolved 
through use of AQP knockout mouse tissue. An osmotic equilibrium study using 
myocardial membrane vesicles was performed to determine the functional contribution of 
AQPs in mouse myocardium. 
 
AQP1, AQP4, AQP7 and AQP11 mRNA were present in myocardium from mouse, rats 
and humans. Sheep myocardium contained AQP1 and AQP4 as well as AQP0, AQP3 and 
AQP9. AQP1 protein was expressed in the endothelium of myocardial vessels in rat and 
sheep. Myocellular expression of AQP1 on immunohistochemistry was supported by 
expression in rat cardiomyocytes which had negligible endothelial tissue present. AQP4 
mRNA was found in rat, sheep, mouse and human heart. AQP4 protein was present in 
mouse and sheep heart on Western blot, although immunohistochemistry in sheep 
myocardium revealed non-specific nuclear staining. Western blots of rat myocardium 
revealed a protein of expected size, although only non-specific staining was present on 
immunohistochemistry. A trial of in vitro ischaemia, using quantitative RT-PCR 
demonstrated a six fold increase in AQP4 compared to baseline, but baseline levels of 
AQP4 were negligible. There was no change in AQP1. Western blot comparison of 
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human and rat myocardium with wild type and AQP4 knockout mouse myocardial tissue 
revealed that humans and rats did not in fact have AQP4 protein in their hearts. However 
sheep and mice did have low levels of AQP4 protein in their myocardium. AQP7 protein 
using available antibodies was present in human and mouse heart, but not in rat heart, 
although it was also shown to be negative in rat adipose tissue. Antibodies to AQP0, 
AQP3, AQP6, AQP9 and AQP11 did not reliably demonstrate AQP protein expression in 
a range of rat, mouse and sheep tissues, including myocardium. Myocardial AQP1 was 
specifically located within the plasma membrane fractions and not within mitochondrial 
membranes. Myocardial membrane vesicles derived from AQP1 knockout mice were 
equivalent in function to wild type and AQP4 and AQP8 knockout vesicles in the 
presence of mercurials; i.e. despite the mouse myocardium expressing a myriad of AQPs, 
only AQP1 appeared to have a functional role in osmotic equilibration. 
 
AQP1 was thus found to be the importantly expressed water channel within rat, sheep, 
mouse and human hearts. Endothelial and myocellular membranes contained AQP1. Of 
all the AQPs expressed in mouse hearts, including AQP7, AQP1 was found to be the only 
functionally relevant AQP. AQP1 mRNA in rat heart was unaltered following a brief 
period of in vitro ischaemia. AQP4 protein exists in relatively small amounts in sheep 
and mouse hearts. A six fold increase in AQP4 mRNA in rat hearts following brief 
ischaemia is almost certainly physiologically irrelevant given the low levels of baseline 
transcript and absence of protein. AQP1 is likely to be the sole important water channel 
in terms of expression and osmotically obligated water movement in mammals and 
served as the primary AQP focus in the animal models of LCOS.  
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3.1 Myocardial Aquaporins 
 
3.1.1 Initial reports 
 
 Soon after AQP1 was first described it was noted to be present within the heart – 
particularly within the endothelium and endocardium of the heart and its vessels (Bondy, 
1993). Its functional role in water handling has been alluded to earlier and was 
demonstrated by several authors. Based on these studies, the role of endothelial AQP1 in 
permitting osmotically obligated water movement also appears to be relatively greater 
than its role within cardiomyocyte membranes (Suleymanian and Baumgarten, 1996; 
Ogura, 2002b; Kellen and Bassingthwaighte, 2003b).  
 
The effect of haemodilution and reduced oncotic pressure on AQP1 expression was 
studied in a foetal lamb model (Jonker, 2003). Over a five day duration the foetus had a 
~50% reduction in Hct. In response to this there was a two fold increase in AQP1 mRNA 
and protein expression in both right and left ventricular tissue. AQP1 was demonstrated 
principally in the endothelial membranes of the myocardium, using 
immunohistochemistry (IHC). The authors concluded that AQP1 was important in 
cardiac fluid balance and speculated about the involvement of other AQPs in the heart 
(Jonker, 2003).  
 
3.1.2 Recent publications on cardiac aquaporins 
 
 Subsequently work from our lab further refined the location of AQP1 within the 
myocardium. AQP1 was confirmed as being mainly endothelial and in addition a 
myocellular pool was present and expression was also seen in the t-tubules of the cell 
membrane (Au, 2004). The t-tubular system is specific to cardiac muscle as opposed to 
skeletal muscle. It consists of a series of shallow tortuous invaginations of the 
sarcolemma into the cardiomyocyte volume – (Figure 1.1). The system is considered to 
be important in increasing the surface area of the cardiomyocyte and improving ionic 
exchange, thus facilitating efficient excitation contraction coupling. On the basis of a 
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screen of human cardiac tissue, no novel AQP sequences were present. AQP1 was 
considered to be present in both myocellular and endothelial membrane pools, but this 
remained to be confirmed (Au, 2004).  
 
AQP1 continues to be the main AQP studied within the heart, although most other AQPs 
have been found to some degree in the heart in most species as discussed in Chapter 1 
and summarised in Table 1.1. Warth et al reported that AQP4 was increased at a 
transcript level following I/R in a mouse model of focal ischaemia (Warth, 2007). It was 
found that mRNA was raised six fold after 45 minutes ischaemia, but only two fold after 
60 minutes ischaemia. Protein expression was not examined. AQP1 was not investigated 
in this model and nor were there measurements of oedema or dysfunction within the 
mouse hearts. Although this was a potentially intriguing result, AQP4 protein is not 
present in human hearts. We sought to develop and confirm the characterisation of AQPs 
in mammalian hearts of interest. 
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3.2 Methods 
 
 The methods for these experiments are detailed in Chapter 2, apart from the 
following. 
 
3.2.1 Ischaemic rat heart study 
 
 A study utilising RT-PCR, qRT-PCR and Western blot analysis of AQP1 and 
AQP4 in ischaemic rat hearts was undertaken.  
 
Rats were anaesthetised with isoflurane (Aerrane, Baxter, Old Toongabbie, NSW, 
Australia) and the hearts from four animals were removed via sternotomy. Four 
individual pieces of ventricular tissue from each animal were placed in a small weigh 
dish and exposed to four graduations of ischaemic insult, (Table 3.1). All myocardial 
tissue was ex vivo and not reperfused.   
 
To quantify the response of rat myocardial AQPs to ischaemia, quantitative RT-PCR 
primers were developed for rat mRNA, and were used to initially examine AQP1 and 
AQP4. Ribosomal 18S RNA was used as an internal house keeping gene. The response of 
AQP1 and AQP4 to a moderate period of warm ischaemia, without reperfusion was 
studied. 
 
Table 3.1. Outline of in vitro rat myocardium ischaemia study. 
 
 
 
 
 
 
 
 
 
Allocation 
 
 
Ischaemic insult prior to processing for mRNA and protein 
1 Nil 
2 30 minutes at room temperature 
3 60 minutes at 4°C 
4 60 minutes at 4°C , then 30 minutes at room temperature 
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3.3 Results 
 
3.3.1 RT-PCR for aquaporins in the myocardium of various species 
 
 A screening RT-PCR experiment was undertaken utilising the myocardial tissues 
from mouse, rat and humans. Neonatal rat derived cardiomyocytes (containing negligible 
endothelial tissue) were also screened.  
 
The RT-PCR screen demonstrated mRNA for AQP1, AQP4, AQP7 and AQP11 in 
mouse, rat and human myocardial tissue. Neonatal cardiomyocytes additionally contained 
AQP3 and AQP5, but lacked AQP6 and AQP9 mRNA compared with adult rat 
myocardium. Mouse myocardium contained all AQPs apart from AQP2, AQP3, AQP5, 
AQP9 and AQP10. Whilst human myocardium had mRNA for all AQPs apart from 
AQP2, AQP6 and AQP8, (Figure 3.1). 
 
 
Figure 3.1. Myocardial AQP expression by RT-PCR; in Mouse, Rat, neonatal 
cardiomyocytes from rat (CM) and human. AQP1, AQP4, AQP7 and AQP11 transcript 
are present in all tissues studied. This figure was prepared by Dr Tanya Butler. 
 85
3.3.2 Aquaporin protein expression in rat tissues 
 
3.3.2.1 Western blot for aquaporin 1 
 
 AQP1 protein was demonstrated in the well vascularised tissues of rat, including 
lung, left ventricle, right ventricle, atrium, liver, kidney, spleen and skeletal muscle. 
There were variable levels of the glycosylated fraction in these rat tissues. AQP1 was not 
demonstrated in the small intestine of the rat, (Figure 3.2). 
Figure 3.2. Western blot for AQP1. Whole cell lysates from rat organ tissues were probed 
for AQP1 (28kDa), with a larger glycosylated band. AQP1 is present in the lung, left 
ventricle (LV), right ventricle (RV), atrium, liver, kidney, spleen and skeletal muscle 
(Skeletal m). It was absent from the small intestine (Small int.). 
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3.3.2.2 Immunohistochemistry for aquaporin 1 
 
 IHC was performed on rat cardiac and skeletal muscle. For AQP1 this 
demonstrated a dominant endothelial staining in both tissues as well as possible 
myocellular expression in the muscles, (Figure 3.3). 
Figure 3.3. Rat muscle immunohistochemistry. Rat cardiac muscle (A) and skeletal 
muscle (B) were stained for AQP1, which demonstrated a strong endothelial signal, 
100X. 
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3.3.2.3 Western blot for aquaporin 4 
 
 A protein of the expected size of AQP4 was found in rat left and right ventricular 
tissue, atrium, kidney and skeletal muscle. It was not seen in the lung, liver, spleen or 
small intestine tissue of the rat. A smaller molecular weight protein was also seen in the 
skeletal muscle of rat, but with reduced signal, (Figure 3.4). 
 
  
Figure 3.4. Western blot for AQP4. Whole cell lysates of rat organ tissues, probed with 
AQP4 antibody. Left ventricle (LV), right ventricle (RV), atrium, kidney and skeletal 
muscle (Skeletal m.) expressed a ~32 kDa protein, the expected size of AQP4. Lung, 
liver, spleen and small intestine (Small int.) did not contain this protein.  
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3.3.2.4 Immunohistochemistry for aquaporin 4  
 
 Rat cardiac and skeletal muscle were stained with AQP4 antibody. Skeletal 
muscle demonstrated expected and typical homogenous sarcolemmal staining. Cardiac 
muscle however had non specific nuclear staining, and a myocellular staining pattern that 
was also present in the absence of the primary antibody, (Figure 3.5). 
 
 
Figure 3.5. Rat muscle immunohistochemistry. AQP4 antibody of rat cardiac muscle (A), 
without primary (B) and skeletal muscle (C). Cardiac muscle revealed a generalised non 
specific staining and nuclear staining. Skeletal muscle showed expected sarcolemmal 
membrane staining, 100X. 
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3.3.2.5 Western blot for other aquaporins 
 
 A protein the size of aquaporin 7 ~(26 kDa) was detected in human and mouse 
myocardium, but not in rat myocardium. This protein was also seen in rat testis. It was 
unexpectedly absent from rat adipose tissue, (Figure 3.6). 
 
Figure 3.6. Western blot for AQP7. Whole cell lysates from human cardiac muscle (CM), 
mouse cardiac muscle (CM), rat cardiac muscle (CM), rat testis and rat adipose tissue 
(AT). Both rat testis and adipose tissue typically express AQP7. This figure was prepared 
by Dr Tanya Butler. 
 
Western blots were also performed using available antibodies to AQP6 and AQP9 in the 
rat. No AQP11 antibody was available. No reliable protein expression data was available 
with these antibodies in a range of rat tissues, including myocardium. 
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3.3.3 Ischaemic rat heart study 
 
 The response of myocardial AQP1 and AQP4 to moderate periods of ischaemia, 
without reperfusion were studied. 
 
3.3.3.1 RT-PCR and Western blot analysis 
 
 AQP1 mRNA was present in all myocardial samples from all four rats, and there 
was no consistent pattern of variation with ischaemic insult. AQP1 protein by Western 
blot was consistently present and did not vary appreciably with insult, (Figure 3.7). 
 
AQP4 mRNA was present in only one of four baseline rat samples and had variable 
expression. AQP4 mRNA was present after 30 minutes room temperature ischaemia in 
three out of four rats. AQP4 protein appeared to be present and did not vary across 
groups, (Figure 3.7). 
 
Figure 3.7. Western blot and RT-PCR of aquaporin 1 and aquaporin 4 in ischaemic 
myocardium. The myocardium of four rats (A–D) was exposed to graduated ischaemic 
insults, without reperfusion; 1=nil, 2=30 minutes room temperature, 3=60 minutes at 4°C 
and 4=60 minutes at 4°C and then 30 minutes at room temperature. mRNA was assessed 
by using RT-PCR and was compared with protein analysed by Western blot. The Western 
blots used in this figure were prepared by Dr Tanya Butler 
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3.3.3.2 Quantitative real time PCR analysis 
 
 AQP4 real time PCR demonstrated a late rise in transcript after at least 35 cycles 
and no transcript was apparent in the baseline samples. The samples that were exposed to 
30 minutes of room temperature ischaemia had greater AQP4 mRNA expression, (Figure 
3.8).   
 
 
Figure 3.8. Aquaporin 4 mRNA cycle threshold output from qRT-PCR. Myocardium was 
exposed to 0 minute ischaemia, 30 minutes room temperature ischaemia (RT), 60 minutes 
at 4°C ischaemia, or 60 minutes at 4°C ischaemia followed by 30 minutes of room 
temperature (RT) ischaemia. A no mRNA sample was also run for 45 cycles. 
 
AQP1 real time PCR showed no significant differences in mRNA from baseline tissue 
compared with all other timepoints, (Figure 3.9).  
 
In the 30 minute room temperature ischaemia group, AQP4 demonstrated a significant 
increase compared to baseline, with a six fold increase in mRNA, (i.e. a relative change 
in cycle threshold compared to baseline and r18S RNA of ~ –3), (Figure 3.9). There was 
also a significant increase in AQP4 transcript after one hr at 4°C and 30 minutes at room 
temperature.  
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Figure 3.9. Rat myocardial aquaporin 1 and aquaporin 4 mRNA. Delta delta cycle 
threshold (CT) controlled by r18S RNA, mean±SEM shown. The 30 minutes room 
temperature ischaemic group tissue was utilised for this figure, n=4, (**p value <0.001) 
using Mann-Whitney U test (MWU) compared to baseline expression. 
 
3.3.3.3 Relative cycle thresholds for aquaporin mRNA in rat myocardium 
 
 The cycle thresholds for AQP1 and AQP4 mRNA in rat myocardium were 
compared with other rat organ tissues of interest. A high cycle threshold means that there 
is very little transcript of interest present in the tissue. 
 
Cycle thresholds for AQP1 in skeletal and cardiac muscle were essentially the same, 
although both were lower than in spleen. Cycle thresholds for AQP4 were higher in 
skeletal muscle, but comparable to brain expression. Rat cardiac tissue had high cycle 
thresholds, over 40, i.e. there was negligible AQP4 mRNA in rat myocardium, (Table 
3.2).  
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Table 3.2 Cycle thresholds in rat. CT of aquaporin 1 and aquaporin 4 in various rat 
tissues in a 45 cycle run.  
 
 
 
Transcript of interest 
 
 
Tissue 
 
Typical cycle threshold(CT) 
AQP1 Skeletal muscle 27 
AQP1 Cardiac muscle 26 
AQP1 Spleen 21 
AQP4 Skeletal muscle 32 
AQP4 Cardiac muscle 42 
AQP4 Brain 26 
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3.3.4 Aquaporin knockout tissue experiments 
  
 To clarify and confirm the expression of AQPs in rat myocardium, tissue from 
AQP knockout mice and litter matched wild type controls, was used as positive and 
negative controls. Western blots were probed with the AQP antibodies of interest.  
 
AQP1 was absent in skeletal muscle, cardiac muscle and brain tissue from AQP-/- 
knockout mice, but present in comparable wild type control tissues. AQP1 was present in 
human cardiac and skeletal muscle. It was also present in rat cardiac and skeletal muscle, 
(Figure 3.10). 
 
Figure 3.10. Western blot utilising knockout tissue for aquaporin 1. Whole cell lysates 
from human, rat and mouse heart (H), muscle (M) and brain (B). AQP1 is absent from 
heart and muscle in the knockout (AQP1-/-) and not present in the brain tissue of rat or 
WT mouse. AQP1 is present in cardiac and skeletal muscle of human, rat and wild type 
mouse (WT Mouse). This figure was prepared by Dr Tanya Butler. 
 
AQP4 was absent from AQP4-/- knockout mice brain, heart and skeletal muscle, but 
present in comparable wild type mouse tissues. Expression was relatively greater in 
mouse skeletal than cardiac muscle. AQP4 was present in human skeletal muscle only – 
not in cardiac muscle. In rats, AQP4 was present in skeletal muscle at low levels, absent 
in cardiac muscle and highly expressed in brain. An unknown higher molecular weight 
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protein was expressed in all muscle tissues of humans, rats and mice – this had previously 
been mistakenly assumed to be AQP4. This unknown protein was relatively more 
abundant than AQP4 in rat skeletal muscle, (Figure 3.11).  
 
 
Figure 3.11. Western blot utilising knockout tissue for aquaporin 4. Whole cell lysates 
from human, rat and mouse heart (H), muscle (M) and brain (B). AQP4 is absent from 
heart, muscle and brain in the knockout mouse (AQP4-/-). AQP4 is present in the mouse 
(WT Mouse) and rat brain. AQP4 is present in the skeletal muscle of human, rat and 
mouse. AQP4 protein is present in mouse heart, but not in rat or human myocardial 
tissue. This figure was prepared by Dr Tanya Butler. 
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3.3.5 Sheep aquaporin expression 
 
 Expression of AQP was studied in sheep myocardium, by qRT-PCR and Western 
blot using available antibodies. 
 
3.3.5.1 RT-PCR in sheep 
 
 Sheep myocardium had AQP1 mRNA present on RT-PCR. There appeared to be 
relatively less AQP4 mRNA. AQP0, AQP3 and AQP9 mRNA were also apparent at low 
levels, (Figure 3.12). 
 
 
Figure 3.12. Sheep aquaporin RT-PCR. A screen using published primers for all or part 
of AQP0, AQP1, AQP2, AQP3, AQP4, AQP5, AQP8 and AQP9 mRNA was conducted 
on sheep tissue. Tissues were studied in comparison to known positive controls and no 
template controls (NT). Tissues studied included Heart (H), Liver (Li), Skeletal muscle 
(SM), Kidney (K) and Lung (Lu). This figure was prepared by Yee Mun Tan. 
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3.3.5.2 Real time PCR in sheep 
 
 Real time primers were developed for AQP0, AQP1, AQP3, AQP4 and AQP9 for 
the sheep. The internal housekeeping transcript r18SRNA was utilised. The relative cycle 
thresholds were compared for the various AQP mRNAs from sheep heart and other 
tissues. AQP1 was most abundant, with AQP4 transcript detectable at low levels and the 
mRNA from other AQPs detected only at low to negligible levels, (Table 3.3). 
 
Table 3.3. Cycle thresholds in sheep. CT of AQP0, AQP1, AQP3, AQP4 and AQP9 in 
various sheep tissues in a 45 cycle run. 
 
 
 
 
 
 
 
 
 
Transcript of interest 
 
 
Sheep tissue 
 
Typical cycle threshold(CT) 
AQP0 Cardiac muscle 33 
AQP1 Kidney 18 
AQP1 Cardiac muscle 21 
AQP3 Cardiac muscle 33 
AQP4 Lung 26 
AQP4 Skeletal muscle 28 
AQP4 Cardiac muscle 36 
AQP9 Cardiac muscle 38* 
* Arbitrary CT as standard curves not reliable. 
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3.3.5.3 Western blot analysis of sheep myocardium for aquaporins 
 
 AQP1 and AQP4 protein were studied using Western blot and IHC in the sheep 
heart. 
 
AQP1 was present in sheep cardiac muscle. Skeletal muscle and lung also expressed 
AQP1 protein. AQP1 was relatively less expressed in the liver of sheep, (Figure 3.13). 
 
 
Figure 3.13. Western blot analysis of sheep organ tissues with aquaporin 1 antibody. 
AQP1 is just above the 24kDa marker, with its larger glycosylated band above. Tissues 
included heart, skeletal muscle (skeletal m.), lung and liver.  
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AQP4 protein was found to be present in sheep cardiac muscle, skeletal muscle, lung and 
liver. However only a relatively low level of AQP4 protein expression was found in 
sheep organs in comparison to rat brain and rat skeletal muscle, (Figure 3.14). 
 
 
Figure 3.14. Western blot analysis of sheep organ tissues with aquaporin 4 antibody. 
Whole cell lysates were probed for AQP4 protein by Western blot analysis. Sheep tissues 
analysed included cardiac muscle (CM), skeletal muscle (SM), Lung (Lu) and Liver (Li). 
For positive controls rat brain [Br(R)] and skeletal muscle [SM(R)] were utilised. 
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3.3.5.4 Immunohistochemistry of sheep muscle 
 
 AQP1 was expressed in the endothelium of cardiac and skeletal muscle in the 
sheep. Additionally AQP1 protein expression was also apparent within the myocellular 
tissue of both cardiac and skeletal muscle. AQP4 was present in the sarcolemma of 
skeletal muscle. There was non specific and faint uptake in cardiac muscle using this 
same AQP4 antibody (AQP4r). Non specific AQP4 staining was seen in both muscle 
types with the other AQP4 antibody utilised (AQP4g), (Figure 3.15). 
 
 
Figure 3.15. Immunohistochemistry of sheep muscle. Cardiac and skeletal muscle probed 
for AQP1 and AQP4 protein – using AQP1, AQP4r (rabbit) and AQP4g (goat) 
antibodies. Control (CTRL) images did not have primary antibody present. AQP1 is 
present in both muscle types and has a dominant endothelial expression pattern. AQP4 is 
present in the sarcolemma of skeletal muscle using the AQP4r antibody. This antibody 
reveals faint cardiac muscle uptake. There is non specific staining of both muscle types 
using the AQP4g antibody, 60X magnification. This figure was prepared by Yee Mun 
Tan. 
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3.3.6 Subcellular location of aquaporin 1 
 
3.3.6.1 Endothelial expression 
 
 Protein samples from rat derived cardiomyocytes – which are relatively 
endothelium poor, myocardium, liver and skeletal muscle were examined for AQP1 and 
endothelial cell specific protein expression. Endothelial cells – as seen by cadherin 
expression – was present in heart, liver and skeletal muscle tissue. Endothelial cells were 
relatively less prevalent in rat derived neonatal cardiomyocytes. The cardiomyocytes had 
AQP1 expression comparable to skeletal muscle and relatively less than cardiac muscle, 
(Figure 3.16).  
 
 
 
Figure 3.16. Endothelial and non-endothelial aquaporin 1. Isolated cardiomyocytes were 
probed for vascular endothelial (VE)-cadherin, actin and AQP1. Cardiomyocytes (CM), 
heart (H), liver (L) and skeletal muscle (M) tissue were probed. Endothelial poor 
cardiomyocytes demonstrate AQP1, whilst AQP1 is expressed to a relatively greater 
extent in the endothelial rich myocardial tissue. This figure was prepared by Dr Tanya 
Butler. 
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3.3.6.2 Mitochondrial membrane aquaporin 1 expression 
 
 Mouse plasma and mitochondrial membrane fractions were analysed to determine 
the expression of AQP1 in mitochondrial membranes. AQP1 was abundantly expressed 
in plasma membrane fractions, but only minimally expressed in mitochondrial membrane 
fractions, (Figure 3.17). 
 
 
Figure 3.17. Western blot of plasma and mitochondrial membranes. Mouse cardiac and 
skeletal muscle was separated into plasma membrane (PM) and mitochondrial (Mit) 
fractions and then probed with AQP1 antibody. Fractions were also probed with porin – a 
mitochondrial specific protein – and β-dystroglycan, a plasma membrane specific 
protein. Glycosylated (Glyc) AQP1 is also shown. AQP1 is essentially found within 
plasma membranes and not mitochondrial fractions. This figure was prepared by Dr 
Tanya Butler. 
 
3.3.7 Aquaporin function  
 
 AQP1 is the predominantly expressed AQP across the species studied. We sought 
to determine the relative contribution of various AQPs in the mouse as a guide to the 
contributions of AQPs in the mouse and other species. The mouse was chosen because of 
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the existence of knockouts, but it also expresses AQP4 and AQP7 at the protein level in 
addition to AQP1.  
 
Membrane vesicles formed from mouse myocardial tissue were subjected to an osmotic 
stress in order to determine the water permeability of the tissue derived vesicles. Tissue 
was obtained from wild type and AQP1-/-, AQP4-/- and AQP8-/- knockout mice 
Myocardial membrane vesicles from AQP4-/- and AQP8-/- knockout mice performed 
similarly to those from wild type mice when subjected to an osmotic challenge. Wild type 
mice in the presence of mercurials performed similarly to AQP1 knockout mice studies. 
AQP1 was found to be the functionally relevant AQP in the mouse, on the basis of 
osmotic permeability studies performed on myocardial membrane vesicle preparations , 
(Figure 3.18).  
 
 
Figure 3.18. Myocardial membrane water permeability in mouse. Wild type (WT), AQP1 
null, AQP4 null and AQP8 null mice were compared. AQP1 null membranes were 
significantly slower and displayed a lower permeability coefficient, (A,B, p<0.01). 
Addition of mercury inhibited AQP function and reduced rate of equilibration and 
permeability of all membranes to AQP1 null equivalent values. This figure was prepared 
by Dr Tanya Butler. 
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3.4 Discussion 
  
 Consistent with earlier findings (Au, 2004), AQP1 was found to be the water 
channel expressed in myocardial tissue of all the mammalian species studied. AQP1 was 
found to be expressed in rat and sheep myocardium, enabling its study in the proposed 
models of LCOS. Fundamentally it was also the only water channel confirmed, through 
comparison with knockout mouse tissue, as being present within human myocardial 
tissue. Hence AQP1 is of central relevance to studying the role of water channels in the 
obligatory movement of water along osmotic gradients within the myocardium in the 
setting of LCOS. 
 
AQP1 was mainly expressed within the endothelial membranes of the heart. A smaller, 
myocellular pool of AQP1 protein was confirmed in endothelial poor isolated 
cardiomyocytes. The myocellular expression of AQP1 was less apparent though, 
compared with the abundance of AQP1 in the endothelium. The predominant endothelial 
expression of AQP1 supports the findings of Kellen et al. The inclusion of the endothelial 
components as part of an isolated heart model demonstrated a significant contribution 
(28–50%) to osmotic water movement by AQP1 (Kellen and Bassingthwaighte, 2003b). 
Whilst in the isolated cardiomyocyte studies, the absence of endothelial AQP1 led to a 
more modest contribution from AQP1 (Suleymanian and Baumgarten, 1996; Ogura, 
2002b). Thus the demonstrated non endothelial AQP1 presumably facilitates interstitial, 
myocellular compartment water transport in the rare circumstances that an osmotic 
gradient develops, e.g. ischaemia. However osmotic gradients are considerably more 
likely to occur across the endothelial, interstitial compartments and hence there are 
relatively more AQP1 channels to cope with fluxes in plasma osmolality, e.g. 
dehydration.  
 
There has been speculation that AQPs may be involved in water transport across 
mitochondrial membranes (Ferri, 2003; Calamita, 2005; Lee, 2005). We found that AQP1 
was minimally expressed in mitochondrial membrane fractions and was principally found 
in plasma membrane fractions. Thus it is unlikely that AQPs have a role in mitochondrial 
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water transport. This confirmed what has been recently shown in a series of experiments 
utilising knockout tissue as controls which found equivalent mitochondrial permeability 
regardless of AQP expression (Yang, 2006).  
 
Although AQPs don’t have a role in mitochondria, there is a suggestion that AQPs may 
be involved in response to ischaemia (Warth, 2007). We found that AQP1 was unaltered 
in response to graduated ischaemic insults in the rat heart. This supported the theory that 
AQPs are constitutively expressed and are not subject to alteration within a short 
timeframe (Ma, 1997a). AQP4 however underwent a six fold increase in transcript in 
response to ischaemia. This fold change was identical to that seen in a mouse model of 
myocardial infarction by Warth et al. However we subsequently found that AQP4 mRNA 
is minimally expressed in rat heart and that AQP4 protein is absent, suggesting that the 
ischaemia associated AQP4 mRNA fold change was physiologically irrelevant. In the 
following animal models we planned to measure AQP1 mRNA and protein over longer 
timeframes, where expression changes have been demonstrated in response to 
haemodilution (Jonker, 2003). 
 
The alterations seen in AQP4 mRNA with ischaemia, the subsequent review of AQP4 
protein expression in the heart, and the eventual finding that AQP4 protein was absent 
from rat and human heart highlights the important role of knockout tissues. Others have 
suggested that AQP4 was present in human heart (Birkenkamp-Demtroeder, 2003), but it 
clearly isn’t. Furthermore in those animals where AQP4 protein does exist in the heart, 
such as the mouse, it does not appear to have a functional role. 
 
We confirmed AQP4 was present in sheep and mouse heart, but from a functional 
perspective only AQP1 had a role in mouse heart. Osmotic equilibration occurred fastest 
in the presence of AQP1. Wild type mice had equivalent permeability to AQP4-/- and 
AQP8-/- knockout mouse tissues. Only in the presence of mercury, did AQP1-/- knockout 
tissue demonstrate equivalent permeability to wild type mice and AQP4-/- and AQP8-/- 
mice. The difference in permeability between wild type and AQP1-/- knockout 
myocardial membranes was ~25%, similar to what Kellen et al demonstrated in the 
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whole heart of rabbits using crystalloid perfusates. AQP1 was thus considered to be the 
sole important water channel in terms of expression and osmotically obligated water 
movement in mammals. Therefore, AQP1 has served as the primary AQP focus in the 
following animal models of LCOS.  
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CHAPTER 4: ISOLATED CARDIOMYOCYTE EXPERIMENTS 
 
Abstract 
 
 To determine the role of oedema in myocardial dysfunction we studied the 
cardiomyocyte. In parallel we investigated the relative contribution of ischaemia to cell 
swelling and function. This permitted the study of the impact on the contractile apparatus 
– albeit without the extracellular framework, but permitted detailed modelling. 
 
The effects of hypo-osmotic stress and ischaemia upon cell size and function were 
modelled. We determined the dimensional and functional responses of the contractile 
apparatus to acute alterations in cell conditions. The benefit of this technique was that the 
contractile effect was isolated. However this limited the external validity of these studies, 
in that there were no extracellular components. Ischaemic stress was modelled by 
exposing the cells to a metabolic milieu which included an acidic (pH 6.8), raised lactate 
and simulated ischaemia with a hypoxic environment. 
 
In a series of isolated cardiomyocyte studies we found that hypotonic buffer induced 
changes in cell size of ~ 7% that were not associated with contractile dysfunction. 
Ischaemia, despite being associated with less cell swelling (~2%), was associated with 
significant contractile dysfunction. Both insults altered calcium handling, but only 
following ischaemia was this associated with dysfunction. 
 
 108
4.1 Introduction 
 
4.1.1 Modelling of hypotonic conditions and ischaemia 
 
 Others have sought to study isolated cardiomyocytes in terms of swelling, 
ischaemia and contractility, but as yet all three parameters have not been assessed in a 
single experimental series. We sought to specifically assess the impact made by oedema 
and by ischaemia to cardiomyocyte dysfunction.  
 
4.2 Methods 
 
 Methodology was as per Chapter 2, an additional schema of the experimental 
protocols is provided here, (Figure 4.1). 
 
4.2.1 Statistics 
 
 Analysis was as per Chapter 2 apart from the following.  
 
For the isolated rat cardiomyocyte studies, the Kruskal-Wallis test followed by Mann-
Whitney U test was used to compare treatment and control groups. Within group 
comparison of baseline, test and recovery values used the Friedman test followed by 
Wilcoxon signed rank test. In isolated cardiomyocyte analyses, to account for variability 
in data and time-dependent changes in cardiomyocyte function, significance was only 
accepted if both within-group significance and between-group significance from the 
isotonic control group was found. 
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Figure 4.1. Isolated cardiomyocyte experiment schema summary. An experimental 
schema of the isolated cell trials at the Victor Chang Cardiac Research Institute (VCCRI) 
and at the Children’s Hospital at Westmead (CHW). Following the stabilisation periods 
cell area ± calcium handling and cell contractility were measured at the end of two – 
three intervals within the protocols. For C and D these intervals were termed basal, test 
and recovery. 
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4.3 Results 
 
4.3.1 Isolated mouse cardiomyocytes 
 
 Cardiomyocytes from adult mice were placed in an isotonic Kreb’s solution and 
their size was measured in diastole after 10 minutes. The solution was then changed to a 
hypotonic Tyrode’s solution and the size was again measured, (Figure 4.1.A). These 
groups of cells were then compared in terms of area. Area increased ~25% in the 
hypotonic solution. There was a non significant decrease in cell length of ~5% and a 
significant increase in cell width of ~30%, (Figure 4.2). 
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Figure 4.2. Mouse cardiomyocyte hypotonic buffer trial. Length and width of cells 
exposed to isotonic (clear column) and hypotonic (grey column) solutions. Length was 
not different, (p=0.5), whilst width varied with treatment, (p=0.001***). This data was 
produced from an experiment conducted with Dr Aisling McCahon.  
***
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4.3.2 Isolated rat cardiomyocytes – hypotonic and ischaemic buffer trials 
 
4.3.2.1 Cardiomyocyte size 
 
 Cardiomyocyte size was studied in relation to exposure to isotonic, hypotonic and 
ischaemic buffers, (Figure 4.1 B, C and D).  
 
Size was unchanged in isotonic conditions. In hypotonic buffer, cardiomyocyte area 
significantly increased by 7%. With re-exposure to isotonic buffer there was a shrinkage 
of cells to ~1% less than their initial size. In ischaemic buffer, cell area significantly 
increased by 2% and then returned to baseline in isotonic buffer. Alternatively, when 
ischaemic cells were recovered in hypotonic buffer, area increased 4% further to ~6% 
above baseline. This was larger compared to both baseline, (p<0.01) and ischaemic, 
(p<0.01) cell size, (Figure 4.3 A, B and C). 
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Figure 4.3. Rat cardiomyocyte size. Cardiomyocyte size relative to baseline, percentage 
change with 8–10 minutes exposure to buffers. Cardiomyocyte dimensions were recorded 
during diastole. A) Cells perfused continuously in isotonic buffer had static size. B) Cells 
in hypotonic buffer swelled, (***p<0.001). Recovery in isotonic buffer resulted in 
shrinking of the cells to less than their original size, (*p<0.05). Ischaemia resulted in 
cardiomyocyte swelling, (**p<0.01) with return to baseline size following reperfusion in 
isotonic buffer. This figure was prepared by Dr Tanya Butler. 
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4.3.2.2 Cardiomyocyte calcium handling 
 
 Cardiomyocyte calcium handling was studied at three time-points (designated 
basal, test and recovery) in each of the three experimental protocols, (Figure 4.1 B, C and 
D). Mean transient data from cells of the three experimental protocols are shown, (Figure 
4.4 A, B and C). Comparison was made within each protocol i.e. variation within the 
three timepoints, and also between different protocols i.e. variation in calcium transients 
during hypotonic vs. ischaemic stress. 
 
Resting calcium transient measurements of control cardiomyocytes demonstrated no 
change across the time-course of the experiments. Resting levels of intracellular calcium 
were unchanged in the cells exposed to hypotonic buffers. Cells exposed to ischaemic 
buffers however had increased calcium in diastole, which resolved in the recovery phase, 
(Figure 4.4 A).  
 
Calcium clearance was unaltered across isotonic and hypotonic protocols. However 
slower calcium clearance was seen in ischaemic cells as an increase in tau, compared to 
baseline and isotonic controls, (Figure 4.4 B). 
 
Peak calcium levels were unchanged with time in the isotonic cells. The hypotonic cells 
however had a lower peak intracellular calcium level compared to baseline and isotonic 
controls. Peak calcium in ischaemic cells was not significantly different from baseline 
and isotonic controls, (Figure 4.4 C). 
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Figure 4.4. Calcium and contractility in rat cardiomyocytes – treatment effects. 
Intracellular calcium transient data (left panel, A,B,C) and sarcomere shortening (right 
panel, D,E,F). Baseline measurements (black column), test measurements (hatched 
columns) and recovery measurements (grey columns) are shown. The isotonic control 
group was produced by continuous perfusion of cells with isotonic buffer. A) Diastolic 
intracellular calcium was significantly increased in ischaemic cells, (***p<0.001) and 
returned to baseline values with isotonic reperfusion. B) The calcium clearance was 
significantly increased during ischaemic exposure, (**p<0.01). C) Peak intracellular 
calcium was reduced in the hypotonic group, (***p<0.001). D) Diastolic sarcomere 
length was not significantly altered by treatment. E) Maximum velocity of shortening 
was significantly reduced by ischaemia, (**p<0.01), but not by hypotonic swelling. F) 
Peak shortening was significantly reduced by ischaemia, (**p<0.01), but not by 
hypotonic challenge. This figure was prepared by Dr Tanya Butler. 
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4.3.2.3 Cardiomyocyte contractility 
 
 Cardiomyocyte contractility was studied in relation to these stresses, (Figure 4.1 
B, C and D). 
 
Similarly to cardiomyocyte calcium handling, contractility was studied at three time-
points (designated basal, test and recovery) in each of the three experimental protocols. 
Mean values for cells from the three experimental protocols are shown, (Figure 4.4 D, E 
and F). Comparison was made within and between protocols in order to confirm 
significant variation. 
 
Resting sarcomere length was measured on three occasions within each protocol and 
there were no significant differences within or between the isotonic, hypotonic or 
ischaemic cells, (Figure 4.4 D). 
 
The maximal shortening velocity of cardiomyocytes were not significantly different in 
isotonic or hypotonic cells. In the Ischaemic cells though there was a significant 
reduction compared to baseline and isotonic controls, (Figure 4.4 E). 
 
The peak shortening of cardiomyocytes was also not significantly different in isotonic or 
hypotonic cells. The ischaemic cells however displayed a significant reduction in peak 
shortening, with some recovery after the insult, (Figure 4.4 F). 
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4.4 Discussion 
 
 Isolated cardiomyocytes were assessed functionally in their response to ischaemic 
and hypotonic insults. We found that cells swelled in response to hypotonic stress (7%), 
more so than they did in response to ischaemia (2%). Cell function however was severely 
impacted by ischaemia and not by swelling induced by hypotonic buffers. Hence in terms 
of the hierarchy of myocardial insults, ischaemia out ranked oedema. Interestingly if a 
hypotonic stress followed the ischaemic insult there was an additional degree of oedema 
seen (increase from 2 to 6%), but no additional contractile dysfunction. So even when 
oedema was added to an already injured and dysfunctional cell it did not contribute to 
additional dysfunction. This supports the assertion that ischaemia is of primary import in 
terms of contributing to contractile dysfunction.  
  
There was a gross decline in diastolic and systolic function in the cardiomyocytes which 
experienced ischaemia. Alterations in calcium handling associated with ischaemia – i.e. 
reduced calcium clearance and increased diastolic/resting calcium could have resulted 
from increased calcium influx seen with ischaemia (Otani, 1989). This influx in calcium 
is likely to be the result of injury to the cardiomyocyte membrane (Otani, 1989). There 
were no changes seen in contractility in cells exposed to hypotonic stress and this was 
despite lower peak calcium levels. This alteration in calcium levels could be attributed to 
swelling induced alterations in ion channels as described by Vandenberg et al 
(Vandenberg, 1996). Alternatively this uncoupling of calcium concentration and 
contractility has been described in similar settings previously (Mangano, 1993). 
 
A reduction in contractility in association with swelling of cardiomyocytes has been 
asserted previously, by Mizutani et al (Mizutani, 2005). There was a 30% decline in 
cardiomyocte shortening in association with 0.6T and 0.9T buffers, although there was 
also a 20% decline with the 1.0T or isotonic buffers – which suggests a lack of stability in 
the model. Because of the reduced contractility in the 1.0T buffer, significantly reduced 
contractility in the 0.6T and 0.9T groups was only demonstrated when compared with the 
2.6T or hypertonic group. So upon review there was no significant difference in cell 
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shortening between 0.6T, 0.9T and isotonic buffers. The cells exposed to 0.6T buffer – 
swelled 30%, whilst the cells exposed to 0.9T had a 7% increase in area – of similar 
magnitude to our findings using 0.75T buffers. If we compare the function between 0.6T 
cells and 0.9T cells there is absolutely no difference, both are ~ 30% reduced from 
baseline. So despite a 23% difference in size there was no difference in function between 
these two groups. This suggests that there is not a direct causal relationship between 
swelling and dysfunction.  
 
A possible explanation for the lack of dysfunction seen in our study was the duration of 
the hypotonic insult. Askenasy et al in whole isolated heart studies found that a hypotonic 
stress was tolerated without functional decline for five to eight minutes (Askenasy and 
Navon, 1997). In the study by Mizutani et al (Mizutani, 2005) there was a 20 minute 
exposure to hypotonic stress, compared to our eight minute duration hypotonic test. 
However Askenasy’s work was following ischaemia. This was similar to our study of 
exposure of ischaemic cells to hypotonic buffers. In these cells we did not demonstrate 
dysfunction over a 10 minute interval, thus it is unlikely that duration of exposure was 
responsible for the difference in swelling related dysfunction. 
 
There are limitations to isolated cardiomyocyte work in translation to clinical work. We 
subsequently utilised the isolated heart model in order to deal with the more obvious 
deficits – namely short experimental time-course and lack of extracellular 
matrix/interstitial compartment. Despite these limitations, isolated cardiomyocyte studies 
provide a glimpse of the isolated myocellular apparatus and its response to swelling and 
ischaemia. The contractile apparatus seemed least capable of tolerating an ischaemic 
insult, as opposed to an oedema inducing insult. 
 
If myocellular swelling is not responsible for dysfunction, but rather ischaemic injury, 
what are the likely mechanisms? Direct damage to the contractile machinery has been 
found in the setting of ischaemia/reperfusion as a result of numerous insults, with the 
predominant causes increased calcium – leading to activation of proteases (Bolli and 
Marban, 1999) and oxygen derived free radicals (Bulkley, 1994). Unfortunately methods 
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of attempting to ameliorate these pathways have not proven successful (Bolli and 
Marban, 1999; Becker, 2004). Thus avoiding ischaemia or at least avoiding the effects of 
ischaemia reaching the myocellular compartment would appear worthy of investigation.  
  
So in conclusion isolated cardiomyocytes were affected by both hypo-osmotic induced 
oedema and ischaemia induced oedema. Both these insults affected the size of the cells 
and calcium handling, but only ischaemia resulted in severe and significant dysfunction. 
These findings are potentially relevant to the postoperative clinical setting and warrant 
assessment in a whole organ model. 
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CHAPTER 5: ISOLATED HEART (LANGENDORFF) 
EXPERIMENTS  
 
Abstract 
 
 As in the isolated cardiomyocyte, the isolated heart model provided the ability to 
study function, oedema and ischaemia. Additionally in the whole heart model it was 
possible to study the global contribution of the interstitial and vascular compartments.  
 
A purpose built Langendorff isolated heart perfusion system was used – with retrograde 
aortic perfusion. Rat hearts were perfused with a standard crystalloid perfusate, which 
was temporarily suspended to model global ischaemia. Global ischaemia was 
conventionally modelled at 37ºC with suspension of aortic root flow, this resulted in 
reversible myocardial contracture. Two series of experiments focused on the contribution 
of oedema and ischaemia to myocardial dysfunction. 
  
Hyposmotic stressed hearts had a 9% increase in water and a < 5mmHg increase in 
diastolic pressure. This was compared with ischaemic hearts that had a 6% increase in 
water and a 25–50mmHg increase in diastolic pressure. Both ischaemic and non-
ischaemic oedematous hearts had mild reductions in systolic function, which resolved 
rapidly in only the non-ischaemic hearts. There were no appreciable changes in AQP1 
mRNA or protein expression.  
  
In conclusion, ischaemia was of great importance functionally. In the whole heart, 
oedema without ischaemia had much less impact, being associated with mild reversible 
dysfunction. Ischaemia induced dysfunction was mainly diastolic, with systolic 
dysfunction occurring with longer durations of ischaemia. During this timeframe no 
measurable changes were seen in AQP1 expression.  
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5.1 Introduction 
 
 A necessary extension from the isolated cardiomyocyte model was the isolated 
heart or Langendorff perfused heart. In the whole organ model it is possible to perform 
experiments of longer duration and to study the contribution of the interstitial and 
vascular compartments (Aliev, 2002). The inclusion of these compartments improves the 
correlation of the model with the clinical setting. The extracellular compartments are also 
relevant as sites of water accumulation and because of the high expression of AQPs in 
endothelial cell membranes. Experiments utilising the Langendorff technique, originally 
described in 1897 by Oscar Langendorff, have contributed greatly to the current 
understanding of mammalian cardiac physiology (Skrzypiec-Spring, 2007). It provides a 
robust, reproducible model with the potential to study function, oedema and proteins of 
interest.  
  
Typically it is accepted that in settings analogous to CPB with or without I/R that water 
accumulates in the interstitial space as a result of endothelial leakiness (Garcia-Dorado 
and Oliveras, 1993; Mehlhorn, 2001; Kellen and Bassingthwaighte, 2003b). However 
contention surrounds the importance and degree of intracellular oedema – as discussed 
previously (Bolli and Marban, 1999; Askenasy, 2001; Kloner and Jennings, 2001). In an 
isolated heart model, Palmer et al showed that progressive increases in duration of 
ischaemia resulted in progressive increases in dysfunction – particularly diastolic. It was 
found that at after 20 minutes ischaemia there was a shift from reversible to irreversible 
injury. This was also associated with increased MWC and increased mitochondrial 
swelling/ oedema. Hence it was concluded that ischaemia was the primary cause of 
myocardial and mitochondrial oedema and that the threshold for irreversible injury was 
20 minutes – this correlates with the standard interval between cardioplegic doses in the 
clinical setting (Palmer, 2004).  
 
Curiously in the work by Palmer et al, myocardial oedema did not occur to any 
significant degree in non-ischaemic hearts, despite a lack of colloid in the perfusate 
(Palmer, 2004). This lack of oedema in non-ischaemic hearts has not been described by 
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others, even when colloid is added to the conventional perfusate (Apstein, 1977). For 
instance Kellen et al describe the accumulation of 1 – 2g of water (~10%) during the 
initial stabilisation phase (30 minutes), despite the inclusion of low concentrations of 
albumin in the perfusate (Kellen and Bassingthwaighte, 2003b). Palmer et al modelled 
ischaemia in the accepted manner, by stopping perfusate flow at room temperature. This 
results in a significant insult – no flow, globally at room temperature (Palmer, 2004). The 
resulting injury and myocardial dysfunction is more severe than with conventional 
planned myocardial ischaemia. In the setting of CPB for instance relative hypothermia 
and blood cardioplegia are utilised to minimise ischaemia induced injury.  
  
We sought to define the relative contributions of ischaemia and oedema in a whole heart 
model of myocardial dysfunction. AQPs have not been studied in this setting either so 
their role was simultaneously studied by looking at myocardial mRNA and protein for 
AQP1 expression.  
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5.2 Methods 
 
 These are outlined in Chapter 2, a supplementary schema of experimental 
protocols is included here, (Figure 5.1). 
 
In the second series of experiments, an additional group of experiments were conducted 
specifically to determine the water content of hearts. Water content of three groups (n=4 
per group) were compared; i) 20 minutes isosmotic Krebs perfusion, ii) 20 minutes 
perfusion with isosmotic Krebs followed by 20 minutes with hyposmotic Krebs, and iii) 
successive perfusion in isosmotic, hyposmotic and isosmotic Krebs for 20 minutes each 
MWC, was then measured. 
  
5.2.1 Statistical analysis 
 
 Statistical analysis was as discussed in Chapter 2 apart from the following 
comments.  
 
For physiological data obtained from Langendorff experiments, values were averaged 
over 10 minutes epochs. Statistical significance was determined by analysis of variance 
with repeated measures. The Mann-Whitney U test was used to compare unrelated groups 
in terms of MWC, analysis of densitometry and real-time RT-PCR experiments. 
 
5.2.2 Tissue Analysis 
 
 This included assessment of MWC, myocardial AQP1 mRNA and protein, as 
discussed in Chapter 2. Only MWC was performed on the second series of experiments.  
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Figure 5.1. Isolated heart experiments – protocol summary. An outline of the 
experimental protocols 1) 20 minute ischaemia experiments and 2) 30 minute ischaemia 
experiments used with the isolated heart experiments. 
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5.3 Results 
 
5.3.1 Twenty minute ischaemia experiments 
 
 All experiments proceeded as planned. Four treatment groups were compared 
with six animals in each group; baseline (hearts excised and not perfused), 20 minute 
perfusion controls, 20 minutes perfusion followed by 20 minutes ischaemia and 70 
minutes reperfusion and finally a 120 minute perfusion control group (without 
ischaemia), (Figure 5.1 – 1). 
  
5.3.1.1 Haemodynamics  
 
 Heart function was assessed as LVDP measured at systole (Figure. 5.2A) and 
diastole (Figure. 5.2B). The ischaemic insult did not affect the systolic LVDP, but 
resulted in a significant increase in diastolic LVDP during the reperfusion phase, 
(p=0.002). This increase in diastolic pressure confirmed that the hearts suffered a 
significant ischaemic insult. Other indexes of heart function, including heart rate, 
recovered to control levels in ischaemic hearts during the reperfusion phase.  
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Figure 5.2. Ischaemic treatment of rat heart. (A-B) Rat hearts were perfused as controls (-
■-), or made ischaemic through cessation of perfusate flow (-●-) for 20 minutes before 
reperfusion, or continuously perfused without ischaemia (-◊-). Left ventricular systolic 
pressure (LVP Sys) recovered well after ischaemia (A) whilst diastolic pressure (LVP 
Dias) was significantly increased, (p=0.002). Mean±SEM is shown. 
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5.3.1.2 Myocardial water 
 
 The baseline control hearts had a MWC of 0.768±(0.0008). The 20 minute control 
perfused hearts had a MWC of 0.823±(0.003) which was significantly greater than 
baseline, (p=0.03). The hearts perfused for 120 minutes without ischaemia had a similar 
MWC to the 20 minutes perfused group of 0.819±(0.0037), and were statistically 
different from baseline control hearts, (p=0.025). The 20 minute ischaemia hearts were 
the wettest 0.832±(0.0013) and were statistically different from the baseline control 
group, (p=0.05) and 20 minute control perfused, (p=0.03) groups and with respect to the 
120 minutes perfused group, (p=0.05), (Figure 5.3). 
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Figure 5.3: Myocardial water content for isolated rat hearts in various allocations. See 
text for details, 20 minute ischaemia hearts were the wettest compared to all other 
allocations, (*#p<0.05). Mean±SEM is shown. 
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5.3.1.3 Molecular results 
 
 AQP1 and AQP4 mRNA and protein levels were measured by quantitative RT–
PCR and Western blotting, respectively. AQP1 transcript, (Figure. 5.4A) and protein, 
(Figure. 5.4B) were not significantly different across all treatment groups. AQP4 protein 
was not evident in the hearts, regardless of treatment (data not shown). Although AQP4 
transcript was detectable, it was several fold less than the amounts measured in skeletal 
muscle and AQP4 protein was absent from rat myocardium. 
 
Figure 5.4. Aquaporin 1 expression. (A) Measured by Western blotting and normalised to 
the expression of cardiac actin, was not affected by osmotic or ischaemic stress. (B) 
AQP1 transcript levels were also unchanged. Mean±SEM is shown. This Figure was 
prepared by Dr Tanya Butler.  
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5.3.2 Thirty minute ischaemia experiments 
 
 All experiments proceeded as planned, (Figure 5.1 – 2). Groups 2A–C related to 
osmotic/oncotic alterations. The hearts were perfused 20 minutes with infusion, 20 
minutes without infusion and 20 minutes with infusion. These infusions were 2A; 15mM 
NaCl and 30mM sucrose (to measure the effects of mild hyperosmolarity), 2B; 0.5% 
dextran (to measure the effects of mild increases in oncotic pressure) and, 2C; 0.75T 
Krebs (to measure the effects of hypotonic stress). The remaining experiments focused on 
ischaemia. Groups 2D; 10 minute baseline stabilisation, 30 minutes ischaemia, 50 
minutes reperfusion and, 2E; 100 minute perfusion control group.  
  
5.3.2.1 Haemodynamics  
 
 Measured pressures were not significantly different with infusion of NaCl with 
sucrose, (Figure 5.5A). Diastolic pressure in the presence of 0.5% dextran was 
significantly higher than without it, (p<0.01, Figure 5.5B) , but systolic pressure was not 
significantly altered. 
  
Alterations from isosmotic to 0.75T hyposmotic perfusate led to a mild, but significant 
increase in diastolic pressure, (p<0.001), which was reversed by return to isosmotic 
solution, (Figure 5.5C). Systolic pressure reduced and then also recovered with return to 
isosmotic perfusion 1.0T to 0.75T, (p<0.01). 
  
Ischaemia induced severe diastolic dysfunction with an increase in diastolic pressure 
compared to baseline, (p<0.05, Figure 5.5D). Systolic pressure was also significantly 
lower in the reperfusion phase compared to baseline, (p<0.05). Although this systolic 
pressure was not significantly different from non-ischaemic controls. 
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5.3.2.2 Myocardial water 
 
 All hearts became oedematous at the completion of experiments ~6%, compared 
to baseline and there were no significant differences for those receiving 15mM NaCl and 
30mM sucrose, 0.5% dextran or those hearts exposed to ischaemia.  
  
In additional experiments focused on 20 minute intervals of perfusion, perfusion with 
0.75T Krebs induced additional swelling. Hearts perfused with 0.75T hyposmotic Krebs 
took on 3.3% more water than hearts perfused with isosmotic Krebs, (p<0.05, Figure 
5.6). Isosmotic recovery allowed resolution of this swelling to baseline values. 
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Figure 5.5. Left ventricular developed pressure; for A – C osmotic challenges and D, 30 
minute ischaemic challenge – see text for details. Mean±SEM is shown. This figure was 
prepared by Dr Tanya Butler.  
 
 
Figure 5.6. Heart water percentage increase; from baseline after perfusion in isosmotic, 
hyposmotic and isosmotic Krebs for 20 minutes each. Hearts perfused in hyposmotic 
0.75T Krebs gained an additional 3.3% water, (*p<0.05). Mean±SEM is shown. This 
figure was prepared by Dr Tanya Butler. 
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5.4 Discussion 
 
 The Langendorff system extended our previous isolated cardiomyocyte work to 
the whole organ level. Although it did not model CPB it provided a recognised oedema 
inducing environment – as a result of the crystalloid perfusate (Rubboli, 1994). It allowed 
global I/R to be modelled and for functional and MWC measurements to be taken 
(Apstein, 1977). Molecular studies could also be undertaken, although the time course 
was still relatively short.  
  
Ischaemia was found to be of principle importance in causing myocardial dysfunction, 
particularly diastolic dysfunction. Systolic dysfunction was only seen with the longer 
duration of global ischaemia, 30 minutes, in the second series of experiments. This 
supports a dose dependent effect of ischaemia upon myocardial dysfunction, similar to 
what others have described (Palmer, 2004). No additional oedema was found in the hearts 
arrested for 30 minutes compared with control non-ischaemic hearts. However in the 
initial series utilising 20 minutes ischaemia, an additional one percent increase in MWC 
was associated with ischaemia. The 20 minute ischaemia hearts with additional oedema 
had better performance overall compared with the subsequent 30 minute ischaemic 
group. So despite the burden of additional oedema, the duration of ischaemia was of 
greater importance in determining the severity of myocardial dysfunction. 
 
In these studies we did not see a relationship between degree of oedema and degree of 
dysfunction. Hyposmotic hearts had a 9% increase in water and a < 5mmHg increase in 
diastolic pressure. This compares with ischaemic hearts that had a six percent increase in 
water and a 25–50mmHg increase in diastolic pressure. Thus despite 30% less oedema, 
ischaemic hearts had a five to 10 fold greater degree of dysfunction that persisted 
throughout the experiment. This further supports a divergence in association between 
important dysfunction and oedema. 
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In the isolated rat heart, oedema was found to cause minimal and reversible dysfunction. 
The rapid and complete reversal in dysfunction would support the role of the reduced 
peak calcium found in our isolated cell work, secondary to stretch induced alterations in 
ion permeability (Vandenberg, 1996). Potentially the amelioration of calcium availability, 
through the administration of additional calcium or novel inodilators which can increase 
free calcium may overcome this mild oedema associated dysfunction (Brixius, 2005). 
Such inodilators have been shown to be beneficial in small clinical studies (Brixius, 
2005; Egan, 2006; Namachivayam, 2006; Osthaus, 2008). Although there is no evidence 
that inodilators such as Levosimendan (Abbott, Botany, NSW, Australia), improve non-
ischaemic or ischaemic oedema, more recent work in isolated hearts suggests beneficial 
effects only when given before ischaemia (Brendt, 2008).  
 
Isolated hearts that had additional swelling as a result of hyposmotic stress showed 
immediate mild dysfunction throughout a 20 minute test interval. This differed from the 
isolated cardiomyocytes that did not demonstrate altered contractility during eight 
minutes exposure. In the isolated heart, water could cause swelling in both the 
myocellular and interstitial compartments. Given the isolated cell data, the most likely 
explanation is that oedema within the interstitial compartment of the isolated heart caused 
a restrictive functional impairment – reduced ventricular distensibility. Alternatively the 
reduced peak calcium levels in swollen cardiomyocytes may have had greater functional 
implications in the whole heart – reduced ventricular contractility, not seen in the isolated 
cell. A trial of supplementary calcium or inodilator could potentially unravel the 
underlying mechanism of oedema induced myocardial dysfunction. 
 
Whatever the cause, the dysfunction associated with oedema was mild. Oedema 
occurring as part of the conventional crystalloid perfusate in isolated hearts has been 
studied by Rubboli et al and shown not to be associated with dysfunction (Rubboli, 
1994). Hearts perfused at conventional pressures for 105 minutes had 12.5% gains in 
water and no significant changes in either developed pressure or change in pressure over 
change in time (Rubboli, 1994). Only when perfusion pressure was escalated to 
supranormal levels did an association occur between MWC and developed pressure. It is 
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likely that normal membrane permeability was breached by excessive perfusion pressures 
(100 – 140mmHg), given the method of inducing oedema which exceeded 30%. Apstein 
et al also showed stability of function and water content in the isolated heart, following 
an initial and rapid gain in water. In this series of experiments it was also demonstrated 
that there was no difference in MWC between ischaemic and non-ischaemic rat hearts 
(Apstein, 1977).  
 
In the isolated heart we also analysed the myocardium for AQP1 mRNA and protein to 
determine if there was any change in expression with the induction of ischaemia and 
oedema. Over this timeframe there were no changes in AQP1 mRNA or protein 
expression. This was in keeping with animal models of ischaemia in other settings of 
relatively short duration, and agrees with the dogma that AQPs do not display rapid 
expression changes (Verkman, 2002a). AQPs tend to undergo slow transcription 
mediated changes in expression as demonstrated in a longer timeframe model of anaemia 
in a foetal sheep model (Jonker, 2003). As a consequence of this finding we deferred 
further molecular work to the large animal, longer timeframe setting. 
 
The use of conductance catheters in vivo would have allowed the capture of pressure 
volume loops and potentially more detailed functional analysis. Nevertheless for the 
significantly large insults studied it is likely that the methods used were adequately 
sensitive. Translating these isolated heart findings to the clinical setting is problematic. 
Recently in a large animal model small degrees of CPB associate oedema ~ 1 – 2% were 
not found to be associated with myocardial dysfunction (Fischer, 2006). Our finding that 
6 – 9% water gains caused mild and reversible dysfunction suggest that myocardial 
oedema, even of this degree clinically, may not have important functional implications. 
 
Thus ischaemia was confirmed as being of primary importance in causing myocardial 
dysfunction – principally diastolic dysfunction. Oedema was shown to be capable of 
causing mild, reversible dysfunction of a significantly lesser degree than that associated 
with ischaemia. The clinical importance of ischaemia and oedema in a whole animal 
model however remains to be established.  
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CHAPTER 6: LAMB CARDIOPULMONARY BYPASS MODEL 
 
Abstract 
 
 To assist in translation of our earlier in vitro work into the clinical environment, 
we established a clinically relevant large animal model to examine relationships between 
myocardial ischaemia, oedema and cardiac dysfunction, and to also assess the role of 
AQPs. 
 
Sixteen lambs were studied. Seven were non-bypass controls and nine underwent CPB. 
Six had 90 minutes of aortic cross clamping with blood cardioplegia and moderate 
hypothermia. The remaining three underwent CPB without aortic cross clamping. 
Haemodynamic and biochemical data were recorded, myocardial oedema, apoptotic 
markers and AQP expression were determined. 
  
The CPB with aortic cross clamp (AXC) group suffered global myocardial ischaemia, 
reperfusion and demonstrated reduced myocardial performance, with early postoperative 
tachycardia, hypotension, elevated serum lactate and impaired tissue oxygen delivery, 
compared to the CPB without AXC group. The CPB with aortic cross clamp lambs had 
increased myocardial water compared with non CPB lambs and a two fold increase in 
AQP1 mRNA expression compared to non CPB and CPB without aortic cross clamp 
lambs.  
  
A temporal association between haemodynamic dysfunction, myocardial oedema and 
increased AQP1 expression was found. CPB without ischaemia was associated with 
minimal oedema, negligible myocardial dysfunction and static AQP expression. 
Ischaemic reperfusion injury was the main cause of myocardial oedema and myocardial 
dysfunction. 
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6.1 Introduction 
 
 A large animal model of CPB was examined for two main reasons. Firstly in 
order to incorporate and extend the findings of the isolated cell and heart studies into the 
near clinical realm. Secondly to examine the effects of CPB ± ischaemia on myocardial 
function, oedema and membrane proteins over a longer duration in a whole animal 
comparable to the human infant. 
 
A similar albeit porcine model of CPB had been previously established locally. We 
decided upon an ovine model because AQP DNA sequences were published for the 
sheep, but not for the pig and because of physiological similarities between lambs and 
human infants. 
 
We replicated CPB with and without ischaemia in the form of aortic cross clamping 
(AXC) and we measured clinically relevant functional indices. We measured oedema, 
apoptosis and proteins of interest terminally as interval samples were considered 
potentially functionally detrimental. Our original intention was to use conductance 
catheter technology, but logistically this was not achievable. 
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6.2 Methods 
 
 As discussed in Chapter 2.  
 
6.2.1 Study design 
 
 Sixteen lambs of either sex were utilised weighing 7.4 ± 0.4kg.  
 
6.2.1.1 Non CPB controls 
 
 There were seven ‘controls’ that underwent cardiectomy without receiving 
cardiopulmonary bypass (non CPB controls). Lambs were prepared and monitored as for 
the CPB groups and maintained under anaesthesia for one hour prior to cardiectomy. 
Cardiac standstill was achieved following a terminal dose of cardioplegia in four of the 
seven controls. Blood was obtained from the ewe for the purpose of making blood 
cardioplegia. The other three non CPB controls were euthenased with pentobarbitone, 
also whilst under anaesthesia with the sternum open, allowing rapid cardiectomy and 
specimen preservation. These two approaches were used to account for the effect of 
cardioplegia on myocardial water, which is recognised to potentially increase MWC 
(Spotnitz, 1995).  
 
6.2.1.2 CPB groups  
 
 Of the nine CPB lambs, three underwent 90 minutes of bypass without aortic 
cross clamping (CPB-AXC) and were maintained for three hours after separation from 
bypass. The remaining six had AXC (CPB+AXC) and were maintained for either three 
(n=3) or six (n=3) hours after separation from bypass.  
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6.2.2 Tissue Analysis 
 
 As per Chapter 2 this included assessment of MWC, myocardial AQPs and 
apoptosis. 
 
6.2.3 Statistical Analysis 
 
 This was as per Chapter 2, apart from the following comments.  
  
Statistical significance for haemodynamic data was determined by both the Mann-
Whitney U test (MWU) and linear mixed models using covariance type AR–1. The 
animals receiving CPB±AXC were compared in terms of haemodynamic variables–both 
functional and biochemical. Haemodynamic variables were analysed over the complete 
survival period and also by comparison of 30 minute epochs. Our sample size gave us 
80% power to demonstrate that a 2.3 standard deviation effect size difference between 
groups was significant at p≤0.05.  
  
For measures of myocardial water, AQP1 expression and apoptosis, comparison was 
made between non CPB control animals and CPB±AXC, using MWU.  
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6.3 Results 
 
 All experiments were completed as intended and there were no significant 
differences in pre CPB haemodynamic values. There were no inotropes or vasodilators 
administered prior to CPB and baseline biochemical indices were not significantly 
different, (Table 6.1). The animals received similar weight-based doses of sedatives, 
analgesics, anaesthetics and muscle relaxants.  
 
Table 6.1. Baseline biochemical variables 
 
Pre CPB indices (mean±SEM) 
 
 
 
 
 
 
 
 
 
 
 
n 
 
Haemoglobin
(g/dL) 
 
 
Glucose 
(mmol/L)
 
Lactate 
(mmol/L)
 
Venous 
Saturation (%) 
 
COP 
(mmHg) 
 
Control 
 
 
4 
 
10.5±0.8 
 
6.5±1.0 
 
1.5±0.3 
 
78±14.9 
 
13.8±1.3 
 
CPB–AXC 
 
 
3 
 
10.3±0.2 
 
5.8±2.3 
 
1.4±0.5 
 
72.5±16.9 
 
12.3±1.5 
 
CPB+AXC 
 
 
6 
 
10.2±0.4 
 
5.7±0.4 
 
2±0.7 
 
76.8±4.7 
 
14.6±0.5 
 
AXC – Aortic cross clamp 
COP – colloid osmotic pressure 
CPB – cardiopulmonary bypass 
 
 
 139
6.3.1 Haemodynamics  
 
 The haemodynamic picture of reduced cardiac performance was seen in those 
animals that had CPB+AXC, (Figure 6.1). The CPB+AXC lambs were more hypotensive 
post CPB. Mean blood pressure (MBP) was significantly less by mixed model analysis, 
(p<0.01) following CPB. Diastolic blood pressure (DBP) was also significantly less using 
mixed model analysis, (p<0.05) after CPB. The differences remained at the end of the 
survival period. Systolic blood pressure (SBP) was lower in the CPB+AXC group and 
this was significantly so using MWU for the early and mid epochs post CPB. Heart rate 
was higher in the CPB+AXC group, also by MWU, in all but the last post CPB epoch. 
Central venous pressure, fluid requirements and doses of vasoactive medications did not 
differ between the groups.  
 
6.3.2 Biochemistry 
 
 The CPB+AXC group had a higher lactate (6.5mmol/L vs 3.6, p<0.05) after CPB. 
However by three hrs post CPB the differences were not significant, 3.1mmol/L in the 
CPB+AXC group and 2.1mmol/L in the CPB–AXC lambs. The CPB+AXC group had a 
persistently lower venous saturation after CPB. The initial post CPB venous saturation 
was 61% in the CPB+AXC group, compared with 76.7%, (p<0.05), in the CPB–AXC 
lambs. The venous saturations at three hrs post CPB were 70.0% and 83.8%, (p<0.05), 
respectively, (Figure 6.1). The glucose and haemoglobin levels remained similar in the 
two CPB groups. The COP was not significantly different between the two CPB groups 
at any time following CPB. COP showed the expected increase following MUF. In the 
CPB–AXC group it rose from 12.3mmHg to 14.5mmHg and in the CPB+AXC group 
from 13.5mmHg to 15.7mmHg. Following a further three hrs the COP values were 
13mmHg and 13.6mmHg respectively.  
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Figure 6.1. Haemodynamic and biochemical variables. In A–F, lambs are grouped as 
CPB without AXC, (solid line) and CPB+AXC (dashed line). A shows similar heart rates 
between groups, but after CPB the CPB+AXC group have a significantly higher heart 
rate until the last 30 minute epoch of postoperative analysis, (MWU). B displays systolic 
blood pressure which is significantly lower in the CPB+AXC group in the mid epochs 
following CPB, (MWU). C and D show mean blood pressure and diastolic blood pressure 
respectively, being significantly lower in CPB+AXC animals throughout the 
postoperative period, (mixed model analysis). E demonstrates a higher lactate in the 
CPB+AXC just prior to the completion of CPB, (MWU). In F, there is a corresponding 
fall in venous saturation in this group which remains throughout the postoperative period, 
(MWU), (*p<0.05). Mean ± SEM is shown. 
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6.3.3 Myocardial oedema 
 
 Myocardial water was increased (but, not significantly) in the control lamb tissue 
that was sacrificed following terminal cardioplegia; 0.785 as opposed to the control 
lambs which received pentobarbitone, 0.781. Myocardial water content in the CPB–AXC 
group was 0.787, whilst in the CPB+AXC group it was 0.796, which was significantly 
greater than cardioplegia control tissue, (p<0.05), but not different to CPB–AXC. In 
summary, there was a 1% increase in myocardial water associated with CPB+AXC with 
only a 0.2% increase in myocardial water in the CPB–AXC group, (Figure 6.2). 
 
 
 
Figure 6.2. Myocardial water. Proportion of heart as water in non CPB controls, CPB 
without AXC and CPB+AXC lambs. Significant myocardial oedema was present in 
CPB+AXC lambs and a non–significant increase in myocardial water occurred in CPB–
AXC lambs, (MWU), (*p<0.05). Mean ± SEM is shown. 
 
 
 
 
 
 
 142
5.3.4 Molecular results 
 
 Myocardial AQP1 mRNA by quantitative real time qRT-PCR was increased two 
fold in the CPB+AXC, compared with control tissue, (p<0.05). AQP1 mRNA in the 
CPB+AXC group was also significantly higher when compared to the CPB–AXC group, 
(p<0.05), (Figure 6.3). There was no associated increase in AQP1 on western blot 
analysis in either of the CPB groups, (Figure 6.4). AQP4 transcript was not altered 
compared to controls in either CPB group and low protein levels were also unchanged by 
experimental group (data not shown). AQP0, AQP3 and AQP9 transcripts were 
detectable at low levels. No appreciable changes were seen in these with qRT-PCR (data 
not shown). Protein for these three AQPs were not demonstrable by Western blot despite 
appropriate antibodies and control tissue (data not shown). 
 
 
Figure 6.3. Myocardial aquaporin 1 transcript expression. RNA was extracted from the 
myocardium of non CPB controls, CPB without AXC and CPB+AXC lambs. The 
quantitative real time PCR results shown are representative of at least three individual 
animals in each group and are representative of three independent sets of experiments. 
AQP1 mRNA was normalised to ribosomal 18S RNA(r18S RNA), (MWU), (*p<0.05) 
versus non CPB controls and CPB–AXC. Mean ± SEM is shown. 
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Figure 6.4. Myocardial aquaporin 1 protein expression. AQP1 protein was obtained from 
the myocardium of non CPB controls, CPB without AXC and CPB+AXC lambs. 
AQP1 protein was measured by Western blotting, analysed by densitometry and 
normalised to the expression of cardiac actin. Representative results demonstrate no 
significant differences between groups, (MWU). Mean ± SEM is shown.  
 
6.3.5 Apoptosis 
 
 Completed apoptosis was not demonstrable by TUNEL staining in any of the 
preparations to a significant degree. H+E stained slides also did not demonstrate necrosis, 
although tissue oedema was more apparent in the CPB+AXC group. Active caspase 3 
protein, an early marker of apoptotic pathway induction (Rodriguez and Schaper, 2005), 
was significantly increased in the CPB+AXC group. The control and CPB–AXC groups 
had comparable levels of caspase 3, (Figure 6.5).  
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Figure 6.5. Myocardial apoptosis. Representative results of non CPB controls, CPB 
without AXC and CPB+AXC lambs. i) H+E micrographs of ventricular myocardium 
taken at 100X magnification. The CPB+AXC images are suggestive of more tissue 
oedema, however there was no apparent necrosis. ii) Micrographs of TUNEL stained 
ventricular myocardium at 100X magnification. Appropriate positive and negative 
controls were performed (data not shown). No significant differences were seen in 
TUNEL staining, these images were prepared by Dr Tanya Butler. iii) Graph of the 
results of active caspase 3 densitometry for the 3 groups from Western blot analysis, 
loading controlled with cardiac actin. The CPB+AXC animals demonstrated a significant 
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increase in active caspase 3 protein, suggestive of active early apoptotic pathways, 
(MWU), (*p<0.05). Mean ± SEM is shown. 
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6.4 Discussion 
 
6.4.1 Haemodynamics 
 
 Haemodynamic changes consistent with reduced myocardial performance were 
seen following CPB. In the CPB+AXC animals there was significant tachycardia and 
systolic dysfunction. Impaired tissue oxygen delivery and lower diastolic pressure also 
occurred in those animals following CPB+AXC. CPB alone did not result in significant 
haemodynamic or biochemical derangements, it was I/R that was primarily associated 
with haemodynamic dysfunction and impaired tissue oxygen delivery. The primacy of 
I/R in precipitating reduced myocardial performance has been alluded to previously 
however in some well controlled animal experiments, this has not been demonstrated 
(Addetia, 1986; Blatchford, 1994). In our series, CPB alone was well tolerated and only 
when coupled with I/R did significant perturbations in circulatory function result. 
Consequently measures to minimise the duration and impact of I/R should be the focus of 
ongoing research into postoperative reduced myocardial performance or LCOS. 
 
6.4.2 Myocardial oedema 
 
 The greatest degree of myocardial oedema was seen in those animals following 
CPB with I/R. CPB without I/R was associated with development of some myocardial 
oedema, although not significantly different from baseline. Together with the isolated cell 
and isolated heart studies this supports a re-evaluation of the dogma surrounding 
myocardial oedema and its contribution to the development of myocardial dysfunction 
following CPB. Ischaemia is a potential confounder in several of the sentinel papers 
involved in asserting the link between oedema and dysfunction (Mehlhorn, 1995a; 
Mehlhorn, 1995b), and there have been no previous attempts to experimentally 
differentiate the contribution of ischaemia to oedema-associated dysfunction. Oedema 
does occur with CPB alone – in our study it was of the order of 0.2%, this was not 
associated with significant myocardial dysfunction. It is likely that oedema in this group 
was mainly interstitial or vasogenic in nature, resolved quickly and was not associated 
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with important dysfunction. Others have shown that such oedema should have resolved 
within six hours (Mehlhorn, 1995b). And in other studies MWC has increased up to 2% 
at two hours, in animal models of CPB, without dysfunction (Fischer, 2006). Hence it 
may have been possible to demonstrate greater myocardial oedema following CPB alone 
if we had looked earlier in the postoperative period, but such a timeframe would not 
correlate with LCOS and dysfunction that is seen 6–12 hours postoperatively. 
 
6.4.3 Ischaemia 
 
 Global ischaemia with aortic cross clamping resulted in raised lactate, reduced 
venous saturations and tended to increase CK. In our study, ischaemia was associated 
with a greater degree of oedema formation compared to CPB alone, and was associated 
with important dysfunction. The 1% increase in myocardial water that we observed 
following I/R could be expected to associated with a 10% reduction in myocardial 
function based on work by Laine et al (Laine and Allen, 1991). Interestingly in our 
isolated heart work there was also an additional 1% of myocardial oedema, compared 
with non-ischaemic hearts associated with a 20 minute ischaemia interval. Similarly 
diastolic dysfunction was more apparent than systolic dysfunction as seen in the CPB 
with I/R lambs. However, 2% water gains in animal CPB models did not result in any 
myocardial dysfunction using ultrasonic crystals and left ventricular micromanometers 
(Fischer, 2006), so it is unlikely that the moderate dysfunction we observed was caused 
by oedema. 
 
We did not measure cardiac output or load independent measures of myocardial function, 
but the average difference in mean blood pressure following CPB, when comparing those 
with or without I/R in our study, was 17mmHg (22%). This suggests that other factors, 
not oedema alone, were responsible. It is likely that I/R results in a greater degree of 
interstitial or vasogenic oedema which persisted, together with cytotoxic or myocellular 
oedema due to accumulation of lactate. In isolated cells, we have established that 
myocellular injury and dysfunction occurs following ischaemia with a degree of 
associated oedema. Cytotoxic oedema has been shown to be short lasting (Askenasy, 
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2001), but may reflect important injury of the contractile apparatus that persists for the 
duration of the LCOS, e.g. partial troponin I degradation as a consequence of calcium 
influx and oxygen derived free radicals (Bolli and Marban, 1999).  
 
6.4.4 Aquaporins 
 
 The increase in myocardial water occurred without a significant reduction in 
COP. This is in keeping with other reports modelling the capillary leak syndrome after 
CPB (Farstad, 2004; Tassani, 2007). Hence there was movement of free water down 
osmotic gradients across the endothelium into the myocardial tissue, as occurs in 
ischaemia (Wright and Rees, 1998). Water moves via AQPs which exist abundantly 
within the endothelium and sarcolemma, to leak into the intracellular space of the 
myocardium if osmotic gradients mandate, and as may occur early during reperfusion as 
a result of intracellular lactate accumulation (Wright and Rees, 1998; Au, 2004). 
 
AQP1 transcript was increased following CPB with ischaemia within the myocardium. 
This increase was specific to those animals that had I/R and not CPB alone. This was a 
two fold increase in transcript, but without an associated protein rise. AQP1 has been 
studied in a neonatal lamb heart previously, in a deep hypothermic circulatory arrest 
(DHCA) model – no change in AQP1 expression was found in this study (Tabbutt, 
1997b). Potentially AQP1 expression may have been modified by inducing deep 
hypothermia as has been described in other tissues and settings (Fujita, 2003). Such 
modifications may impact on oedema formation and function as reported elsewhere 
(Wernovsky, 1995; Tassani, 2002a), however the impact of DHCA vs. continuous flow 
on AQP expression was not examined in our study. There is an intriguing discrepancy in 
AQP1 mRNA following CPB + AXC and DHCA, perhaps underlying the differential in 
water accumulation with these two modalities of support. 
 
The finding that AQP1 transcript increased in the lamb after CPB+AXC extends our 
earlier results utilising a rat isolated heart model. In the rat, a brief period of global 
ischaemia with reperfusion was not associated with changes in AQP1 transcript or protein 
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levels. Species differences, duration of ischaemia and post ischaemic observation as well 
as utilisation of CPB may explain these differences. On the basis of our earlier work, we 
do not feel that species uniqueness adequately explain this difference since the AQP 
expression profile of the sheep is similar to rat and human. Duration of ischaemia may be 
important as up-regulation of AQP1 has been shown in interventions lasting hours or 
days rather than minutes. In a foetal sheep model, anaemia induced myocardial AQP1 
increase over five days, suggesting that longer timeframes permitted adjustments in 
myocardial AQP1 protein levels (Jonker, 2003). As longer duration experiments have 
permitted changes in AQP transcript to be uncovered, it is likely that 9–12hr experiments 
would be necessary to determine if protein changes occur. We cannot determine the 
significance of the demonstrated two fold rise in AQP1 transcript and this finding 
warrants further study. Interestingly though, the two fold increase we found was identical 
to the increase described by Jonker et al after a more prolonged insult. A two fold 
increase could represent the maximal upscaling of AQP1 expression. 
 
6.4.5 Apoptosis 
 
 The suggestion by Calderone et al that induction of apoptotic pathways may cause 
post-ischaemic dysfunction, as well as later cell loss, is an intriguing hypothesis 
(Caldarone, 2004). We sought to corroborate these findings, but did not demonstrate 
completed apoptosis as an important factor in LCOS over the early time period. We did 
however demonstrate increased expression of active caspase 3 in the CPB+AXC animals 
suggestive of early apoptotic activation (Rodriguez and Schaper, 2005). Mitochondrial 
function was not measured in our study. The negative predictive value of TUNEL is 
greater than its positive predictive value, especially because it can be positive during 
tissue regeneration and recovery (Rodriguez and Schaper, 2005). We support the 
possibility that apoptosis may be a contributing factor to LCOS and this may be 
particularly important in young infants having multiple operations with progressive cell 
loss over time. Since ischaemia is the likely pro–apoptotic trigger, the findings reinforce 
the importance of better managing the myocardium during ischaemia.  
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6.4.6 Limitations 
 
 These experiments were limited by their small size and that they were conducted 
in animals. The animals also did not have structural heart disease and hence no 
preoperative volume or pressure loading. Measurements of vascular/ventricular coupling 
as well as load independent measurements of systolic and diastolic function would be 
preferable in future experiments. The haemodynamic and functional monitoring used to 
support our findings were somewhat rudimentary, but equivalent to techniques relied 
upon in the clinical setting. 
 
6.4.7 Conclusions 
 
 Ischaemia and reperfusion were associated with a significant degree of 
myocardial oedema, clinically relevant dysfunction and increased expression of AQP1. 
Oedema formation is mostly related to ischaemia and not CPB. The main focus in LCOS 
research should be the prevention of post-ischaemic dysfunction rather than the systemic 
inflammatory response to CPB and generalised water accumulation.  
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CHAPTER 7. MYOCARDIAL MEMBRANE INJURY AND 
POLOXAMER 188  
 
Abstract  
 
 Poloxamer 188 (P188) was studied in isolated heart models, focusing on oedema, 
ischaemia and function. P188 was then studied in an extended duration lamb CPB model 
together with an assessment of membrane injury and the membrane proteins dystrophin, 
dysferlin and AQP1. 
 
Low and high dose P188 trials in isolated rat hearts were undertaken with and without 
global ischaemia, with measurement of function (LVDP and Dp/Dtmin) and MWC. In a 
lamb CPB model, eight lambs were randomised to saline±P188. Lambs underwent two 
hours of CPB and aortic cross clamping. After a further nine hours of monitoring the 
hearts were assessed for water content, capillary leak and protein expression. 
  
In the isolated rat heart with low dose P188, there was a significant reduction in non-
ischaemia associated myocardial oedema, (p=0.03). Whilst in the high dose trial, P188 
was associated with a trend towards improved diastolic function following ischaemia, 
(p=0.06), and no difference in myocardial water. In the lambs, P188 was associated with 
an improved haemodynamic profile (higher blood pressure, higher venous saturation and 
lower lactate), although the heart rate tended to be higher. Dystrophin expression was 
unaffected by ischaemia/reperfusion and dysferlin expression was reduced. AQP1 protein 
increased following ischemia/reperfusion. P188 administration was associated with 
supra-normal levels of dystrophin, preservation of dysferlin expression and normalisation 
of AQP1 expression. P188 was associated with less capillary leak, maintained colloid 
osmotic pressure and less haemodilution.  
  
Isolated heart trials of P188 support a non-rheological mechanism of action. Low micelle 
doses appear to reduce endothelial leakiness in non-ischaemic settings, whilst higher 
doses are associated with a trend towards improved diastolic function in the setting of 
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ischaemia. In the lamb CPB model, indicators of reduced myocardial performance such 
as lower blood pressure and lower oxygen delivery, were lessened in association with the 
administration of P188. Changes in protein expression within the myocardial membrane 
were found in a clinically relevant model of paediatric cardiac surgery. P188 was also 
associated with potentially beneficial changes in membrane protein expression, reduced 
capillary leakage and less haemodilution. P188 is a potentially useful therapy in the 
setting of planned ischaemia/reperfusion.  
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7.1 Introduction 
 
 Given the primacy of ischaemic injury seen in the isolated cell, isolated heart and 
initial lamb CPB studies, we focused our investigations on the myocardial membranes. 
Markers of injury and a therapy to potentially protect the membranes of the heart were 
investigated. P188 was an acceptable candidate therapy – as discussed in Chapter 1, and 
therefore was initially trialled at a low dose to avoid free micelle formation in an isolated 
heart model. Subsequently at a higher, more clinically relevant dose – as discussed in 
Chapter 2, P188 was tested in isolated rat hearts and then in the lamb. The lamb CPB 
experiments utilised an extended recovery period to determine if AQP1 protein as well as 
mRNA changes occurred. Dystrophin and dysferlin, which both have roles in membrane 
integrity and repair, were also examined. The focus was to determine the impact of 
ischaemia/reperfusion on dystrophin and dysferlin, as well as whether P188 may reduce 
ischaemic injury related dysfunction in a clinically relevant model. 
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7.2 Methods 
 
 As per Chapter 2, an additional schema of the isolated rat heart trials and lamb 
CPB model are included here, (Figure 7.1). 
 
7.2.1 Isolated rat heart trials of P188 
 
7.2.1.1 Low dose P188 trial 
 
 Five treatment groups with at least six animals in each were compared. Ischaemic 
and non-ischaemic groups were randomised to P188 or conventional buffer, (Figure 7.1 – 
1A – D). Tissue analysis and statistics was as per Chapter 2. 
 
7.2.1.2 High dose P188 trial 
 
 Two groups of five animals were randomised to P188 or placebo, (Figure 7.1 – 
2A). Tissue analysis and statistics were as per Chapter 2. 
 
7.2.2 Lamb CPB trial of P188 
 
 Eight lambs of either sex were utilised weighing 20.3±1.7kg. Three lambs 
received placebo (CPB–P188) and five received P188 (CPB+P188), (Figure 7.1 – 3).  
  
In earlier experiments, (see Chapter 6), lambs underwent CPB±AXC. Myocardial tissue 
from these animals was assessed for dystrophin and dysferlin expression. Also in these 
earlier experiments, three lambs were anaesthetised, received no PBS±P188 and were 
sacrificed prior to CPB, for non CPB data (non CPB controls). 
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Figure 7.1. P188 experimental protocol summary, including 1). low and 2). high dose 
isolated heart trials and the 3). lamb CPB P188 trial. 
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7.2.2.1 Tissue analysis 
 
 This was as per Chapter 2 and included assessment of MWC, myocardial AQPs, 
dystrophin, dysferlin and Evans blue staining. 
  
7.2.2.2 Statistical Analysis 
 
 This was as per Chapter 2, apart from these comments.  
 
The lambs ± P188 were compared in terms of haemodynamic variables–both functional 
and biochemical. Haemodynamic data variables were analysed over the complete 
survival period and also by comparison of 60 minute epochs. Our sample size gave us 
80% power to demonstrate that a 0.7 standard deviation effect size difference between 
groups was significant at a p value of 0.05. For measures of protein expression, 
myocardial water and blood tests, comparison was made between control animals and 
nine hour post CPB ± P188, using MWU.  
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7.3 Results 
 
7.3.1 Isolated heart trials 
 
7.3.1.1 Low dose trial 
 
 All experiments proceeded as planned. Five treatment groups were compared with 
at least six animals in each group; baseline (hearts excised and not perfused), 20 minute 
perfusion controls, 120 minute perfusion controls (without ischaemia) ± P188, and 20 
minute perfusion followed by 30 minutes ischaemia, followed by 80 minutes reperfusion 
± P188, (Figure 7.1 A – D). 
  
7.3.1.2 Haemodynamics  
 
 Heart function was assessed as LVDP measured at systole (LVDP–S) and diastole 
(LVDP–D) without ischaemia ± P188 (Figure. 7.2). Hearts that were perfused for 120 
minutes were stable, with a slight decline in systolic and slight rise in diastolic pressures. 
Animals that received P188 had a trend towards a higher diastolic pressure, (p=0.116), 
whilst the systolic pressure of P188 perfused animals was similar, (p=0.473) to standard 
perfusate animals, (Figures 7.2). Ischaemia for 30 minutes principally affected diastolic 
function, there was no significant difference between groups in terms of systolic, 
(p=0.313) or diastolic function, (p=0.684), (Figure 7.3).  
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Figure 7.2. Left ventricular developed pressure (LVDP) in non-ischaemic rat isolated 
hearts. These hearts were perfused for 120 min ± P188. See text for details. 
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Figure 7.3. Left ventricular developed pressure (LVDP) in ischaemic rat isolated hearts. 
These hearts were perfused ± P188, initially for 20 minutes, then after 30 minutes global 
ischaemia were again perfused for 70 minutes. See text for details. 
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7.3.1.3 Myocardial water 
 
 The baseline hearts had a MWC of 0.768 ± 0.0008. The MWC of non-ischaemic 
hearts perfused for 120minutes was 0.819 ± 0.0037, (p=0.025 compared with baseline) 
and for those with P188 was 0.78± 0.0069, (p=0.05 compared to baseline and p=0.025 
between groups). The MWC of ischaemic hearts was 0.827 ± 0.0055, (p=0.025 compared 
with baseline) and for those with P188, 0.827 ± 0.0035, (p=0.02 compared to baseline 
and p=0.58 between groups), (Figure 7.4). 
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Figure 7.4. Myocardial water content for isolated rat hearts; allocations including ± P188. 
See text for details, 120 min+P188 hearts were the driest perfused hearts, compared with 
baseline and 120 min–P188, (*#p<0.05). 
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7.3.1.4 High dose trial 
 
 All experiments proceeded as planned. Two treatment groups were compared 
with five animals in each group; 20 minutes perfusion followed by 30 minutes ischaemia, 
followed by 60 minutes reperfusion±P188, (Figure 7.1 – 2A). 
  
7.3.1.5 Haemodynamics  
 
 Heart function was assessed as LVDP and analysed in systole and diastole. There 
were no appreciable differences in systolic pressures between groups, (p=0.557), (Figure 
7.5). There was a trend towards lower diastolic pressures in the P188 group, (p=0.128), 
(Figure 7.6). Improved diastolic function was supported by a trend towards Dp/Dtmin 
being lower in the P188 group, (p=0.064), (Figure 7.7). 
0
20
40
60
80
100
120
140
160
10 20 30 40 50 60 70 80 90 100 110
Time(mins)
L
V
D
P-
sy
st
ol
ic
(m
m
H
g)
M
ea
n±
SE
M
–P188
+P188
 
Figure 7.5. Left ventricular developed pressure (LVDP) – systolic ± P188. See text for 
details. This figure was prepared by Dr Tanya Butler. 
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Figure 7.6. Left ventricular developed pressure (LVDP) – diastolic ± P188. See text for 
details, there was a trend to lower diastolic pressures with P188, (p=0.1). This figure was 
prepared  by Dr Tanya Butler. 
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Figure 7.7. Contractility; Dp/Dtmin. See text for details, there was a trend to lower 
Dp/Dtmin with P188, (p=0.06). This figure was prepared by Dr Tanya Butler. 
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7.3.1.6 Myocardial water 
 
 There was no differences between the MWC of these two groups. P188 hearts had 
an MWC of 0.827 ± 0.008 and non P188 hearts were 0.827 ± 0.023, (p=0.917). 
 
7.3.2 Lamb CPB trial 
 
 All experiments were completed as intended. No inotropes or vasodilators were 
administered prior to CPB and rates of administration following CPB were similar, 
(Table 7.1). There were no significant differences in pre CPB haemodynamic values, 
apart from a lower heart rate in the CPB+P188 group, (Table 7.2). 
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Table 7.1. Various measurements pre and post CPB. 
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Table 7.2. Haemodynamic and laboratory variables post CPB 
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7.3.2.1 Molecular results 
 
 Dystrophin measured in membrane fractions by Western blot was unchanged in 
the CPB–P188 group compared with non CPB controls, (p=0.3). Membrane dystrophin 
expression was higher in the CPB+P188 group (using antibodies to both C-terminus and 
rod domain) compared to CPB–P188 and non CPB control groups, (p<0.05, Figure 
7.8A). Antibodies to the N-terminus of the human form of dystrophin did not cross-react 
with sheep dystrophin. 
 
Dystrophin in membrane fractions by Western blot was also examined in our earlier 
work, from Chapter 6. No significant differences were seen with and without AXC or 
following various durations post CPB, (Figure 7.9). 
  
Dysferlin expression was significantly reduced in membrane fractions following CPB in 
the CPB–P188 group compared with non CPB controls by Western blot, (p<0.05). In the 
CPB+P188 group there was maintenance of dysferlin expression at levels similar to those 
in the non CPB control animals, (p=0.8, Figure 7.8B). 
 
Dysferlin expression in membrane fractions was also examined in our earlier work by 
Western blot. In these experiments we found a reduction in dysferlin with AXC and an 
increased reduction with a longer duration of reperfusion following CPB, (Figure 7.9). 
  
AQP1 protein levels were increased nine hours following CPB in the CPB–P188 group 
compared with non CPB controls by Western blot, (p<0.05). The CPB+P188 animals 
displayed less of a rise in AQP1 protein expression compared with non CPB controls, 
(p=0.28, Figure 7.10). 
 
Active caspase 3 protein was analysed by Western blot. There were no significant 
differences between groups and compared with baseline levels, (Figure 7.11). 
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Figure 7.8. Myocardial membrane fraction densitometry. Membrane fractions were 
measured by densitometry of Western blots (controlled for protein loading by α actinin-2 
measurement). Lambs were grouped as non CPB controls (dark column), CPB–P188 
(grey column) and CPB+P188 (open column). Protein levels were compared between 
groups using the Mann-Whitney U test. A. The CPB+P188 group showed higher 
membrane dystrophin levels compared with non CPB controls, (*p<0.05) and CPB–P188 
(#p<0.05). B. The CPB–P188 group showed a significant decrease in dysferlin 
expression compared to non CPB controls, (*p<0.05). Mean ± SEM is shown. 
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Figure 7.10. Myocardial aquaporin 1 protein expression. Western blot analysis of total 
AQP1 protein was normalised to cardiac actin. Lambs were grouped as non CPB controls 
(dark column), CPB–P188 (grey column) and CPB+P188 (open column). Protein levels 
were compared between groups using the Mann-Whitney U test. Representative results 
demonstrate a significant increase at 9hrs after CPB in the CPB–P188 group, compared 
with non CPB controls, (*p<0.05). Mean ± SEM is shown. 
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Figure 7.11. Active caspase 3 protein expression. Western blot analysis was normalised 
to cardiac actin. Lambs were grouped as non CPB controls (dark column), CPB–P188 
(grey column) and CPB+P188 (open column). Protein levels were compared between 
groups, using the Mann-Whitney U test, there were no differences. Mean ± SEM is 
shown. 
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7.3.2.2 Myocardial oedema 
 
 The myocardium of CPB–P188 animals tended to be more oedematous 0.78 ± 
0.005 compared to the hearts of the CPB+P188 group 0.77 ± 0.003 although non-
significantly, (p=0.08). Evans Blue uptake was greater in the CPB–P188 group, (2.6±0.2) 
compared to the CPB+P188 group, (1.7±0.2, p<0.05). Albumin tended to fall by more in 
the CPB–P188 animals than the CPB+P188 group (3.33 ± 0.67g/L, vs 0.8 ± 1.7g/L), 
although non-significantly, (p=0.17). Colloid osmotic pressure (COP) was significantly 
reduced by 3.5 ± 0.46mmHg in the CPB–P188 animals at nine hours compared to 1.46 ± 
0.58mmHg in the CPB+P188 animals, (p<0.05), (Figure 7.12A and Table 7.2). There 
were no significant differences in volumes of crystalloid or colloid fluid administered, 
(Table 7.1). There was a trend towards greater chest drain losses in the CPB–P188 group, 
(p=0.13, Table 7.1). 
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Figure 7.12. Measures of colloid osmotic pressure and haemoglobin. Lambs were 
grouped as CPB–P188 (dashed line) and CPB+P188 (solid line). Comparison between 
groups was by the Mann-Whitney U test. A. Reduction in Colloid osmotic pressure 
(COP) was greater at nine hours in the CPB–P188 group 3.5 ± 0.46mmHg compared to a 
drop of 1.46 ± 0.58mmHg in the CPB+P188 animals, (*p<0.05). B. Haemoglobin 
dropped in the CPB–P188 group following CPB compared with the CPB+P188 animals, 
(*p<0.05).  
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7.2.2.3 Biochemistry and haematology 
 
 Creatinine increased in the CPB–P188 group by 10.7 ± 4.4µmol/L, compared 
with a reduction in the CPB+P188 animals of 11 ± 6.9µmol/L, (p<0.05). Urea tended to 
increase not significantly in the CPB–P188 group 1.78 ± 0.49mmol/L, whilst in the 
CPB+P188 animals it rose by 0.72 ± 0.67mmol/L, (p=0.18). Total CK and troponin T did 
not differ significantly between groups, (Table 7.1). The CPB–P188 group initially had a 
higher lactate following reperfusion compared with the CPB+P188 animals, (p<0.05, 
Figure 7.13E and Table 7.2). Venous saturation was increased from baseline in those 
receiving P188 at six and nine hours post CPB, (p=0.05, Figure 7.13F and Table 7.2). 
P188 was associated with a maintenance of Hb and Hct compared to baseline, (Figure 
7.12B and Table 7.2). There were no significant differences in other haematology and 
coagulation tests, (Table 7.1).  
 
7.2.2.4 Haemodynamics  
 
 Heart rate and systolic blood pressure (SBP) tended to be lower in the CPB–P188 
animals in the later epochs, (p<0.01 at 7–9 hrs post CPB), but overall were not different, 
(p=0.15 and p=0.12 respectively), (Figures 7.13A&B and Table 7.2). The CPB–P188 
animals had significantly lower mean blood pressure (MBP) and diastolic blood pressure 
(DBP) throughout the nine hour period following CPB, (p<0.01), (Figures 7.13C&D and 
Table 7.2). Central venous pressure (CVP) was similar overall between groups, (p=0.88, 
Table 7.2).  
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Figure 7.13. Haemodynamic and biochemical variables. Lambs were grouped as CPB–
P188 (dashed line) and CPB+P188 (solid line). Comparison between groups was by both 
the Mann-Whitney U test and linear mixed models using covariance type AR–1 as 
appropriate. A. Heart rate (HR) was higher in the CPB+P188 group during the later 
epochs, but overall the difference was not significant. B. Systolic blood pressure (SBP) 
was significantly higher in the CPB+P188 group during the later epochs, but overall not 
different. C and D show mean blood pressure (MBP) and diastolic blood pressure (DBP) 
respectively. Both are significantly higher overall in the CPB+P188 group, (*p<0.01). E. 
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Demonstrates a lower lactate in the CPB+P188 group following reperfusion, (*p<0.05), 
but similar levels subsequently. F. The change in venous saturation after CPB compared 
with baseline, was significantly higher in the CPB+P188 group at six and nine hours post 
CPB, with a final increase of 10 ± 7% compared with a drop in the CPB–P188 group of 9 
± 3%, (*p=0.05). Mean ± SEM is shown. 
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7.4 Discussion  
 
7.4.1 Isolated heart models 
 
 The ischaemic isolated heart model produced diastolic dysfunction which was not 
ameliorated by low dose P188. At this dose where P188 has been shown to fill 
endothelial defects (Maskarinec, 2002) there was no appreciable effect on function or 
myocardial water gain in the setting of ischaemia. However at this dose in non-ischaemic 
hearts P188 was associated with significantly drier hearts, ~ 4% drier. This is a 
substantial difference in myocardial oedema. Interestingly, this degree of oedema 
reduction had no functional impact and these hearts trended towards slightly worse 
diastolic dysfunction than the non P188 treated hearts. Thus a therapy associated with a 
4% reduction in MWC had no measurable functional benefit in the isolated heart. This 
was an interesting and novel finding suggesting that P188 was able to block the hypo–
oncotic induction of oedema that is an inherent anomaly of the crystalloid Langendorff 
perfusate (Apstein, 1977). A potential mechanism would be by blocking endothelial 
leakiness, perhaps by endothelial clefts or AQPs. 
 
The subsequent trial of P188 at higher doses was improved by blinding, and 
demonstrated a trend towards improved diastolic function associated with P188 
administration. The developed diastolic pressure was ~ 15–20mmHg less than placebo. 
The lower Dp/Dtmin in the P188 group was also supportive of improved diastolic function 
in this small trial. No changes in systolic function or MWC were seen. Given the lack of 
blood in the study it suggested that non-rheological mechanisms, such as membrane 
protective mechanisms may be at work. The absence of differences in MWC further 
suggested that the blocking of endothelial leakiness was not effective in the setting of 
ischaemia and that other mechanisms were present. Again the discrepancy between 
oedema and function was seen, no difference in oedema was found despite differential 
function, this time in the setting of ischaemia. This finding was supportive of subsequent 
work and of extrapolation to the large animal model to determine if there was any benefit 
in the setting of the combined insults of CPB and I/R.   
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7.4.2 Lamb CPB model 
 
 A clinically accurate animal model of reduced myocardial performance was 
studied with a blinded trial of P188. Previously undescribed changes in expression of 
proteins within the myocardial membrane were found. Hallmarks of reduced 
performance, such as lower blood pressure and lower oxygen delivery were lessened in 
association with the administration of P188. P188 treatment was also associated with 
potentially beneficial changes in membrane protein expression, reduced capillary leakage 
and reduced haemodilution. However this was a small study and consequently its 
findings can at best suggest avenues for further analysis. Our use of clinically relevant 
surgical, perfusion and anaesthetic techniques provided a clinically valid model of the 
milder spectrum of LCOS.  
 
7.4.3 Dystrophin 
 
 Dystrophin is a candidate protein in the contractile failure which occurs in the 
setting of LCOS and has not been previously investigated in this context. Regional 
ischaemia by coronary occlusion in animals, has been shown to reduce both its membrane 
location and overall expression (Kido, 2004; Rodriguez, 2005). Ischaemic 
cardiomyopathy has also been associated with reduced dystrophin expression (Vatta, 
2002). In several ways, regional ischaemia and end stage ventricular failure represent 
more severe forms of pathology than that experienced with present day infant heart 
surgery. In our clinical model of LCOS we found no change in dystrophin following CPB 
with I/R. This was supported by earlier work which showed no difference with respect to 
CPB±AXC or duration of reperfusion. Evidence from others suggests it is possible that 
changes occurred only at the N-terminus which we were not able to study with the 
antibodies available for sheep. However we consider this unlikely, given that we 
observed changes in dystrophin expression associated with P188 therapy that were 
identical with both the rod domain and C-terminus antibodies. Others have similarly 
shown ischaemia related changes in dystrophin that were not specific to the N terminus 
(Toyo-Oka, 2004). CPB with I/R represents a planned insult and current myocardial 
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protection techniques appear adequate in preventing an acute dystrophinopathy occurring 
in this setting.  
 
7.4.4 Dysferlin 
 
 Dysferlin has been shown to have a specific and critical role in membrane repair 
in animal models of both skeletal and cardiac muscle (Bansal, 2003; Han, 2007), but its 
response to CPB and I/R has not previously been determined. In earlier work, membrane 
dysferlin was found to be reduced in association with ischaemia (AXC) and further 
reduced with longer reperfusion durations. Membrane dysferlin protein expression was 
again confirmed to be reduced following CPB and I/R in this current study. Thus we have 
shown reduced dysferlin expression in association with ischaemia and increased duration 
of reperfusion, but not with CPB alone. Dysferlin loss was also associated with evidence 
of increased membrane damage and a greater reduction in COP. Available studies 
suggest dysferlin-mediated membrane repair is indispensable for the maintenance of 
cellular integrity in models of myocellular stress (Han, 2007). Thus, the reduction in 
dysferlin associated with I/R may represent an important aspect of the pathophysiology 
contributing to LCOS. 
 
Our findings are in keeping with the role of dysferlin in maintaining membrane integrity 
and reducing membrane leakiness in skeletal and cardiac muscle models (Bansal, 2003; 
Han and Campbell, 2007). In the endothelium of the brain, dysferlin has been shown to 
be present in areas of inflammation and to increase perivascular leakiness. Dysferlin 
expression was also increased by tumour necrosis factor in brain endothelial tissue 
(Hochmeister, 2006). Dysferlin has not been described in the blood vessels of muscle. 
However this is an intriguing interaction worthy of further exploration, as tumour 
necrosis factor is generally accepted as having a role in postoperative myocardial 
dysfunction (Wan, 1997). 
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7.4.5 Low cardiac output state 
 
 LCOS in this study was mild and characterised by lower blood pressure and 
impaired oxygen delivery. Lactate was raised following CPB whilst venous saturations 
and blood pressure were reduced after CPB in the control group. Post CPB venous 
saturations, blood pressure and lactate were improved in association with P188. 
Haemoglobin was preserved following CPB in association with P188 administration and 
this is likely to have partly contributed to improved oxygen delivery and haemodynamics 
in this group. Large studies have shown an association between reduced haemodilution 
and improved outcome. Interestingly Jonas et al in the Boston Haemodilution study also 
reported an initially raised lactate following CPB in the more haemodiluted group (Jonas, 
2003). The control animals in our study had a drop in Hb on CPB, and following CPB 
were more haemodiluted than the CPB+P188 animals. These control animals also had an 
initially raised lactate following CPB. This pattern of haemodilution was also seen in our 
previous large animal experiments – outlined in Chapter 6. In the P188 group of animals 
however there was a stable haemoglobin on CPB and the lactate was not as elevated as in 
the control group following CPB. This rise in haemoglobin was maintained throughout 
the postoperative period. Given that there were no substantive differences in coagulation, 
P188 may be responsible for minimising red cell loss and minimising haemodilution 
through reducing membrane injury. 
 
7.4.6 Dystrophin and P188 
 
 Animals in the control group had unaltered dystrophin, reduced dysferlin 
expression and increased membrane damage. P188 has been shown by others to rapidly 
correct abnormalities in dystrophin (Yasuda, 2005), although in the post cardiac surgery 
setting an acute dystrophinopathy was not apparent in our study. Interestingly, P188 
therapy was associated with an increase in membrane dystrophin to supra-normal levels. 
Increased membrane dystrophin has been shown to occur in response to ischaemic 
preconditioning in an animal model, suggesting increased expression of dystrophin may 
have beneficial functional effects (Kido, 2004). The role of this increase in dystrophin 
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expression cannot at this stage be linked to the apparent improvements seen with this 
treatment. 
 
7.4.7 Dysferlin and P188 
 
 It has been suggested that P188 would also be beneficial in the setting of 
abnormalities in dystrophin-related proteins such as dysferlin (Yasuda, 2005). P188 
administration prior to CPB and I/R was associated with maintenance of normal dysferlin 
levels. Maintenance of dysferlin levels has been shown in other settings to be associated 
with less membrane injury (Han, 2007). There was evidence of less membrane injury in 
the animals receiving P188 and these animals also had higher dysferlin expression levels. 
Hence dysferlin warrants further study in this post CPB setting. 
 
7.4.8 Other effects of P188 
 
 P188 may have other haemodynamic effects. The prophylactic use of P188 has 
shown benefit in improving blood viscosity (Hunter, 1990; Fatkin, 1997). P188 was also 
shown to have benefits on neurological outcome after deep hypothermic circulatory arrest 
in a large animal CPB model (Mezrow, 1992). Despite these benefits in planned 
ischaemia, it was not beneficial in a large clinical trial as adjunctive therapy following 
acute myocardial infarction (Yusuf, 1997). There were no beneficial effects on infarct 
size or haemodynamics and concerns arose regarding renal impairment from P188. It is 
possible that benefits associated with P188 were obscured by patient heterogeneity and 
the failure of P188 to treat, rather than prevent ischaemia related injury. In studies of 
membrane integrity following electrical injury, membrane integrity was enhanced only 
by prophylactic treatment with P188 (Lee, 1992). In our study the use of MUF with CPB 
may have removed excess P188 and perhaps minimised any renal injury. We did not 
demonstrate a rise in creatinine associated with P188, creatinine was in fact reduced in 
those animals, as it also was in an earlier animal myocardial infarct study (Justicz, 1991). 
We found a maintenance of haemoglobin levels and no coagulopathy associated with its 
use, therefore P188 may have reduced red cell fragility.  
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7.4.9 Aquaporins 
 
 The role of oedema and water transport proteins in the setting of LCOS has not 
been established. We have previously demonstrated that AQP1 mRNA increased two fold 
in the setting of LCOS following CPB with I/R, but did not observe an associated rise in 
AQP1 protein at three hours, Chapter 6. Following a longer period ( nine hours) of 
observation both AQP1 mRNA and protein were increased two fold. Whilst a two fold 
increase was modest, the associated changes in capillary leak suggested that AQP1 may 
have a role in capillary leak. To determine whether this change in AQP1 expression was a 
pathological or beneficial compensatory response will require direct modulation of the 
channel. Increased AQP1 expression could be part of the explanation for the transudate 
which occurs into the tissues of the body following CPB and I/R (Farstad, 2004). It is 
likely that AQP1 has a role in permitting water to meet its osmotic obligations in this 
setting. Because AQP1 is so prevalent already in the endothelial membrane and because 
increased AQP1 transcript was primarily seen after I/R, perhaps the increased AQP1 
expression is just at the myocellular membrane to permit water movement across this 
membrane, which is particularly vulnerable to ischaemia. 
 
7.4.10 Limitations 
 
 This study was limited by its small size and that it was conducted in animals. A 
range of clinically relevant refinements such as inotropes, vasodilators, cardioplegia and 
MUF were used to improve the clinical validity of the model. These therapies are likely 
to have reduced the underlying severity of myocardial dysfunction and may have had 
other effects, but given their place in current clinical practice they were included. The 
haemodynamic and functional monitoring used to support our findings was simple, but 
equivalent and relevant to techniques relied upon in the clinical setting. All animals were 
managed in the post CPB period by one individual in the same way with a view to 
maintaining critical parameters within acceptable limits. This best reflects clinical 
practice but added a potentially confounding variable in assessing outcomes, blinding to 
therapy should effectively have minimised any impact from this variable.  
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The molecular changes which occurred in dysferlin and AQP proteins are novel and 
warrant further investigation. Load-independent measurements of systolic and diastolic 
function would be beneficial in future studies to completely define the functional effects 
related to P188. Although we have not sought to define the mechanistic action of P188 in 
this study, we have generated data to support further study of P188 in this setting. The 
demonstration of less oedema and better functional indices associated with P188 was in 
agreement with the initial isolated heart studies. Whether the insults of CPB and or I/R 
are principally protected against by P188, can only be speculated upon at this stage. 
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CHAPTER 8: CONCLUSIONS 
 
8.1 Key findings and future work 
 
 Ischaemia was of primary importance in causing myocardial dysfunction in 
models analogous with the postoperative LCOS setting. CPB without ischaemia was well 
tolerated and not associated with myocardial dysfunction or oedema compatible with 
contributing to early postoperative dysfunction. Ischaemia of increasing duration initially 
resulted in greater degrees of diastolic dysfunction and eventually in associated systolic 
dysfunction. Ischaemic injury to the myocardium resulted in increased acidosis, reduced 
myocardial oxygen delivery and higher ischaemic markers. This injury was also 
associated with increased intracellular calcium, membrane injury and myocardial 
oedema.  
 
In comparison, oedema as a result of CPB or non-ischaemic hypo–osmotic exposure was 
generally greater than that seen with ischaemia, but associated with mild and reversible 
dysfunction at most. There was no evidence of membrane injury, apoptosis or calcium 
excess in the non-ischaemic setting. Thus myocardial ischaemia was of significantly 
greater relative importance in its contribution to myocardial dysfunction, compared with 
myocardial oedema. 
 
Ischaemia clearly needs to be the focus of myocardial protective strategies, rather than 
oedema or CPB which are not associated with significant dysfunction. Insulating the 
contractile apparatus from reperfusion injury with novel agents – such as P188 may have 
a role. Alternatively providing better myocardial protection during planned ischaemia by 
utilising new myocardial protection strategies – such as adenosine/lignocaine based 
cardioplegia (Dobson and Jones, 2004; Jin, 2008), may potentially improve the 
myocellular metabolic environment during I/R. Associated oedema in response to 
osmotic obligated movement via AQPs is apparent, but does not contribute to important 
dysfunction.  
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AQP1 is the only water channel responsible for water movement within mammalian 
hearts. It permits rapid water flux across endothelial membranes and slightly slower 
transit across the myocellular membrane. It is not important in mitochondrial membranes 
and expression does not rapidly alter in response to ischaemia or other severe osmotic 
insults. AQPs permit osmotically obligated water transit and over lengthy durations will 
increase expression, but probably only to the extent of doubling their protein expression. 
With ischaemia associated increases in AQP expression, it is likely that most of the 
increased expression is at the myocellular membrane, given the abundant endothelial 
expression that already exists. In this setting, AQPs are passive and subject to the 
gradients generated by ischaemia, haemodilution and albumin leakage. There is no 
apparent role for their modulation in the postoperative setting. In the preoperative setting 
however, some infants become particularly oedematous whilst receiving prostaglandin 
infusions to maintain ductal patency. The diuretic acetazolamide is known to inhibit 
AQPs (Tanimura, 2008) and this could potentially minimise preoperative oedema which 
tends to contribute further to postoperative fluid accumulation in the soft tissues. 
Examination of the AQP1-/- knockout mouse cardiac phenotype is nearing completion 
and it will be interesting to see if there is an improved phenotype in the setting of 
ischaemia and reperfusion. 
 
The membrane expression of dystrophin was not altered in the setting of myocardial 
dysfunction following CPB and varying durations of ischaemia and reperfusion. The 
insults involved in CPB and aortic cross clamping are obviously not severe enough and or 
the current methods of supporting the myocardium are adequate in preventing an acute 
dystrophinopathy. Dystrophin is not a key target protein in the setting of LCOS.  
 
Whilst dystrophin was not overtly affected, membrane expression of dysferlin was 
reduced in response to increasing durations of ischaemia. Its reduction was associated 
with increased tissue damage, increased oedema and reduced contractility. Given the 
association of tumour necrosis factor and endothelial expressed dysferlin in the blood 
brain barrier (Hochmeister, 2006), it would be intriguing to examine any such interaction 
in the heart, given the role of tumour necrosis factor in ischaemia and CPB (Wan, 1997). 
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Interestingly P188 appeared to interact with the endothelium and was associated with 
normalisation of dysferlin following CPB with ischaemia. 
 
Poloxamer 188 was associated with reductions in the severe diastolic dysfunction seen 
with ischaemia. It was associated with less membrane injury, tissue oedema and reduced 
haemodilution. In association with improved haemodynamics there was no reduction in 
renal function. Previous animal work in the setting of myocardial infarction had also been 
favourable, only for large human trials to prove otherwise. What remains to be seen is 
whether pre-emptively administering P188 to a larger animal CPB series justifies further 
trials of P188 in humans. Given the previous failures in treating myocardial infarction, 
there will need to be a strong positive animal experience prior to proceeding. 
Mechanistically P188 certainly appears to have membrane insulating attributes in an 
asanguinous model as well as likely effects on viscosity that additionally make it an 
attractive therapy. 
  
In conclusion, the experiments outlined in this thesis have contributed to our 
understanding of how ischaemia and oedema impact on postoperative myocardial 
dysfunction. They have also clarified the role of water channels, dysferlin and dystrophin. 
P188 has potential as a membrane protecting therapy which may offer dysferlin and other 
membrane proteins protection from ischaemia in particular. Hopefully an increased 
understanding of the pathophysiological processes involved in LCOS will led to 
reductions in both its occurrence and severity. 
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